🏷

Classifications

Harrison's Chapter

Mechanistic Nosology

👪

Inheritance

1

Autosomal recessive inheritance HP:0000007

PEOB1 is inherited in an autosomal recessive manner; both POLG alleles must carry a pathogenic variant. Sibs of a proband have a 25% recurrence risk. Heterozygous sibs are typically asymptomatic. The autosomal dominant POLG PEO (PEOA1) is a separate MONDO entity and must not be conflated with this one.

Autosomal recessive inheritance

Show evidence (2 references)

PMID:20301791 SUPPORT Human Clinical

"If both parents are known to be heterozygous for a POLG pathogenic variant, each sib of an affected individual has at conception a 25% chance of inheriting biallelic pathogenic variants and being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial..."

GeneReviews states the standard autosomal recessive recurrence risks for POLG-related disorders.

PMID:20301791 SUPPORT Human Clinical

"Heterozygous sibs of a proband with an autosomal recessive POLG-related disorder are typically asymptomatic."

Confirms that single-allele carriers do not develop the recessive phenotype.

?

Discussions and Knowledge Gaps

3

Why are the extraocular muscles and levator palpebrae superioris the earliest and most severely affected tissue in POLG-related recessive PEO, when the POLG defect is present in every cell?

KNOWLEDGE GAP OPEN peob1_extraocular_selectivity_gap

Attached to

pathophysiology#Selective Extraocular and Levator Muscle Vulnerability

Extraocular muscle carries a threefold higher burden of COX-deficient fibres than limb muscle in CPEO patients, and accumulates somatic mtDNA deletions faster during normal ageing. Candidate explanations - a lower heteroplasmy threshold, a faster deletion generation rate, more permissive clonal expansion, lower mitophagy efficiency, or fibre-type-specific mitochondrial fusion dynamics - have not been discriminated. This matters because the tissue-selectivity, not the enzymology, is what makes PEO a distinct clinical entity from the other POLG phenotypes carrying the same alleles.

Proposed experiments

Single-fibre heteroplasmy threshold mapping across muscle groups

peob1_single_fibre_threshold_mapping

Measure single-fibre mtDNA deletion load and the heteroplasmy threshold for COX negativity in extraocular, levator palpebrae and limb muscle from the same POLG-mutant donor, to test whether extraocular selectivity reflects a lower threshold or a faster accumulation rate.

Fibre-type-resolved mitophagy and mitochondrial dynamics imaging

peob1_fibre_type_mitophagy_imaging

Compare mitophagy flux and mitochondrial fusion/fission dynamics across fibre types in human extraocular versus limb muscle, to test the quality-control-capacity explanation for selective vulnerability.

Show evidence (1 reference)

PMID:33057669 SUPPORT Model Organism

"Therefore, our results showing that type IIB fibers in EOMs are affected earlier and more extensively (see Figs. 3A, 3B, 3E), suggest that these fibers might either have a faster rate of mitochondrial DNA deletion accumulation, clonal expansion, or a lower threshold compared to the other fiber types."

Explicitly leaves the three candidate mechanisms unresolved.

What determines whether a given recessive POLG genotype - most starkly, p.A467T homozygosity - presents as late-onset PEO rather than as Alpers-Huttenlocher syndrome or MIRAS?

KNOWLEDGE GAP OPEN peob1_genotype_phenotype_modifier_gap

Attached to

pathophysiology#POLG Catalytic and Proofreading Deficiency

68 p.A467T homozygotes across eight centres span essentially the entire POLG phenotypic spectrum, and clinical presentation clusters within sibships, implying heritable modifiers. Yet a genome-directed search within POLG and its flanking regulatory regions, and in POLG2, TWNK/PEO1 and ANT1, found no correlating nuclear variant. The only signal identified was mitochondrial DNA haplogroup U, which was protective against epilepsy. So the modifiers that decide a PEO versus an Alpers presentation remain unidentified, and this is the central unsolved problem of POLG nosology - it is also why PEOB1 cannot be predicted from genotype alone.

Proposed experiments

Genome-wide modifier scan in phenotype-discordant POLG homozygotes

peob1_genome_wide_modifier_scan

Run an unbiased genome-wide (rather than candidate-gene) modifier scan in large sibship-matched cohorts of p.A467T homozygotes stratified by presentation (PEO versus Alpers versus ataxia-neuropathy).

Tissue-resolved mtDNA copy number and deletion-load profiling

peob1_tissue_mtdna_copy_number_profiling

Profile tissue-specific mtDNA copy number and deletion load across presentations to test whether the phenotype tracks a quantitative replication-capacity threshold rather than a discrete modifier allele.

Show evidence (2 references)

PMID:23250882 SUPPORT Human Clinical

"Interestingly, the clinical presentation was similar in siblings, implying a genetic basis for the phenotypic variability amongst homozygotes. However, the p.Ala467Thr allele was present on a shared haplotype in each affected individual, and there was no correlation between the clinical..."

Documents both the evidence for a genetic modifier and the failure of the candidate-gene search to find one.

PMID:23250882 SUPPORT Human Clinical

"Our results suggest that the mitochondrial DNA background plays an important role in modifying the disease phenotype but nuclear modifiers, epigenetic and environmental factors may also influence the severity of disease."

States the residual uncertainty about which class of modifier dominates.

Is the excess severity of p.A467T/p.W748S compound heterozygotes a true dominant-negative interaction between the two mutant Pol-gamma-A subunits, or simply the additive effect of two partially-overlapping catalytic defects?

KNOWLEDGE GAP OPEN peob1_compound_heterozygote_dominant_negative

Attached to

pathophysiology#POLG Catalytic and Proofreading Deficiency

Compound heterozygotes have significantly shorter survival than homozygotes for either allele, which is not what a simple additive loss-of-function model predicts. A dominant-negative mechanism was proposed but has not been tested biochemically - Pol gamma functions as a heterotrimer, so a poisoned-complex model is plausible but unproven. Resolving this would change how compound-heterozygote prognosis is counselled.

Proposed experiments

Mixed-subunit Pol gamma reconstitution assay

peob1_mixed_subunit_polgamma_reconstitution

Reconstitute heterotrimeric Pol gamma with mixed A467T and W748S catalytic subunits in vitro and compare polymerase activity and processivity against each homomeric mutant, to test for a poisoned-complex (dominant-negative) effect.

Genotype-stratified muscle mtDNA deletion load comparison

peob1_genotype_stratified_deletion_load

Compare mtDNA deletion load and copy number in matched skeletal muscle from compound-heterozygote versus homozygote patients.

Show evidence (1 reference)

PMID:16638794 SUPPORT Human Clinical

"Compound heterozygotes have a significantly more severe phenotype raising the possibility of a dominant negative effect."

Raises the dominant-negative hypothesis without testing it.

⚙

Pathophysiology

11

POLG Catalytic and Proofreading Deficiency

Biallelic pathogenic POLG variants impair the catalytic A subunit of mitochondrial DNA polymerase gamma, the only polymerase that replicates the mitochondrial genome. Depending on the domain affected, the consequence is reduced 5'-3' polymerase activity (polymerase-domain variants such as p.T914P, which is catalytically inactive), reduced 3'-5' exonuclease proofreading fidelity (exonuclease-domain variants such as p.F197S), or loss of the linker-domain interaction with the POLG2 accessory subunit that confers processivity (the common p.A467T allele). In autosomal recessive disease two such hypomorphic or null alleles are required; the residual activity of the less severe allele largely determines how much mtDNA replication capacity survives.

DNA-directed DNA polymerase activity GO:0003887 ↓ DECREASED 3'-5' exonuclease (proofreading) activity GO:0008408 ↓ DECREASED

mitochondrion GO:0005739

Downstream

Impaired Mitochondrial DNA Replication Loss of polymerase activity, proofreading, and accessory-subunit-dependent processivity directly reduces the fidelity and completion of mitochondrial genome replication.

Show evidence (4 references)

PMID:11431686 SUPPORT Human Clinical

"POLG is the only DNA polymerase responsible for mtDNA replication."

Establishes that POLG is the sole replicative polymerase of the mitochondrial genome, so its impairment has no redundant backup.

PMID:32042919 SUPPORT Human Clinical

"Biochemical characterization revealed that the novel F197S mutant protein had reduced exonuclease and DNA polymerase activities and confirmed that T914P was inactive."

Direct biochemical demonstration in an arPEO patient that one allele abolishes polymerase activity and the other degrades both polymerase and exonuclease (proofreading) function.

PMID:16024923 SUPPORT In Vitro

"The A467T mutant enzyme possesses only 4% of wild-type DNA polymerase activity, and the catalytic defect is manifest primarily through a 6-fold reduction in kcat with minimal effect on exonuclease function."

Quantifies the catalytic defect of the most common recessive POLG allele in purified enzyme assays.

+ 1 more reference

Impaired Mitochondrial DNA Replication

Reduced polymerase gamma activity slows and destabilises mtDNA replication. Stalled or aborted replication forks are resolved by illegitimate recombination or slipped-strand mispairing between the direct repeats that flank the mitochondrial major arc, generating large-scale deletions; the simultaneous shortfall in completed replication events lowers mtDNA copy number (depletion) in the most replication-demanding tissues.

mitochondrial DNA replication GO:0006264 ↓ DECREASED mitochondrial DNA metabolic process GO:0032042 ⚠ ABNORMAL

mitochondrion GO:0005739

Downstream

Multiple Large-Scale mtDNA Deletions and Depletion Error-prone and incomplete replication yields a heteroplasmic population of deleted mtDNA molecules alongside reduced total mtDNA copy number.

Show evidence (1 reference)

PMID:32042919 SUPPORT Human Clinical

"The reduction in polymerase activity explains the presence of multiple pathogenic large-scale deletions in the patient's mtDNA."

States the causal link from reduced polymerase activity to multiple large-scale mtDNA deletions in an arPEO patient.

Multiple Large-Scale mtDNA Deletions and Depletion

The molecular hallmark of PEOB1 is the accumulation, in post-mitotic tissue (especially skeletal and extraocular muscle), of multiple different large-scale mtDNA deletions, frequently accompanied by a variable degree of mtDNA depletion. Unlike the single, clonal, sporadic deletion of Kearns-Sayre syndrome, these deletions are heterogeneous in breakpoint and are generated continuously throughout life because the nuclear replication defect persists. Deep sequencing of muscle mtDNA in arPEO allows the rearrangements to be mapped and their load quantified.

skeletal muscle tissue UBERON:0001134

Downstream

Clonal Expansion Above the Biochemical Threshold Individual deleted mtDNA genomes replicate preferentially within single post-mitotic cells until they exceed the heteroplasmy threshold for respiratory-chain failure.

Valproate-Precipitated Hepatic Decompensation Reduced hepatic mtDNA maintenance capacity is the susceptible background on which valproate exposure precipitates hepatotoxicity: the liver's regenerative response to the drug requires mtDNA replication that a POLG-deficient hepatocyte cannot deliver. The edge is conditional on drug exposure, so it is indirect rather than an obligate consequence of the genotype.

Show evidence (3 references)

PMID:12565911 SUPPORT Human Clinical

"Autosomal recessive progressive external ophthalmoplegia is a mitochondrial disease characterized by accumulation of multiple large-scale deletions of mitochondrial DNA."

Defines multiple large-scale mtDNA deletions as the defining molecular lesion of autosomal recessive PEO specifically.

PMID:32042919 SUPPORT Human Clinical

"By deep sequencing of mitochondrial DNA (mtDNA) extracted from muscle, multiple large-scale rearrangements were mapped and quantified."

Demonstrates that multiple large-scale mtDNA rearrangements are directly detectable and quantifiable in arPEO muscle.

PMID:21550804 SUPPORT Human Clinical

"We showed that 10 cases (48%) display mutations in POLG, including eight previously reported variants and two novel mutations (namely, p.Trp585X and p.Arg1081Gln)."

POLG accounted for roughly half of all patients presenting with multiple mtDNA deletions in skeletal muscle, establishing it as the dominant genetic cause of this molecular phenotype.

Clonal Expansion Above the Biochemical Threshold

Deleted mtDNA genomes are shorter and are amplified preferentially within individual long-lived post-mitotic cells (muscle fibre segments, neurons). Because mtDNA is polyploid, a cell remains biochemically normal until the mutant fraction crosses a threshold, after which mtDNA-encoded respiratory chain subunits become limiting. This threshold effect explains the characteristic mosaic (fibre-to-fibre) pattern of the defect rather than a uniform tissue-wide deficiency.

skeletal muscle fiber CL:0008002

mitochondrial DNA replication GO:0006264 ⚠ ABNORMAL

Downstream

Mosaic Respiratory-Chain (OXPHOS) Deficiency Once the mutant mtDNA load exceeds threshold in a cell, mtDNA-encoded subunits of complexes I, III, IV and V become insufficient and oxidative phosphorylation fails in that cell.

Show evidence (1 reference)

PMID:33057669 PARTIAL Model Organism

"Therefore, our results showing that type IIB fibers in EOMs are affected earlier and more extensively (see Figs. 3A, 3B, 3E), suggest that these fibers might either have a faster rate of mitochondrial DNA deletion accumulation, clonal expansion, or a lower threshold compared to the other fiber types."

A mouse mtDNA-deletion model directly frames the fibre-type-specific defect in terms of deletion accumulation rate, clonal expansion, and heteroplasmy threshold. Model-organism evidence, offered as mechanistic support for the threshold/clonal-expansion step rather than as proof in human tissue.

Mosaic Respiratory-Chain (OXPHOS) Deficiency

Loss of intact mtDNA templates reduces the supply of the thirteen mtDNA-encoded respiratory-chain polypeptides. Complex IV (cytochrome c oxidase) is the most sensitive readout because three of its catalytic subunits are mtDNA-encoded and none are supplied by the nuclear genome, so affected cells become COX-negative on histochemistry while succinate dehydrogenase (entirely nuclear-encoded, complex II) is preserved or upregulated. The bioenergetic deficit affects the most oxidative, highest-demand post-mitotic cells first.

skeletal muscle fiber CL:0008002 sensory neuron of dorsal root ganglion CL:1001451

oxidative phosphorylation GO:0006119 ↓ DECREASED cellular respiration GO:0045333 ↓ DECREASED

Downstream

Ragged-Red and COX-Negative Fibre Pathology Respiratory-chain-deficient fibre segments lose COX histochemical activity and undergo compensatory subsarcolemmal mitochondrial proliferation, the histological substrate of ragged-red fibres.

Selective Extraocular and Levator Muscle Vulnerability The same OXPHOS deficit is expressed disproportionately in extraocular muscle, which is tonically active, has a mitochondrial content several-fold higher than limb muscle, and has a lower heteroplasmy threshold for COX deficiency than limb muscle.

Neurological Extension of the POLG Phenotype Long, metabolically demanding post-mitotic neurons - dorsal root ganglion sensory neurons, cerebellar circuits, cochlear neurons - accumulate the same bioenergetic deficit, producing the PEO-plus features.

Show evidence (1 reference)

PMID:32042919 SUPPORT Human Clinical

"Muscle biopsy showed slight variability in muscle fiber size, scattered ragged red fibers, and partial cytochrome c oxidase deficiency."

Muscle histochemistry in a genetically confirmed arPEO patient shows the mosaic (scattered, partial) pattern of respiratory-chain deficiency predicted by threshold-dependent clonal expansion.

Ragged-Red and COX-Negative Fibre Pathology

In respiratory-chain-deficient fibre segments, a retrograde signalling response drives compensatory mitochondrial biogenesis. The resulting subsarcolemmal and intermyofibrillar accumulation of structurally abnormal mitochondria produces the ragged-red fibre on modified Gomori trichrome and the COX-negative / SDH-hyperreactive fibre on sequential COX-SDH histochemistry. Fibre atrophy, increased fibre-size variability, and endomysial fibrosis accompany the change.

skeletal muscle fiber CL:0008002

skeletal muscle tissue UBERON:0001134

Downstream

Mitochondrial Myopathy and Exercise Intolerance Accumulation of respiratory-chain-deficient, atrophic fibre segments across limb and axial muscle produces proximal weakness, fatigability, and exercise intolerance.

Show evidence (2 references)

PMID:32042919 SUPPORT Human Clinical

"Muscle biopsy showed slight variability in muscle fiber size, scattered ragged red fibers, and partial cytochrome c oxidase deficiency."

Documents ragged-red fibres, COX deficiency and fibre-size variability in arPEO muscle.

PMID:33057669 PARTIAL Model Organism

"We observed fiber atrophy, ragged-red fibers, increased collagen fibrosis, and infiltration of mono-nucleated non-muscle cells"

A mouse model of accumulating mtDNA deletions reproduces the full histological package (atrophy, ragged-red fibres, fibrosis), supporting the causal link from mtDNA deletions to this pathology.

Selective Extraocular and Levator Muscle Vulnerability

Extraocular muscles are the earliest and most severely affected tissue in all forms of PEO. They are tonically active with the fastest shortening velocities and highest firing rates of any skeletal muscle, they carry a mitochondrial content several-fold higher than limb muscle, and - critically - they show a lower mtDNA mutational threshold for COX deficiency together with a higher rate of somatic mtDNA deletion accumulation than limb muscle. The levator palpebrae superioris shares this vulnerability, which is why ptosis is typically the first sign. The reason this selective vulnerability exists is still only partly explained.

skeletal muscle fiber CL:0008002

extra-ocular muscle UBERON:0001601

Downstream

Progressive Ptosis and External Ophthalmoplegia Progressive loss of contractile capacity in the levator palpebrae and the recti produces the cardinal, slowly progressive, symmetric ptosis and ophthalmoparesis.

Show evidence (2 references)

PMID:33057669 PARTIAL Model Organism

"Previous studies in CPEO patients with mtDNA deletions reported a threefold higher proportion of COX deficient fibers in EOMs compared to limb skeletal muscles"

Reports that extraocular muscle carries a threefold higher burden of COX-deficient fibres than limb muscle in CPEO patients - the tissue-selectivity that defines the PEO phenotype. Tagged MODEL_ORGANISM because the citing publication is a mouse K320E-Twinkle study and this sentence sits in its Discussion restating a prior human report rather than presenting new human data; cited PARTIAL for the same reason.

PMID:33057669 PARTIAL Model Organism

"Ptosis due to impaired levator muscle function is a common and early clinical symptom in patients with mitochondrial myopathies"

Connects levator palpebrae involvement to the same respiratory-chain defect; the accompanying mouse data show extensive respiratory-chain deficiency in the levator palpebrae superioris.

Progressive Ptosis and External Ophthalmoplegia

The defining clinical expression of PEOB1: bilateral, usually symmetric, slowly progressive ptosis followed by restriction of horizontal and vertical gaze. Because the deficit is symmetric and evolves over years, diplopia is often absent or late, and patients may adopt a chin-up head posture and frontalis overaction rather than complain of eye-movement limitation.

extra-ocular muscle UBERON:0001601

Show evidence (1 reference)

PMID:32042919 SUPPORT Human Clinical

"The patient had slowly progressive bilateral ptosis and severely reduced horizontal and vertical gaze."

Describes the cardinal arPEO presentation in a genetically and biochemically confirmed patient.

Mitochondrial Myopathy and Exercise Intolerance

Beyond the eye, PEOB1 produces a generalised mitochondrial myopathy with proximal limb weakness, fatigability, exercise intolerance, and in some patients bulbar involvement with dysphagia. Myopathy is a consistent accompaniment of POLG-related PEO rather than an optional extra.

skeletal muscle tissue UBERON:0001134

Show evidence (1 reference)

PMID:20301791 PARTIAL Human Clinical

"Characterized by ptosis and PEO, with additional features such as peripheral neuropathy, ataxia, and muscle weakness."

GeneReviews groups muscle weakness with ptosis and PEO in its late-onset POLG presentation. Cited PARTIAL because GeneReviews' Genetic Counseling section says late-onset PEO "may be caused by a heterozygous POLG pathogenic variant" - so this paragraph spans the autosomal DOMINANT PEOA1 as well as PEOB1 and does not on its own establish the finding in biallelic disease. The biallelic-specific GeneReviews anchor is the juvenile/adult-onset paragraph, used for the PEO and neuropathy phenotypes.

Neurological Extension of the POLG Phenotype

Most patients with POLG-related recessive PEO develop a "PEO-plus" phenotype because the mtDNA maintenance defect is systemic. The commonest extensions are a length-dependent sensory ataxic axonal neuropathy (from dorsal root ganglion neuron loss), cerebellar and sensory ataxia, dysarthria and/or dysphagia, and sensorineural hearing loss. In a subset, epilepsy, migraine, myoclonus, parkinsonism, or hepatic involvement appear, blurring the boundary with the SANDO, MIRAS/ataxia-neuropathy and Alpers ends of the POLG spectrum.

sensory neuron of dorsal root ganglion CL:1001451

Show evidence (3 references)

PMID:14745080 SUPPORT Human Clinical

"The authors identified two novel heterozygous missense transitions in the gene for the mitochondrial polymerase gammaA subunit (POLG) in a family with an autosomal recessive syndrome comprising progressive external ophthalmoplegia (PEO), polyneuropathy, ataxia, sensorineural hearing loss, and..."

A family with autosomal recessive POLG disease in which PEO co-segregates with polyneuropathy, ataxia and sensorineural hearing loss - the canonical PEO-plus extension.

PMID:12565911 SUPPORT Human Clinical

"Sensory neuropathy is the initial feature in Belgian compound heterozygote autosomal recessive progressive external ophthalmoplegia patients, all carrying the POLG A467T mutation"

In the original Belgian recessive PEO cohort the sensory neuropathy actually preceded the ophthalmoplegia, showing that the neurological extension is intrinsic to the disease rather than a late complication.

PMID:16621917 SUPPORT Human Clinical

"The clinical presentation ranged from the neonatal period to late adult life, with an overlapping phenotypic spectrum from severe encephalopathy and liver failure to late-onset external ophthalmoplegia, ataxia, myopathy and isolated muscle pain or epilepsy."

Situates recessive POLG PEO at the late-onset end of a continuous phenotypic spectrum whose other features may co-occur in the same patient.

Valproate-Precipitated Hepatic Decompensation

Exposure to valproic acid on a POLG-deficient background can precipitate or accelerate hepatotoxicity and fulminant liver failure. This is a gene-drug interaction rather than a spontaneous feature of PEOB1: valproate impairs hepatocyte proliferation and regeneration, which a liver already limited by defective mtDNA maintenance cannot compensate for. It is the single most important actionable contraindication in the POLG-related disorders and is most often encountered when valproate is chosen to treat POLG-related epilepsy before the genetic diagnosis is known.

Show evidence (3 references)

PMID:16638794 SUPPORT Human Clinical

"Liver failure was the sole cause of death in two patients and evolved terminally in six others, all but one of whom were being treated with sodium valproate."

In a 26-patient recessive POLG cohort carrying the same p.A467T/p.W748S alleles that cause PEOB1, fatal liver failure clustered almost entirely in valproate-exposed patients.

PMID:21038416 SUPPORT Human Clinical

"Heterozygous genetic variation in POLG was strongly associated with VPA-induced liver toxicity"

A prospective Drug Induced Liver Injury Network study establishing POLG genotype as a strong determinant of valproate hepatotoxicity risk.

PMID:21038416 SUPPORT Human Clinical

"These findings implicate impaired liver regeneration in VPA toxicity and show that prospective genetic testing of POLG will identify individuals at high risk of this potentially fatal consequence of treatment."

Identifies impaired hepatocyte regeneration as the mechanism and supports pre-treatment POLG genotyping as a preventive strategy.

✶

Histopathology

4

Ragged-Red Fibers on Modified Gomori Trichrome

Scattered fibres with irregular, red-staining subsarcolemmal masses of proliferated mitochondria on modified Gomori trichrome staining of skeletal muscle. In arPEO these are typically sparse and scattered rather than widespread, matching the mosaic threshold-dependent pathology. (No NCIT Histopathology Result term exists for this finding; the HP binding HP:0003200 is carried on the corresponding phenotype entry.)

Show evidence (1 reference)

PMID:32042919 SUPPORT Human Clinical

"Muscle biopsy showed slight variability in muscle fiber size, scattered ragged red fibers, and partial cytochrome c oxidase deficiency."

Muscle biopsy in an arPEO patient with biallelic POLG variants shows scattered ragged-red fibres.

Partial Cytochrome c Oxidase Deficiency on COX-SDH Histochemistry

Sequential COX / SDH histochemistry shows a mosaic of COX-negative, SDH-hyperreactive fibre segments among normally reacting fibres. Because SDH (complex II) is wholly nuclear-encoded and COX (complex IV) has three mtDNA-encoded catalytic subunits, this COX-negative / SDH-positive pattern is the specific signature of an mtDNA rather than a nuclear OXPHOS lesion. (HP:0003688 is carried on the corresponding phenotype entry.)

Show evidence (2 references)

PMID:32042919 SUPPORT Human Clinical

"Muscle biopsy showed slight variability in muscle fiber size, scattered ragged red fibers, and partial cytochrome c oxidase deficiency."

Partial COX deficiency alongside preserved fibres in arPEO muscle biopsy.

PMID:33057669 PARTIAL Model Organism

"Ragged red fibers were mainly COX− / SDH++"

In a mouse mtDNA-deletion model, ragged-red fibres are predominantly COX-negative and SDH-hyperreactive, confirming that the two histochemical findings mark the same fibre population.

Fiber Size Variability, Atrophy and Endomysial Fibrosis

Non-specific myopathic change with increased fibre-size variability and atrophy of respiratory-chain-deficient fibre segments, accompanied in longstanding disease by increased endomysial connective tissue.

Show evidence (2 references)

PMID:32042919 SUPPORT Human Clinical

"Muscle biopsy showed slight variability in muscle fiber size"

Fibre-size variability recorded on arPEO muscle biopsy.

PMID:33057669 PARTIAL Model Organism

"We observed fiber atrophy, ragged-red fibers, increased collagen fibrosis, and infiltration of mono-nucleated non-muscle cells"

Mouse model with accumulating mtDNA deletions reproduces fibre atrophy and endomysial fibrosis alongside ragged-red fibres.

Multiple Large-Scale mtDNA Rearrangements in Muscle

Molecular analysis of the biopsy (long-range PCR, Southern blot, or deep sequencing of muscle-extracted mtDNA) demonstrates multiple heterogeneous large-scale mtDNA deletions. This is the finding that redirects the diagnostic workup from the mitochondrial to the nuclear genome; POLG accounted for 48% (10/21) of such patients in a Portuguese diagnostic cohort.

Show evidence (2 references)

PMID:32042919 SUPPORT Human Clinical

"By deep sequencing of mitochondrial DNA (mtDNA) extracted from muscle, multiple large-scale rearrangements were mapped and quantified."

Direct demonstration and quantification of multiple large-scale mtDNA rearrangements in arPEO muscle.

PMID:21550804 SUPPORT Human Clinical

"The relatively high diagnostic yield (about one in two cases) supports the notion that it is recommended to test POLG routinely in diagnostic laboratories whenever multiple mtDNA deletions are present, regardless of the age of onset of patients and their clinical phenotype."

Establishes the diagnostic workflow implication: multiple mtDNA deletions on muscle biopsy should trigger POLG sequencing.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

16

Digestive 2

Dysphagia Dysphagia HP:0002015

Show evidence (1 reference)

PMID:20301791 PARTIAL Human Clinical

"Liver involvement, feeding difficulties, seizures, hypotonia, and muscle weakness are the most common clinical features."

GeneReviews records feeding difficulty within the POLG-related spectrum; cited as partial support because the quoted sentence describes the early-onset group rather than PEOB1 specifically.

Hepatic Failure Hepatic failure HP:0001399

Show evidence (1 reference)

PMID:16638794 SUPPORT Human Clinical

"Liver failure was the sole cause of death in two patients and evolved terminally in six others, all but one of whom were being treated with sodium valproate."

Documents liver failure in recessive POLG disease and its near-exclusive association with valproate exposure.

Ear 1

Sensorineural Hearing Impairment Sensorineural hearing impairment HP:0000407

Show evidence (1 reference)

PMID:14745080 SUPPORT Human Clinical

"an autosomal recessive syndrome comprising progressive external ophthalmoplegia (PEO), polyneuropathy, ataxia, sensorineural hearing loss, and affective disorders"

Sensorineural hearing loss is an explicit component of this autosomal recessive POLG PEO syndrome.

Eye 1

Ptosis Ptosis HP:0000508

Course: PROGRESSIVE

GeneReviews names ptosis only in its late-onset paragraph, which its Genetic Counseling section says may be caused by a heterozygous POLG variant (i.e. the dominant PEOA1). That paragraph is therefore not cited here; the ptosis claim rests on the biallelic, biochemically confirmed arPEO case instead.

Show evidence (1 reference)

PMID:32042919 SUPPORT Human Clinical

"The patient had slowly progressive bilateral ptosis and severely reduced horizontal and vertical gaze."

Bilateral slowly progressive ptosis in a genetically confirmed arPEO patient.

Musculoskeletal 2

Myopathy Myopathy HP:0003198

Show evidence (1 reference)

PMID:16621917 SUPPORT Human Clinical

"late-onset external ophthalmoplegia, ataxia, myopathy and isolated muscle pain or epilepsy"

Myopathy is listed together with late-onset external ophthalmoplegia in the POLG phenotypic spectrum corresponding to recessive PEO.

Muscle Weakness Muscle weakness HP:0001324

Course: PROGRESSIVE

Show evidence (2 references)

PMID:20301791 PARTIAL Human Clinical

"Characterized by ptosis and PEO, with additional features such as peripheral neuropathy, ataxia, and muscle weakness."

GeneReviews lists muscle weakness among the additional features of its late-onset POLG PEO presentation. Cited PARTIAL because GeneReviews' Genetic Counseling section says late-onset PEO "may be caused by a heterozygous POLG pathogenic variant", so this paragraph spans the dominant PEOA1 as well as PEOB1.

PMID:16621917 SUPPORT Human Clinical

"late-onset external ophthalmoplegia, ataxia, myopathy and isolated muscle pain or epilepsy"

Biallelic-anchored support: this cohort was made up predominantly of sporadic compound heterozygotes, and places myopathy (the substrate of the weakness) alongside late-onset external ophthalmoplegia.

Nervous System 4

Peripheral Neuropathy Peripheral neuropathy HP:0009830

Course: PROGRESSIVE

Show evidence (2 references)

PMID:12565911 SUPPORT Human Clinical

"Sensory neuropathy is the initial feature in Belgian compound heterozygote autosomal recessive progressive external ophthalmoplegia patients, all carrying the POLG A467T mutation"

Sensory neuropathy was the initial feature in every compound-heterozygote recessive PEO patient in the founding Belgian cohort.

PMID:20301791 SUPPORT Human Clinical

"Disease is typically characterized by peripheral neuropathy, ataxia, seizures, stroke-like episodes, and, in individuals with longer survival, progressive external ophthalmoplegia (PEO)."

GeneReviews lists peripheral neuropathy first in its juvenile/adult-onset paragraph - the group it explicitly attributes to BIALLELIC POLG variants and autosomal recessive inheritance - alongside the PEO that defines this entry.

Ataxia Ataxia HP:0001251

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:14745080 SUPPORT Human Clinical

"an autosomal recessive syndrome comprising progressive external ophthalmoplegia (PEO), polyneuropathy, ataxia, sensorineural hearing loss, and affective disorders"

Ataxia co-segregates with PEO in this autosomal recessive POLG family.

Dysarthria Dysarthria HP:0001260

Show evidence (1 reference)

PMID:12565911 SUPPORT Human Clinical

"the clinical triad of sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO)"

Dysarthria appears together with ophthalmoparesis in the recessive POLG PEO phenotype described here.

Seizures Seizure HP:0001250

Show evidence (1 reference)

PMID:16621917 PARTIAL Human Clinical

"late-onset external ophthalmoplegia, ataxia, myopathy and isolated muscle pain or epilepsy"

Epilepsy sits within the same POLG phenotypic spectrum as late-onset external ophthalmoplegia, though it is not a defining PEOB1 feature.

Other 6

Progressive External Ophthalmoplegia Progressive external ophthalmoplegia HP:0000590

Course: PROGRESSIVE

Show evidence (2 references)

PMID:32042919 SUPPORT Human Clinical

"The patient had slowly progressive bilateral ptosis and severely reduced horizontal and vertical gaze."

Documents severe restriction of horizontal and vertical gaze in a genetically confirmed late-onset arPEO patient.

PMID:20301791 SUPPORT Human Clinical

"Disease is typically characterized by peripheral neuropathy, ataxia, seizures, stroke-like episodes, and, in individuals with longer survival, progressive external ophthalmoplegia (PEO)."

GeneReviews' juvenile/adult-onset paragraph - the group it explicitly attributes to BIALLELIC POLG variants and autosomal recessive inheritance - lists progressive external ophthalmoplegia. Deliberately anchored here rather than on the late-onset paragraph, which GeneReviews notes may be caused by a heterozygous variant (i.e. the dominant PEOA1).

Sensory Ataxia Sensory ataxia HP:0010871

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:12565911 SUPPORT Human Clinical

"The novel patient presented with sensory ataxic neuropathy and has the clinical triad of sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO)."

A recessive POLG PEO patient with sensory ataxic neuropathy; the paper explicitly argues that SANDO is a variant of autosomal recessive PEO.

Ragged-Red Muscle Fibers Ragged-red muscle fibers HP:0003200

Show evidence (1 reference)

PMID:32042919 SUPPORT Human Clinical

"Muscle biopsy showed slight variability in muscle fiber size, scattered ragged red fibers, and partial cytochrome c oxidase deficiency."

Ragged-red fibres documented on muscle biopsy in a genetically confirmed arPEO patient.

Cytochrome C Oxidase-Negative Muscle Fibers Cytochrome C oxidase-negative muscle fibers HP:0003688

Show evidence (1 reference)

PMID:32042919 SUPPORT Human Clinical

"Muscle biopsy showed slight variability in muscle fiber size, scattered ragged red fibers, and partial cytochrome c oxidase deficiency."

Partial (mosaic) cytochrome c oxidase deficiency documented in arPEO muscle.

Increased Variability in Muscle Fiber Diameter Increased variability in muscle fiber diameter HP:0003557

Show evidence (1 reference)

PMID:32042919 SUPPORT Human Clinical

"Muscle biopsy showed slight variability in muscle fiber size"

Fibre-size variability recorded on arPEO muscle biopsy.

Multiple Mitochondrial DNA Deletions Multiple mitochondrial DNA deletions HP:0003689

Show evidence (1 reference)

PMID:12565911 SUPPORT Human Clinical

"Autosomal recessive progressive external ophthalmoplegia is a mitochondrial disease characterized by accumulation of multiple large-scale deletions of mitochondrial DNA."

Multiple large-scale mtDNA deletions are definitional for autosomal recessive PEO.

🧬

Genetic Associations

1

POLG (Biallelic pathogenic variants in POLG, encoding the catalytic A subunit of mitochondrial DNA polymerase gamma, cause autosomal recessive progressive external ophthalmoplegia 1 by impairing mtDNA replication and producing multiple large-scale mtDNA deletions with variable mtDNA depletion. POLG is also the commonest identified nuclear cause of the multiple-mtDNA-deletion molecular phenotype irrespective of clinical presentation.)

Gene: POLG hgnc:9179 relationship_type: CAUSATIVE

Autosomal recessive inheritance

Show evidence (3 references)

PMID:11431686 SUPPORT Human Clinical

"Progressive external ophthalmoplegias (PEO) characterized by accumulation of large-scale mitochondrial DNA (mtDNA) deletions are rare human diseases."

Frames the disease entity - PEO with large-scale mtDNA deletions - in the paper that first implicated POLG.

PMID:21550804 SUPPORT Human Clinical

"We showed that 10 cases (48%) display mutations in POLG, including eight previously reported variants and two novel mutations (namely, p.Trp585X and p.Arg1081Gln)."

POLG is the single commonest nuclear gene in patients with multiple mtDNA deletions in skeletal muscle.

PMID:28695364 SUPPORT Human Clinical

"Among the 722 patients with a definite genetic diagnosis, ocular myopathy was observed in 399 subjects (55.3%) and was positively associated with mtDNA single deletions and POLG mutations."

In a large genetically diagnosed mitochondrial disease cohort, ocular myopathy was positively associated with POLG mutations.

💊

Medical Actions

6

Supportive and Multidisciplinary Care

Action: Supportive Care NCIT:C15747

There is no disease-modifying therapy for PEOB1. Management is supportive and multidisciplinary: occupational, physical and speech therapy for the myopathy, ataxia and dysarthria; nutritional and swallowing support; respiratory support where needed; and standard treatment of any epilepsy, movement, vision and hearing complications - subject to the valproate contraindication below.

Show evidence (1 reference)

PMID:20301791 SUPPORT Human Clinical

"Clinical management is largely supportive and involves standard approaches for associated complications including occupational, physical, and speech therapy; nutritional support; respiratory support"

GeneReviews specifies supportive multidisciplinary management for POLG-related disorders.

Ptosis Surgery (Levator Advancement or Frontalis Suspension)

Action: Ophthalmologic Surgical Procedure NCIT:C15331

Surgical correction is the mainstay of symptomatic treatment for the ptosis of PEOB1, chosen according to levator excursion: levator advancement or resection where levator function is preserved, frontalis suspension (sling) where it is not. Myogenic ptosis is a particularly difficult surgical target because the ptosis continues to worsen and because the same mitochondrial myopathy impairs protective corneal mechanisms (Bell's phenomenon, orbicularis closure). Deliberate under-correction is therefore standard - enough to clear the visual axis without producing exposure keratopathy - at the cost of a high recurrence rate.

Target Phenotypes: Ptosis HP:0000508

Show evidence (3 references)

PMID:36178005 SUPPORT Human Clinical

"Surgical techniques predominantly involved levator advancement, levator resection, frontalis sling, blepharoplasty, and Fasanella-Servat."

Enumerates the surgical options used for progressive myogenic ptosis, including the CPEO subgroup.

PMID:36178005 SUPPORT Human Clinical

"However, myogenic ptosis is especially challenging as it is characterized by worsening ptosis and the loss of protective corneal mechanisms."

Explains why myogenic (mitochondrial) ptosis carries a higher surgical risk than other ptosis aetiologies.

PMID:36178005 SUPPORT Human Clinical

"The goals of care with myogenic ptosis involves repairing ptosis just sufficiently to alleviate visual obstruction while avoiding adverse post-operative complications."

Establishes the deliberate-under-correction principle that governs ptosis surgery in mitochondrial ocular myopathy.

Avoidance of Valproic Acid (Contraindicated)

Action: Pharmacotherapy NCIT:C15986

Agent: valproic acid CHEBI:39867

Valproic acid (Depakene) and sodium divalproate/divalproex (Depakote) must be avoided in all POLG-related disorders, including PEOB1, because they can precipitate or accelerate liver disease and fatal hepatic failure. This is not a theoretical caution: in a 26-patient recessive POLG cohort, liver failure caused or contributed to death in eight patients, all but one of whom were on valproate. The risk is genotype-driven and detectable prospectively, so POLG genotyping should precede valproate in anyone with a suspected mitochondrial or unexplained epilepsy phenotype. This record is curated with negative valence - the intervention is withholding the drug, not administering it.

Show evidence (3 references)

PMID:20301791 SUPPORT Human Clinical

"because of the risk of precipitating and/or accelerating liver disease"

GeneReviews lists valproic acid and sodium divalproate under Agents/circumstances to avoid for POLG-related disorders because of hepatic risk.

PMID:16638794 SUPPORT Human Clinical

"Patients with this disorder are at high risk of death from status epilepticus and from liver failure, if exposed to sodium valproate."

Direct clinical evidence of fatal valproate-associated liver failure in recessive POLG disease.

PMID:21038416 SUPPORT Human Clinical

"These findings implicate impaired liver regeneration in VPA toxicity and show that prospective genetic testing of POLG will identify individuals at high risk of this potentially fatal consequence of treatment."

Supports pre-treatment POLG genotyping to identify patients at high risk of valproate hepatotoxicity.

Hepatic and Anti-Seizure Medication Surveillance

Action: Supportive Care NCIT:C15747

Liver enzymes should be monitored every three months or as clinically indicated, and liver function retested after introduction of any new anti-seizure medication - the surveillance counterpart of the valproate contraindication.

Show evidence (1 reference)

PMID:20301791 SUPPORT Human Clinical

"monitoring of liver enzymes every three months or as clinically indicated; monitoring of epilepsy with repeat liver function tests after introduction of any new anti-seizure medication."

GeneReviews surveillance recommendation for POLG-related disorders.

Deoxynucleoside (dC/dT) Substrate Supplementation

Action: Pharmacotherapy NCIT:C15986

Agent: deoxycytidine CHEBI:15698 deoxythymidine CHEBI:17748

Investigational, not standard of care. Enteral deoxycytidine plus deoxythymidine (dC/dT) aims to replenish the mitochondrial dNTP pool and so partially compensate for the reduced replication capacity of mutant polymerase gamma - the only curated treatment here that targets the causal mechanism rather than the consequences. An open-label single-arm phase 2 trial (NCT04802707) in POLG-related disorders reported improvement in the Newcastle Mitochondrial Disease Scale and stable-or-falling GDF-15 at 6 months. Important scope caveat for PEOB1: the interim cohort was children, six of ten with Alpers-Huttenlocher syndrome and two with ataxia-neuropathy spectrum, so efficacy in adult-onset recessive PEO specifically is untested.

Mechanism Target:

RESTORES Impaired Mitochondrial DNA Replication

Show evidence (3 references)

PMID:39091670 PARTIAL Human Clinical

"we assessed the safety and efficacy of combination therapy with deoxycytidine and deoxythymidine (dC/dT) in children with POLG-related disorders."

Phase 2 open-label trial of enteral dC/dT across POLG-related disorders. Cited PARTIAL for PEOB1 because the interim cohort was children with Alpers-Huttenlocher syndrome and ataxia-neuropathy spectrum, not adult-onset recessive PEO.

PMID:39091670 PARTIAL Human Clinical

"During the 6 months of treatment, NMDS score improved from a mean of 27.3 at baseline to 20.7 at 6 months"

Quantifies the primary efficacy signal. PARTIAL because it is an uncontrolled single-arm interim result in a mixed POLG cohort.

PMID:39091670 SUPPORT Human Clinical

"At present, there are no effective treatments for POLG-related disorders."

Confirms that no disease-modifying therapy is established for the POLG spectrum, which is why the rest of this section is supportive care.

Genetic Counseling

Action: genetic counseling Ontology label: Genetic Counseling NCIT:C15240

Autosomal recessive counselling with a 25% sib recurrence risk, carrier testing for at-risk relatives once the familial variants are known, and the option of prenatal or preimplantation genetic testing. Counselling should explicitly cover the valproate contraindication for heterozygous relatives, who are at increased risk of valproate hepatotoxicity even though they do not develop PEO.

Show evidence (1 reference)

PMID:20301791 SUPPORT Human Clinical

"Once the POLG pathogenic variants have been identified in an affected family member, testing for at-risk family members is possible."

GeneReviews genetic counselling guidance for autosomal recessive POLG-related disorders.

🔬

Biochemical Markers

1

Serum Lactate (VARIABLE)

Show evidence (1 reference)

PMID:28695364 SUPPORT Human Clinical

"Increased lactate was associated with central neurological involvement."

In a 722-patient genetically diagnosed mitochondrial cohort in which ocular myopathy was positively associated with POLG mutations, raised lactate marked CNS involvement rather than the ocular myopathy.

🔀

Differential Diagnoses

5

Conditions with similar clinical presentations that must be differentiated from Autosomal Recessive Progressive External Ophthalmoplegia 1:

Autosomal Dominant Progressive External Ophthalmoplegia 1 (PEOA1)

Overlapping Features The dominant POLG sibling disorder, caused by a single heterozygous POLG variant (classically p.Y955C in polymerase motif B, mapped to 15q22-q26 in the original Belgian pedigree). Same gene, same molecular endpoint (multiple mtDNA deletions), different inheritance and typically later, milder, more ocular-restricted disease. This is the single most important entity to keep distinct from PEOB1.

Show evidence (1 reference)

PMID:11431686 SUPPORT Human Clinical

"We mapped a new locus for dominant PEO at 15q22-q26 in a Belgian pedigree and identified a heterozygous mutation (Y955C) in the polymerase motif B of the mtDNA polymerase gamma (POLG)."

Describes the dominant POLG PEO entity, defined by a single heterozygous p.Y955C variant, in the same paper that identified the recessive form.

SANDO / Ataxia-Neuropathy Spectrum (POLG)

Overlapping Features Sensory ataxic neuropathy, dysarthria and ophthalmoparesis is caused by the same biallelic POLG genotypes and is arguably a phenotypic variant of autosomal recessive PEO rather than a separate disease - the boundary is clinical emphasis (neuropathy-first versus ophthalmoplegia-first), not mechanism.

Show evidence (1 reference)

PMID:12565911 SUPPORT Human Clinical

"This is the first finding of a genetic cause of Sensory Ataxic Neuropathy, Dysarthria and Ophthalmoparesis and it implies that this disorder may actually be a variant of autosomal recessive progressive external ophthalmoplegia."

Explicitly proposes SANDO as a variant of autosomal recessive PEO, defining the boundary problem between the two entries.

Alpers-Huttenlocher Syndrome and MIRAS (POLG)

Overlapping Features The early-onset (hepatocerebral, intractable epilepsy) and ataxia-predominant ends of the same POLG continuum. They share the p.A467T and p.W748S founder alleles with PEOB1, so genotype does not separate them; age of onset and organ emphasis do.

Show evidence (1 reference)

PMID:16621917 SUPPORT Human Clinical

"POLG1 mutations cause an overlapping clinical spectrum of disease with both dominant and recessive modes of inheritance."

Establishes the overlapping-spectrum framing that makes these entities differential diagnoses of one another.

Other Nuclear mtDNA Maintenance Disorders (TWNK, RRM2B, SLC25A4, TYMP)

Overlapping Features Other nuclear genes produce PEO with multiple mtDNA deletions - TWNK (the replicative helicase; formerly C10orf2/PEO1), RRM2B, SLC25A4/ANT1, and TYMP (MNGIE). POLG accounts for roughly half of cases, so a negative POLG result should prompt testing of the rest of the panel.

Show evidence (1 reference)

PMID:21550804 SUPPORT Human Clinical

"Diseases affecting mtDNA stability, termed nuclear-mitochondrial intergenomic communication disorders, are caused by a primary nuclear gene defect resulting in multiple mtDNA deletions."

Frames the class of nuclear mtDNA maintenance disorders within which POLG accounted for 48% of cases in this cohort.

Single Large-Scale mtDNA Deletion Syndromes (CPEO, Kearns-Sayre)

Overlapping Features Sporadic PEO and Kearns-Sayre syndrome are caused by a SINGLE clonal large-scale mtDNA deletion arising in the germline or early embryogenesis, with no nuclear-gene lesion and negligible recurrence risk. Distinguishing single from multiple deletions on muscle mtDNA analysis is the decisive step.

Show evidence (1 reference)

PMID:28695364 SUPPORT Human Clinical

"Among the 722 patients with a definite genetic diagnosis, ocular myopathy was observed in 399 subjects (55.3%) and was positively associated with mtDNA single deletions and POLG mutations."

Shows that both single mtDNA deletions and POLG mutations converge on the ocular myopathy phenotype, which is why they must be separated molecularly.

🔬

Clinical Trials

1

NCT04802707 PHASE_II

Single-arm phase 2 trial of combined deoxycytidine (dC) and deoxythymidine (dT) nucleoside substrate supplementation as early treatment for mitochondrial DNA depletion syndromes, including POLG-related disease. The only interventional trial curated here that targets the mtDNA-replication defect underlying PEOB1 rather than its downstream consequences.

Show evidence (1 reference)

clinicaltrials:NCT04802707 SUPPORT Human Clinical

"In this phase II Trial a mix of Deoxynucleosides Pyrimidine (Deoxycytidine dC and Deoxythymidine dT) will be used as early treatment of MDS."

Phase II trial of dC/dT substrate supplementation enrolling mtDNA maintenance/depletion disorders including POLG-related disease.

{ }

Source YAML

click to show

name: Autosomal Recessive Progressive External Ophthalmoplegia 1
creation_date: "2026-07-31T00:00:00Z"
category: Mendelian
synonyms:
- PEOB1
- arPEO
- POLG autosomal recessive progressive external ophthalmoplegia
- autosomal recessive progressive external ophthalmoplegia caused by mutation in POLG
- progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal
  recessive 1
description: >
  Autosomal recessive progressive external ophthalmoplegia 1 (PEOB1, arPEO) is a
  nuclear-encoded disorder of mitochondrial DNA (mtDNA) maintenance caused by
  biallelic pathogenic variants in POLG, the gene encoding the catalytic A subunit
  of mitochondrial DNA polymerase gamma (Pol-gamma-A). Pol gamma is the only DNA
  polymerase responsible for replicating the mitochondrial genome, and it carries
  both a 5'-3' polymerase domain and a 3'-5' exonuclease (proofreading) domain,
  linked by a linker region that mediates binding to the POLG2 accessory subunit
  required for processive synthesis. Recessive POLG variants reduce polymerase
  activity, proofreading fidelity, and/or accessory-subunit interaction; the
  resulting replication stalling and error-prone mtDNA synthesis produce multiple
  large-scale mtDNA deletions in post-mitotic tissue, often with a degree of mtDNA
  depletion. Clonal expansion of deleted mtDNA species above the biochemical
  threshold causes a mosaic respiratory-chain (oxidative phosphorylation) defect,
  seen histologically as ragged-red and cytochrome c oxidase (COX)-negative fibres.
  Extraocular muscle and the levator palpebrae superioris are affected earliest and
  most severely, giving the cardinal phenotype of progressive bilateral ptosis and
  slowly progressive external ophthalmoplegia, typically with a proximal
  mitochondrial myopathy and exercise intolerance. Because the same molecular lesion
  affects all post-mitotic tissue, most patients have a "PEO-plus" phenotype with
  neurological extensions - sensory ataxic axonal neuropathy, cerebellar and sensory
  ataxia, dysarthria/dysphagia, sensorineural hearing loss, and in some patients
  epilepsy and hepatic involvement.

  PEOB1 sits within the POLG-related disorder spectrum, a continuum whose severity
  correlates broadly with age of onset. It must be distinguished from its autosomal
  DOMINANT sibling PEOA1 (heterozygous POLG variants, classically p.Y955C), and from
  the neighbouring recessive POLG phenotypes Alpers-Huttenlocher syndrome, MIRAS,
  SANDO, and ataxia-neuropathy spectrum, with which it shares the two common European
  founder alleles p.A467T and p.W748S. Management is supportive - ptosis surgery,
  multidisciplinary rehabilitation, genetic counselling - and the single most
  important actionable fact is the absolute contraindication to valproic acid, which
  can precipitate or accelerate fatal liver failure on a POLG-deficient background.
disease_term:
  preferred_term: progressive external ophthalmoplegia with mitochondrial DNA deletions,
    autosomal recessive 1
  term:
    id: MONDO:0009783
    label: progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal
      recessive 1
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
  mechanistic_category:
  - classification_value: mitochondrial disease
  icimd_category:
  - classification_value: mtdna_replication_and_maintenance
parents:
- POLG-Related Disorders
- Progressive External Ophthalmoplegia with Multiple mtDNA Deletions
- Mitochondrial DNA Maintenance Disorder
- Mitochondrial Disease
references:
- reference: PMID:20301791
  title: "POLG-Related Disorders."
  tags:
  - GeneReviews
pathophysiology:
- name: POLG Catalytic and Proofreading Deficiency
  biological_scale: MOLECULAR
  description: >
    Biallelic pathogenic POLG variants impair the catalytic A subunit of
    mitochondrial DNA polymerase gamma, the only polymerase that replicates the
    mitochondrial genome. Depending on the domain affected, the consequence is
    reduced 5'-3' polymerase activity (polymerase-domain variants such as
    p.T914P, which is catalytically inactive), reduced 3'-5' exonuclease
    proofreading fidelity (exonuclease-domain variants such as p.F197S), or loss
    of the linker-domain interaction with the POLG2 accessory subunit that confers
    processivity (the common p.A467T allele). In autosomal recessive disease two
    such hypomorphic or null alleles are required; the residual activity of the
    less severe allele largely determines how much mtDNA replication capacity
    survives.
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  molecular_functions:
  - preferred_term: DNA-directed DNA polymerase activity
    term:
      id: GO:0003887
      label: DNA-directed DNA polymerase activity
    modifier: DECREASED
  - preferred_term: 3'-5' exonuclease (proofreading) activity
    term:
      id: GO:0008408
      label: 3'-5' exonuclease activity
    modifier: DECREASED
  evidence:
  - reference: PMID:11431686
    reference_title: "Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "POLG is the only DNA polymerase responsible for mtDNA replication."
    explanation: >
      Establishes that POLG is the sole replicative polymerase of the
      mitochondrial genome, so its impairment has no redundant backup.
  - reference: PMID:32042919
    reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Biochemical characterization revealed that the novel F197S mutant protein had reduced exonuclease and DNA polymerase activities and confirmed that T914P was inactive."
    explanation: >
      Direct biochemical demonstration in an arPEO patient that one allele
      abolishes polymerase activity and the other degrades both polymerase and
      exonuclease (proofreading) function.
  - reference: PMID:16024923
    reference_title: "The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The A467T mutant enzyme possesses only 4% of wild-type DNA polymerase activity, and the catalytic defect is manifest primarily through a 6-fold reduction in kcat with minimal effect on exonuclease function."
    explanation: >
      Quantifies the catalytic defect of the most common recessive POLG allele in
      purified enzyme assays.
  - reference: PMID:16024923
    reference_title: "The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "However, the A467T mutant enzyme failed to interact with and was not stimulated by the accessory subunit, as judged by processivity, heat inactivation, and N-ethylmaleimide protection assays in vitro."
    explanation: >
      Shows that p.A467T additionally destroys the processivity-conferring
      interaction with the POLG2 accessory subunit, a distinct second hit on
      replication capacity.
  downstream:
  - target: Impaired Mitochondrial DNA Replication
    description: >-
      Loss of polymerase activity, proofreading, and accessory-subunit-dependent
      processivity directly reduces the fidelity and completion of mitochondrial
      genome replication.
    causal_link_type: DIRECT
    evidence:
    - reference: PMID:16024923
      reference_title: "The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "We propose that reduced polymerase activity and loss of accessory subunit interaction are responsible for the depletion and deletion of mitochondrial DNA observed in patients with this POLG mutation."
      explanation: >
        Links the enzymatic defect mechanistically to the mtDNA deletion and
        depletion phenotype seen in patients.
- name: Impaired Mitochondrial DNA Replication
  biological_scale: MOLECULAR
  description: >
    Reduced polymerase gamma activity slows and destabilises mtDNA replication.
    Stalled or aborted replication forks are resolved by illegitimate
    recombination or slipped-strand mispairing between the direct repeats that
    flank the mitochondrial major arc, generating large-scale deletions; the
    simultaneous shortfall in completed replication events lowers mtDNA copy
    number (depletion) in the most replication-demanding tissues.
  locations:
  - preferred_term: mitochondrion
    term:
      id: GO:0005739
      label: mitochondrion
  biological_processes:
  - preferred_term: mitochondrial DNA replication
    term:
      id: GO:0006264
      label: mitochondrial DNA replication
    modifier: DECREASED
  - preferred_term: mitochondrial DNA metabolic process
    term:
      id: GO:0032042
      label: mitochondrial DNA metabolic process
    modifier: ABNORMAL
  evidence:
  - reference: PMID:32042919
    reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The reduction in polymerase activity explains the presence of multiple pathogenic large-scale deletions in the patient's mtDNA."
    explanation: >
      States the causal link from reduced polymerase activity to multiple
      large-scale mtDNA deletions in an arPEO patient.
  downstream:
  - target: Multiple Large-Scale mtDNA Deletions and Depletion
    description: >-
      Error-prone and incomplete replication yields a heteroplasmic population of
      deleted mtDNA molecules alongside reduced total mtDNA copy number.
    causal_link_type: DIRECT
- name: Multiple Large-Scale mtDNA Deletions and Depletion
  biological_scale: MOLECULAR
  description: >
    The molecular hallmark of PEOB1 is the accumulation, in post-mitotic tissue
    (especially skeletal and extraocular muscle), of multiple different
    large-scale mtDNA deletions, frequently accompanied by a variable degree of
    mtDNA depletion. Unlike the single, clonal, sporadic deletion of Kearns-Sayre
    syndrome, these deletions are heterogeneous in breakpoint and are generated
    continuously throughout life because the nuclear replication defect persists.
    Deep sequencing of muscle mtDNA in arPEO allows the rearrangements to be
    mapped and their load quantified.
  locations:
  - preferred_term: skeletal muscle tissue
    term:
      id: UBERON:0001134
      label: skeletal muscle tissue
  evidence:
  - reference: PMID:12565911
    reference_title: "Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Autosomal recessive progressive external ophthalmoplegia is a mitochondrial disease characterized by accumulation of multiple large-scale deletions of mitochondrial DNA."
    explanation: >
      Defines multiple large-scale mtDNA deletions as the defining molecular
      lesion of autosomal recessive PEO specifically.
  - reference: PMID:32042919
    reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "By deep sequencing of mitochondrial DNA (mtDNA) extracted from muscle, multiple large-scale rearrangements were mapped and quantified."
    explanation: >
      Demonstrates that multiple large-scale mtDNA rearrangements are directly
      detectable and quantifiable in arPEO muscle.
  - reference: PMID:21550804
    reference_title: "Relative frequency of known causes of multiple mtDNA deletions: two novel POLG mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We showed that 10 cases (48%) display mutations in POLG, including eight previously reported variants and two novel mutations (namely, p.Trp585X and p.Arg1081Gln)."
    explanation: >
      POLG accounted for roughly half of all patients presenting with multiple
      mtDNA deletions in skeletal muscle, establishing it as the dominant genetic
      cause of this molecular phenotype.
  downstream:
  - target: Clonal Expansion Above the Biochemical Threshold
    description: >-
      Individual deleted mtDNA genomes replicate preferentially within single
      post-mitotic cells until they exceed the heteroplasmy threshold for
      respiratory-chain failure.
    causal_link_type: DIRECT
  - target: Valproate-Precipitated Hepatic Decompensation
    description: >-
      Reduced hepatic mtDNA maintenance capacity is the susceptible background on
      which valproate exposure precipitates hepatotoxicity: the liver's
      regenerative response to the drug requires mtDNA replication that a
      POLG-deficient hepatocyte cannot deliver. The edge is conditional on drug
      exposure, so it is indirect rather than an obligate consequence of the
      genotype.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Therapeutic valproic acid or sodium divalproate exposure (usually prescribed
      for POLG-related epilepsy before the genetic diagnosis is known)
    - Valproate-induced inhibition of hepatocyte proliferation and regeneration
    evidence:
    - reference: PMID:21038416
      reference_title: "Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "AHS is a neurometabolic disorder associated with an increased risk of developing fatal VPA hepatotoxicity."
      explanation: >
        Establishes that the POLG genotype itself is the substrate on which
        valproate hepatotoxicity risk is conferred, which is what this causal
        edge asserts.
- name: Clonal Expansion Above the Biochemical Threshold
  biological_scale: CELLULAR
  description: >
    Deleted mtDNA genomes are shorter and are amplified preferentially within
    individual long-lived post-mitotic cells (muscle fibre segments, neurons).
    Because mtDNA is polyploid, a cell remains biochemically normal until the
    mutant fraction crosses a threshold, after which mtDNA-encoded respiratory
    chain subunits become limiting. This threshold effect explains the
    characteristic mosaic (fibre-to-fibre) pattern of the defect rather than a
    uniform tissue-wide deficiency.
  cell_types:
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  biological_processes:
  - preferred_term: mitochondrial DNA replication
    term:
      id: GO:0006264
      label: mitochondrial DNA replication
    modifier: ABNORMAL
  evidence:
  - reference: PMID:33057669
    reference_title: "Extraocular Muscle Reveals Selective Vulnerability of Type IIB Fibers to Respiratory Chain Defects Induced by Mitochondrial DNA Alterations."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "Therefore, our results showing that type IIB fibers in EOMs are affected earlier and more extensively (see Figs. 3A, 3B, 3E), suggest that these fibers might either have a faster rate of mitochondrial DNA deletion accumulation, clonal expansion, or a lower threshold compared to the other fiber types."
    explanation: >
      A mouse mtDNA-deletion model directly frames the fibre-type-specific defect
      in terms of deletion accumulation rate, clonal expansion, and heteroplasmy
      threshold. Model-organism evidence, offered as mechanistic support for the
      threshold/clonal-expansion step rather than as proof in human tissue.
  downstream:
  - target: Mosaic Respiratory-Chain (OXPHOS) Deficiency
    description: >-
      Once the mutant mtDNA load exceeds threshold in a cell, mtDNA-encoded
      subunits of complexes I, III, IV and V become insufficient and oxidative
      phosphorylation fails in that cell.
    causal_link_type: DIRECT
- name: Mosaic Respiratory-Chain (OXPHOS) Deficiency
  biological_scale: CELLULAR
  description: >
    Loss of intact mtDNA templates reduces the supply of the thirteen
    mtDNA-encoded respiratory-chain polypeptides. Complex IV (cytochrome c
    oxidase) is the most sensitive readout because three of its catalytic
    subunits are mtDNA-encoded and none are supplied by the nuclear genome, so
    affected cells become COX-negative on histochemistry while succinate
    dehydrogenase (entirely nuclear-encoded, complex II) is preserved or
    upregulated. The bioenergetic deficit affects the most oxidative,
    highest-demand post-mitotic cells first.
  cell_types:
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  - preferred_term: sensory neuron of dorsal root ganglion
    term:
      id: CL:1001451
      label: sensory neuron of dorsal root ganglion
  biological_processes:
  - preferred_term: oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: DECREASED
  - preferred_term: cellular respiration
    term:
      id: GO:0045333
      label: cellular respiration
    modifier: DECREASED
  evidence:
  - reference: PMID:32042919
    reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle biopsy showed slight variability in muscle fiber size, scattered ragged red fibers, and partial cytochrome c oxidase deficiency."
    explanation: >
      Muscle histochemistry in a genetically confirmed arPEO patient shows the
      mosaic (scattered, partial) pattern of respiratory-chain deficiency
      predicted by threshold-dependent clonal expansion.
  downstream:
  - target: Ragged-Red and COX-Negative Fibre Pathology
    description: >-
      Respiratory-chain-deficient fibre segments lose COX histochemical activity
      and undergo compensatory subsarcolemmal mitochondrial proliferation, the
      histological substrate of ragged-red fibres.
    causal_link_type: DIRECT
  - target: Selective Extraocular and Levator Muscle Vulnerability
    description: >-
      The same OXPHOS deficit is expressed disproportionately in extraocular
      muscle, which is tonically active, has a mitochondrial content several-fold
      higher than limb muscle, and has a lower heteroplasmy threshold for COX
      deficiency than limb muscle.
    causal_link_type: DIRECT
  - target: Neurological Extension of the POLG Phenotype
    description: >-
      Long, metabolically demanding post-mitotic neurons - dorsal root ganglion
      sensory neurons, cerebellar circuits, cochlear neurons - accumulate the same
      bioenergetic deficit, producing the PEO-plus features.
    causal_link_type: DIRECT
- name: Ragged-Red and COX-Negative Fibre Pathology
  biological_scale: TISSUE
  description: >
    In respiratory-chain-deficient fibre segments, a retrograde signalling
    response drives compensatory mitochondrial biogenesis. The resulting
    subsarcolemmal and intermyofibrillar accumulation of structurally abnormal
    mitochondria produces the ragged-red fibre on modified Gomori trichrome and
    the COX-negative / SDH-hyperreactive fibre on sequential COX-SDH
    histochemistry. Fibre atrophy, increased fibre-size variability, and
    endomysial fibrosis accompany the change.
  locations:
  - preferred_term: skeletal muscle tissue
    term:
      id: UBERON:0001134
      label: skeletal muscle tissue
  cell_types:
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  evidence:
  - reference: PMID:32042919
    reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle biopsy showed slight variability in muscle fiber size, scattered ragged red fibers, and partial cytochrome c oxidase deficiency."
    explanation: >
      Documents ragged-red fibres, COX deficiency and fibre-size variability in
      arPEO muscle.
  - reference: PMID:33057669
    reference_title: "Extraocular Muscle Reveals Selective Vulnerability of Type IIB Fibers to Respiratory Chain Defects Induced by Mitochondrial DNA Alterations."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "We observed fiber atrophy, ragged-red fibers, increased collagen fibrosis, and infiltration of mono-nucleated non-muscle cells"
    explanation: >
      A mouse model of accumulating mtDNA deletions reproduces the full
      histological package (atrophy, ragged-red fibres, fibrosis), supporting the
      causal link from mtDNA deletions to this pathology.
  downstream:
  - target: Mitochondrial Myopathy and Exercise Intolerance
    description: >-
      Accumulation of respiratory-chain-deficient, atrophic fibre segments across
      limb and axial muscle produces proximal weakness, fatigability, and
      exercise intolerance.
    causal_link_type: DIRECT
- name: Selective Extraocular and Levator Muscle Vulnerability
  biological_scale: TISSUE
  description: >
    Extraocular muscles are the earliest and most severely affected tissue in all
    forms of PEO. They are tonically active with the fastest shortening velocities
    and highest firing rates of any skeletal muscle, they carry a mitochondrial
    content several-fold higher than limb muscle, and - critically - they show a
    lower mtDNA mutational threshold for COX deficiency together with a higher
    rate of somatic mtDNA deletion accumulation than limb muscle. The levator
    palpebrae superioris shares this vulnerability, which is why ptosis is
    typically the first sign. The reason this selective vulnerability exists is
    still only partly explained.
  locations:
  - preferred_term: extra-ocular muscle
    term:
      id: UBERON:0001601
      label: extra-ocular muscle
  cell_types:
  - preferred_term: skeletal muscle fiber
    term:
      id: CL:0008002
      label: skeletal muscle fiber
  evidence:
  - reference: PMID:33057669
    reference_title: "Extraocular Muscle Reveals Selective Vulnerability of Type IIB Fibers to Respiratory Chain Defects Induced by Mitochondrial DNA Alterations."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "Previous studies in CPEO patients with mtDNA deletions reported a threefold higher proportion of COX deficient fibers in EOMs compared to limb skeletal muscles"
    explanation: >
      Reports that extraocular muscle carries a threefold higher burden of
      COX-deficient fibres than limb muscle in CPEO patients - the
      tissue-selectivity that defines the PEO phenotype. Tagged MODEL_ORGANISM
      because the citing publication is a mouse K320E-Twinkle study and this
      sentence sits in its Discussion restating a prior human report rather than
      presenting new human data; cited PARTIAL for the same reason.
  - reference: PMID:33057669
    reference_title: "Extraocular Muscle Reveals Selective Vulnerability of Type IIB Fibers to Respiratory Chain Defects Induced by Mitochondrial DNA Alterations."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "Ptosis due to impaired levator muscle function is a common and early clinical symptom in patients with mitochondrial myopathies"
    explanation: >
      Connects levator palpebrae involvement to the same respiratory-chain defect;
      the accompanying mouse data show extensive respiratory-chain deficiency in
      the levator palpebrae superioris.
  downstream:
  - target: Progressive Ptosis and External Ophthalmoplegia
    description: >-
      Progressive loss of contractile capacity in the levator palpebrae and the
      recti produces the cardinal, slowly progressive, symmetric ptosis and
      ophthalmoparesis.
    causal_link_type: DIRECT
- name: Progressive Ptosis and External Ophthalmoplegia
  biological_scale: ORGANISM
  description: >
    The defining clinical expression of PEOB1: bilateral, usually symmetric,
    slowly progressive ptosis followed by restriction of horizontal and vertical
    gaze. Because the deficit is symmetric and evolves over years, diplopia is
    often absent or late, and patients may adopt a chin-up head posture and
    frontalis overaction rather than complain of eye-movement limitation.
  locations:
  - preferred_term: extra-ocular muscle
    term:
      id: UBERON:0001601
      label: extra-ocular muscle
  evidence:
  - reference: PMID:32042919
    reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient had slowly progressive bilateral ptosis and severely reduced horizontal and vertical gaze."
    explanation: >
      Describes the cardinal arPEO presentation in a genetically and
      biochemically confirmed patient.
- name: Mitochondrial Myopathy and Exercise Intolerance
  biological_scale: ORGANISM
  description: >
    Beyond the eye, PEOB1 produces a generalised mitochondrial myopathy with
    proximal limb weakness, fatigability, exercise intolerance, and in some
    patients bulbar involvement with dysphagia. Myopathy is a consistent
    accompaniment of POLG-related PEO rather than an optional extra.
  locations:
  - preferred_term: skeletal muscle tissue
    term:
      id: UBERON:0001134
      label: skeletal muscle tissue
  evidence:
  - reference: PMID:20301791
    reference_title: "POLG-Related Disorders."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Characterized by ptosis and PEO, with additional features such as peripheral neuropathy, ataxia, and muscle weakness."
    explanation: >
      GeneReviews groups muscle weakness with ptosis and PEO in its late-onset
      POLG presentation. Cited PARTIAL because GeneReviews' Genetic Counseling
      section says late-onset PEO "may be caused by a heterozygous POLG
      pathogenic variant" - so this paragraph spans the autosomal DOMINANT PEOA1
      as well as PEOB1 and does not on its own establish the finding in biallelic
      disease. The biallelic-specific GeneReviews anchor is the
      juvenile/adult-onset paragraph, used for the PEO and neuropathy phenotypes.
- name: Neurological Extension of the POLG Phenotype
  biological_scale: ORGANISM
  description: >
    Most patients with POLG-related recessive PEO develop a "PEO-plus" phenotype
    because the mtDNA maintenance defect is systemic. The commonest extensions are
    a length-dependent sensory ataxic axonal neuropathy (from dorsal root ganglion
    neuron loss), cerebellar and sensory ataxia, dysarthria and/or dysphagia, and
    sensorineural hearing loss. In a subset, epilepsy, migraine, myoclonus,
    parkinsonism, or hepatic involvement appear, blurring the boundary with the
    SANDO, MIRAS/ataxia-neuropathy and Alpers ends of the POLG spectrum.
  cell_types:
  - preferred_term: sensory neuron of dorsal root ganglion
    term:
      id: CL:1001451
      label: sensory neuron of dorsal root ganglion
  evidence:
  - reference: PMID:14745080
    reference_title: "POLG mutations causing ophthalmoplegia, sensorimotor polyneuropathy, ataxia, and deafness."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The authors identified two novel heterozygous missense transitions in the gene for the mitochondrial polymerase gammaA subunit (POLG) in a family with an autosomal recessive syndrome comprising progressive external ophthalmoplegia (PEO), polyneuropathy, ataxia, sensorineural hearing loss, and affective disorders."
    explanation: >
      A family with autosomal recessive POLG disease in which PEO co-segregates
      with polyneuropathy, ataxia and sensorineural hearing loss - the canonical
      PEO-plus extension.
  - reference: PMID:12565911
    reference_title: "Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sensory neuropathy is the initial feature in Belgian compound heterozygote autosomal recessive progressive external ophthalmoplegia patients, all carrying the POLG A467T mutation"
    explanation: >
      In the original Belgian recessive PEO cohort the sensory neuropathy actually
      preceded the ophthalmoplegia, showing that the neurological extension is
      intrinsic to the disease rather than a late complication.
  - reference: PMID:16621917
    reference_title: "Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The clinical presentation ranged from the neonatal period to late adult life, with an overlapping phenotypic spectrum from severe encephalopathy and liver failure to late-onset external ophthalmoplegia, ataxia, myopathy and isolated muscle pain or epilepsy."
    explanation: >
      Situates recessive POLG PEO at the late-onset end of a continuous
      phenotypic spectrum whose other features may co-occur in the same patient.
- name: Valproate-Precipitated Hepatic Decompensation
  biological_scale: ORGANISM
  description: >
    Exposure to valproic acid on a POLG-deficient background can precipitate or
    accelerate hepatotoxicity and fulminant liver failure. This is a gene-drug
    interaction rather than a spontaneous feature of PEOB1: valproate impairs
    hepatocyte proliferation and regeneration, which a liver already limited by
    defective mtDNA maintenance cannot compensate for. It is the single most
    important actionable contraindication in the POLG-related disorders and is
    most often encountered when valproate is chosen to treat POLG-related
    epilepsy before the genetic diagnosis is known.
  triggers:
  - preferred_term: valproic acid exposure
    term:
      id: CHEBI:39867
      label: valproic acid
  evidence:
  - reference: PMID:16638794
    reference_title: "The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Liver failure was the sole cause of death in two patients and evolved terminally in six others, all but one of whom were being treated with sodium valproate."
    explanation: >
      In a 26-patient recessive POLG cohort carrying the same p.A467T/p.W748S
      alleles that cause PEOB1, fatal liver failure clustered almost entirely in
      valproate-exposed patients.
  - reference: PMID:21038416
    reference_title: "Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Heterozygous genetic variation in POLG was strongly associated with VPA-induced liver toxicity"
    explanation: >
      A prospective Drug Induced Liver Injury Network study establishing POLG
      genotype as a strong determinant of valproate hepatotoxicity risk.
  - reference: PMID:21038416
    reference_title: "Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings implicate impaired liver regeneration in VPA toxicity and show that prospective genetic testing of POLG will identify individuals at high risk of this potentially fatal consequence of treatment."
    explanation: >
      Identifies impaired hepatocyte regeneration as the mechanism and supports
      pre-treatment POLG genotyping as a preventive strategy.
phenotypes:
- name: Progressive External Ophthalmoplegia
  category: Ocular
  description: >
    Slowly progressive, bilateral, largely symmetric restriction of horizontal and
    vertical eye movement due to mitochondrial myopathy of the extraocular
    muscles. This is the defining feature of PEOB1.
  phenotype_term:
    preferred_term: Progressive external ophthalmoplegia
    term:
      id: HP:0000590
      label: Progressive external ophthalmoplegia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:32042919
    reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient had slowly progressive bilateral ptosis and severely reduced horizontal and vertical gaze."
    explanation: >
      Documents severe restriction of horizontal and vertical gaze in a
      genetically confirmed late-onset arPEO patient.
  - reference: PMID:20301791
    reference_title: "POLG-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Disease is typically characterized by peripheral neuropathy, ataxia, seizures, stroke-like episodes, and, in individuals with longer survival, progressive external ophthalmoplegia (PEO)."
    explanation: >
      GeneReviews' juvenile/adult-onset paragraph - the group it explicitly
      attributes to BIALLELIC POLG variants and autosomal recessive inheritance -
      lists progressive external ophthalmoplegia. Deliberately anchored here
      rather than on the late-onset paragraph, which GeneReviews notes may be
      caused by a heterozygous variant (i.e. the dominant PEOA1).
- name: Ptosis
  category: Ocular
  description: >
    Bilateral, slowly progressive droop of the upper eyelids from involvement of
    the levator palpebrae superioris. Usually the presenting sign, often
    accompanied by compensatory frontalis overaction and a chin-up head posture.
  phenotype_term:
    preferred_term: Ptosis
    term:
      id: HP:0000508
      label: Ptosis
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:32042919
    reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The patient had slowly progressive bilateral ptosis and severely reduced horizontal and vertical gaze."
    explanation: >
      Bilateral slowly progressive ptosis in a genetically confirmed arPEO
      patient.
  notes: >
    GeneReviews names ptosis only in its late-onset paragraph, which its Genetic
    Counseling section says may be caused by a heterozygous POLG variant (i.e.
    the dominant PEOA1). That paragraph is therefore not cited here; the ptosis
    claim rests on the biallelic, biochemically confirmed arPEO case instead.
- name: Myopathy
  category: Neuromuscular
  description: >
    Mitochondrial myopathy affecting limb and axial muscle in addition to the
    extraocular muscles, producing weakness and fatigability.
  phenotype_term:
    preferred_term: Myopathy
    term:
      id: HP:0003198
      label: Myopathy
  evidence:
  - reference: PMID:16621917
    reference_title: "Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "late-onset external ophthalmoplegia, ataxia, myopathy and isolated muscle pain or epilepsy"
    explanation: >
      Myopathy is listed together with late-onset external ophthalmoplegia in the
      POLG phenotypic spectrum corresponding to recessive PEO.
- name: Muscle Weakness
  category: Neuromuscular
  description: >
    Predominantly proximal limb weakness reflecting the generalised mitochondrial
    myopathy.
  phenotype_term:
    preferred_term: Muscle weakness
    term:
      id: HP:0001324
      label: Muscle weakness
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:20301791
    reference_title: "POLG-Related Disorders."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Characterized by ptosis and PEO, with additional features such as peripheral neuropathy, ataxia, and muscle weakness."
    explanation: >
      GeneReviews lists muscle weakness among the additional features of its
      late-onset POLG PEO presentation. Cited PARTIAL because GeneReviews' Genetic
      Counseling section says late-onset PEO "may be caused by a heterozygous POLG
      pathogenic variant", so this paragraph spans the dominant PEOA1 as well as
      PEOB1.
  - reference: PMID:16621917
    reference_title: "Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "late-onset external ophthalmoplegia, ataxia, myopathy and isolated muscle pain or epilepsy"
    explanation: >
      Biallelic-anchored support: this cohort was made up predominantly of
      sporadic compound heterozygotes, and places myopathy (the substrate of the
      weakness) alongside late-onset external ophthalmoplegia.
- name: Peripheral Neuropathy
  category: Neurological
  description: >
    A length-dependent, sensory-predominant axonal polyneuropathy is one of the
    most consistent non-ocular features of POLG-related recessive PEO and may
    precede the ophthalmoplegia.
  phenotype_term:
    preferred_term: Peripheral neuropathy
    term:
      id: HP:0009830
      label: Peripheral neuropathy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:12565911
    reference_title: "Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sensory neuropathy is the initial feature in Belgian compound heterozygote autosomal recessive progressive external ophthalmoplegia patients, all carrying the POLG A467T mutation"
    explanation: >
      Sensory neuropathy was the initial feature in every compound-heterozygote
      recessive PEO patient in the founding Belgian cohort.
  - reference: PMID:20301791
    reference_title: "POLG-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Disease is typically characterized by peripheral neuropathy, ataxia, seizures, stroke-like episodes, and, in individuals with longer survival, progressive external ophthalmoplegia (PEO)."
    explanation: >
      GeneReviews lists peripheral neuropathy first in its juvenile/adult-onset
      paragraph - the group it explicitly attributes to BIALLELIC POLG variants
      and autosomal recessive inheritance - alongside the PEO that defines this
      entry.
- name: Sensory Ataxia
  category: Neurological
  description: >
    Ataxia arising from large-fibre sensory deafferentation due to dorsal root
    ganglion neuron degeneration; clinically manifests as a broad-based,
    Romberg-positive gait disturbance.
  phenotype_term:
    preferred_term: Sensory ataxia
    term:
      id: HP:0010871
      label: Sensory ataxia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:12565911
    reference_title: "Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The novel patient presented with sensory ataxic neuropathy and has the clinical triad of sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO)."
    explanation: >
      A recessive POLG PEO patient with sensory ataxic neuropathy; the paper
      explicitly argues that SANDO is a variant of autosomal recessive PEO.
- name: Ataxia
  category: Neurological
  description: >
    Combined cerebellar and sensory ataxia is common in the POLG-related recessive
    spectrum and is part of the PEO-plus presentation.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:14745080
    reference_title: "POLG mutations causing ophthalmoplegia, sensorimotor polyneuropathy, ataxia, and deafness."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an autosomal recessive syndrome comprising progressive external ophthalmoplegia (PEO), polyneuropathy, ataxia, sensorineural hearing loss, and affective disorders"
    explanation: >
      Ataxia co-segregates with PEO in this autosomal recessive POLG family.
- name: Dysarthria
  category: Neurological
  description: >
    Speech disturbance, usually of mixed ataxic and bulbar type, frequently
    accompanying the ataxia and neuropathy.
  phenotype_term:
    preferred_term: Dysarthria
    term:
      id: HP:0001260
      label: Dysarthria
  evidence:
  - reference: PMID:12565911
    reference_title: "Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the clinical triad of sensory ataxic neuropathy, dysarthria and ophthalmoparesis (SANDO)"
    explanation: >
      Dysarthria appears together with ophthalmoparesis in the recessive POLG PEO
      phenotype described here.
- name: Sensorineural Hearing Impairment
  category: Auditory
  description: >
    Sensorineural hearing loss occurs in a subset of patients, reflecting
    respiratory-chain deficiency in cochlear and auditory neural tissue.
  phenotype_term:
    preferred_term: Sensorineural hearing impairment
    term:
      id: HP:0000407
      label: Sensorineural hearing impairment
  evidence:
  - reference: PMID:14745080
    reference_title: "POLG mutations causing ophthalmoplegia, sensorimotor polyneuropathy, ataxia, and deafness."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "an autosomal recessive syndrome comprising progressive external ophthalmoplegia (PEO), polyneuropathy, ataxia, sensorineural hearing loss, and affective disorders"
    explanation: >
      Sensorineural hearing loss is an explicit component of this autosomal
      recessive POLG PEO syndrome.
- name: Seizures
  category: Neurological
  description: >
    Epilepsy is not a defining feature of PEOB1 but occurs in patients whose
    recessive POLG genotype places them toward the ataxia-neuropathy/MIRAS end of
    the spectrum. Its presence matters clinically because it is the usual reason
    valproate gets prescribed - which is contraindicated.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:16621917
    reference_title: "Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "late-onset external ophthalmoplegia, ataxia, myopathy and isolated muscle pain or epilepsy"
    explanation: >
      Epilepsy sits within the same POLG phenotypic spectrum as late-onset
      external ophthalmoplegia, though it is not a defining PEOB1 feature.
- name: Dysphagia
  category: Neuromuscular
  description: >
    Bulbar involvement with swallowing difficulty may accompany the myopathy and
    dysarthria in more advanced disease.
  phenotype_term:
    preferred_term: Dysphagia
    term:
      id: HP:0002015
      label: Dysphagia
  evidence:
  - reference: PMID:20301791
    reference_title: "POLG-Related Disorders."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "Liver involvement, feeding difficulties, seizures, hypotonia, and muscle weakness are the most common clinical features."
    explanation: >
      GeneReviews records feeding difficulty within the POLG-related spectrum;
      cited as partial support because the quoted sentence describes the
      early-onset group rather than PEOB1 specifically.
- name: Hepatic Failure
  category: Hepatic
  description: >
    Liver failure is rare in isolated recessive PEO but is the feared consequence
    of valproate exposure on a POLG-deficient background, and defines the
    early-onset (Alpers-Huttenlocher) end of the POLG spectrum.
  phenotype_term:
    preferred_term: Hepatic failure
    term:
      id: HP:0001399
      label: Hepatic failure
  evidence:
  - reference: PMID:16638794
    reference_title: "The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Liver failure was the sole cause of death in two patients and evolved terminally in six others, all but one of whom were being treated with sodium valproate."
    explanation: >
      Documents liver failure in recessive POLG disease and its near-exclusive
      association with valproate exposure.
- name: Ragged-Red Muscle Fibers
  category: Muscle Pathology
  description: >
    Subsarcolemmal accumulation of abnormal mitochondria in respiratory-chain
    deficient fibre segments, seen on modified Gomori trichrome staining of muscle
    biopsy.
  phenotype_term:
    preferred_term: Ragged-red muscle fibers
    term:
      id: HP:0003200
      label: Ragged-red muscle fibers
  evidence:
  - reference: PMID:32042919
    reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle biopsy showed slight variability in muscle fiber size, scattered ragged red fibers, and partial cytochrome c oxidase deficiency."
    explanation: >
      Ragged-red fibres documented on muscle biopsy in a genetically confirmed
      arPEO patient.
- name: Cytochrome C Oxidase-Negative Muscle Fibers
  category: Muscle Pathology
  description: >
    Focal loss of complex IV histochemical activity in a mosaic subset of fibres,
    the direct biochemical readout of clonally expanded mtDNA deletions above
    threshold.
  phenotype_term:
    preferred_term: Cytochrome C oxidase-negative muscle fibers
    term:
      id: HP:0003688
      label: Cytochrome C oxidase-negative muscle fibers
  evidence:
  - reference: PMID:32042919
    reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle biopsy showed slight variability in muscle fiber size, scattered ragged red fibers, and partial cytochrome c oxidase deficiency."
    explanation: >
      Partial (mosaic) cytochrome c oxidase deficiency documented in arPEO muscle.
- name: Increased Variability in Muscle Fiber Diameter
  category: Muscle Pathology
  description: >
    Non-specific myopathic change on muscle biopsy, reflecting atrophy of
    respiratory-chain-deficient fibre segments alongside preserved fibres.
  phenotype_term:
    preferred_term: Increased variability in muscle fiber diameter
    term:
      id: HP:0003557
      label: Increased variability in muscle fiber diameter
  evidence:
  - reference: PMID:32042919
    reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle biopsy showed slight variability in muscle fiber size"
    explanation: >
      Fibre-size variability recorded on arPEO muscle biopsy.
- name: Multiple Mitochondrial DNA Deletions
  category: Molecular
  description: >
    Multiple different large-scale deletions of the mitochondrial genome in
    post-mitotic tissue - the molecular signature that distinguishes PEOB1 (a
    nuclear-gene mtDNA maintenance disorder) from single-deletion PEO.
  phenotype_term:
    preferred_term: Multiple mitochondrial DNA deletions
    term:
      id: HP:0003689
      label: Multiple mitochondrial DNA deletions
  evidence:
  - reference: PMID:12565911
    reference_title: "Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Autosomal recessive progressive external ophthalmoplegia is a mitochondrial disease characterized by accumulation of multiple large-scale deletions of mitochondrial DNA."
    explanation: >
      Multiple large-scale mtDNA deletions are definitional for autosomal
      recessive PEO.
histopathology:
- name: Ragged-Red Fibers on Modified Gomori Trichrome
  description: >
    Scattered fibres with irregular, red-staining subsarcolemmal masses of
    proliferated mitochondria on modified Gomori trichrome staining of skeletal
    muscle. In arPEO these are typically sparse and scattered rather than
    widespread, matching the mosaic threshold-dependent pathology. (No NCIT
    Histopathology Result term exists for this finding; the HP binding
    HP:0003200 is carried on the corresponding phenotype entry.)
  diagnostic: false
  evidence:
  - reference: PMID:32042919
    reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle biopsy showed slight variability in muscle fiber size, scattered ragged red fibers, and partial cytochrome c oxidase deficiency."
    explanation: >
      Muscle biopsy in an arPEO patient with biallelic POLG variants shows
      scattered ragged-red fibres.
- name: Partial Cytochrome c Oxidase Deficiency on COX-SDH Histochemistry
  description: >
    Sequential COX / SDH histochemistry shows a mosaic of COX-negative,
    SDH-hyperreactive fibre segments among normally reacting fibres. Because SDH
    (complex II) is wholly nuclear-encoded and COX (complex IV) has three
    mtDNA-encoded catalytic subunits, this COX-negative / SDH-positive pattern is
    the specific signature of an mtDNA rather than a nuclear OXPHOS lesion.
    (HP:0003688 is carried on the corresponding phenotype entry.)
  diagnostic: false
  evidence:
  - reference: PMID:32042919
    reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle biopsy showed slight variability in muscle fiber size, scattered ragged red fibers, and partial cytochrome c oxidase deficiency."
    explanation: >
      Partial COX deficiency alongside preserved fibres in arPEO muscle biopsy.
  - reference: PMID:33057669
    reference_title: "Extraocular Muscle Reveals Selective Vulnerability of Type IIB Fibers to Respiratory Chain Defects Induced by Mitochondrial DNA Alterations."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "Ragged red fibers were mainly COX− / SDH++"
    explanation: >
      In a mouse mtDNA-deletion model, ragged-red fibres are predominantly
      COX-negative and SDH-hyperreactive, confirming that the two histochemical
      findings mark the same fibre population.
- name: Fiber Size Variability, Atrophy and Endomysial Fibrosis
  description: >
    Non-specific myopathic change with increased fibre-size variability and
    atrophy of respiratory-chain-deficient fibre segments, accompanied in
    longstanding disease by increased endomysial connective tissue.
  diagnostic: false
  evidence:
  - reference: PMID:32042919
    reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Muscle biopsy showed slight variability in muscle fiber size"
    explanation: >
      Fibre-size variability recorded on arPEO muscle biopsy.
  - reference: PMID:33057669
    reference_title: "Extraocular Muscle Reveals Selective Vulnerability of Type IIB Fibers to Respiratory Chain Defects Induced by Mitochondrial DNA Alterations."
    supports: PARTIAL
    evidence_source: MODEL_ORGANISM
    snippet: "We observed fiber atrophy, ragged-red fibers, increased collagen fibrosis, and infiltration of mono-nucleated non-muscle cells"
    explanation: >
      Mouse model with accumulating mtDNA deletions reproduces fibre atrophy and
      endomysial fibrosis alongside ragged-red fibres.
- name: Multiple Large-Scale mtDNA Rearrangements in Muscle
  description: >
    Molecular analysis of the biopsy (long-range PCR, Southern blot, or deep
    sequencing of muscle-extracted mtDNA) demonstrates multiple heterogeneous
    large-scale mtDNA deletions. This is the finding that redirects the diagnostic
    workup from the mitochondrial to the nuclear genome; POLG accounted for 48%
    (10/21) of such patients in a Portuguese diagnostic cohort.
  diagnostic: true
  evidence:
  - reference: PMID:32042919
    reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "By deep sequencing of mitochondrial DNA (mtDNA) extracted from muscle, multiple large-scale rearrangements were mapped and quantified."
    explanation: >
      Direct demonstration and quantification of multiple large-scale mtDNA
      rearrangements in arPEO muscle.
  - reference: PMID:21550804
    reference_title: "Relative frequency of known causes of multiple mtDNA deletions: two novel POLG mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The relatively high diagnostic yield (about one in two cases) supports the notion that it is recommended to test POLG routinely in diagnostic laboratories whenever multiple mtDNA deletions are present, regardless of the age of onset of patients and their clinical phenotype."
    explanation: >
      Establishes the diagnostic workflow implication: multiple mtDNA deletions on
      muscle biopsy should trigger POLG sequencing.
biochemical:
- name: Serum Lactate
  biomarker_term:
    preferred_term: Increased circulating lactate concentration
    term:
      id: HP:0002151
      label: Increased circulating lactate concentration
  presence: VARIABLE
  evidence:
  - reference: PMID:28695364
    reference_title: "Revisiting mitochondrial ocular myopathies: a study from the Italian Network."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Increased lactate was associated with central neurological involvement."
    explanation: >
      In a 722-patient genetically diagnosed mitochondrial cohort in which ocular
      myopathy was positively associated with POLG mutations, raised lactate
      marked CNS involvement rather than the ocular myopathy.
  notes: >
    Resting serum lactate is frequently normal in pure ocular myopathy and is not
    a sensitive screening test for PEOB1. In the large Italian mitochondrial
    network cohort, raised lactate tracked with central nervous system involvement
    rather than with the ocular myopathy itself - so a normal lactate does not
    exclude the diagnosis, and an elevated lactate should prompt a search for
    encephalopathic features. Creatine kinase is typically normal or only mildly
    elevated in mitochondrial ocular myopathy and is not curated here as a
    separate marker because no quotable PEOB1-specific figure was found.
genetic:
- name: POLG
  gene_term:
    preferred_term: POLG
    term:
      id: hgnc:9179
      label: POLG
  relationship_type: CAUSATIVE
  association: >-
    Biallelic pathogenic variants in POLG, encoding the catalytic A subunit of
    mitochondrial DNA polymerase gamma, cause autosomal recessive progressive
    external ophthalmoplegia 1 by impairing mtDNA replication and producing
    multiple large-scale mtDNA deletions with variable mtDNA depletion. POLG is
    also the commonest identified nuclear cause of the multiple-mtDNA-deletion
    molecular phenotype irrespective of clinical presentation.
  inheritance:
  - name: Autosomal recessive inheritance
    inheritance_term:
      preferred_term: Autosomal recessive inheritance
      term:
        id: HP:0000007
        label: Autosomal recessive inheritance
    description: >-
      PEOB1 requires two pathogenic POLG alleles - most often compound
      heterozygosity for one of the common European founder alleles (p.A467T,
      p.W748S) plus a second, frequently polymerase-domain, variant. Heterozygous
      carriers are typically asymptomatic for PEO, although carrier status is
      itself a risk factor for valproate hepatotoxicity. This recessive
      requirement is what separates PEOB1 from its autosomal dominant sibling
      PEOA1, in which a single heterozygous POLG variant (classically p.Y955C in
      polymerase motif B) suffices.
    evidence:
    - reference: PMID:20301791
      reference_title: "POLG-Related Disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Early-onset and juvenile/adult-onset POLG-related disorders are typically caused by biallelic pathogenic variants and inherited in an autosomal recessive manner."
      explanation: >
        GeneReviews establishes biallelic POLG variants and autosomal recessive
        inheritance for the recessive POLG-related disorders.
    - reference: PMID:11431686
      reference_title: "Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We identified three additional POLG missense mutations compatible with recessive PEO In two nuclear families."
      explanation: >
        The founding report that distinguished recessive POLG PEO (this entry)
        from the dominant p.Y955C form described in the same paper.
    - reference: PMID:12565911
      reference_title: "Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "we report a novel POLG missense mutation (R627W) in a sporadic patient and we provide genetic support that all these POLG mutations are actually causal and recessive"
      explanation: >
        Provides the genetic proof of recessive causality for the POLG variants
        underlying arPEO.
  evidence:
  - reference: PMID:11431686
    reference_title: "Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Progressive external ophthalmoplegias (PEO) characterized by accumulation of large-scale mitochondrial DNA (mtDNA) deletions are rare human diseases."
    explanation: >
      Frames the disease entity - PEO with large-scale mtDNA deletions - in the
      paper that first implicated POLG.
  - reference: PMID:21550804
    reference_title: "Relative frequency of known causes of multiple mtDNA deletions: two novel POLG mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We showed that 10 cases (48%) display mutations in POLG, including eight previously reported variants and two novel mutations (namely, p.Trp585X and p.Arg1081Gln)."
    explanation: >
      POLG is the single commonest nuclear gene in patients with multiple mtDNA
      deletions in skeletal muscle.
  - reference: PMID:28695364
    reference_title: "Revisiting mitochondrial ocular myopathies: a study from the Italian Network."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among the 722 patients with a definite genetic diagnosis, ocular myopathy was observed in 399 subjects (55.3%) and was positively associated with mtDNA single deletions and POLG mutations."
    explanation: >
      In a large genetically diagnosed mitochondrial disease cohort, ocular
      myopathy was positively associated with POLG mutations.
  variants:
  - name: p.Ala467Thr (c.1399G>A)
    description: >
      The most frequent recessive POLG allele in populations of European descent.
      It lies in the linker domain and acts through two distinct defects: the
      purified enzyme retains only ~4% of wild-type polymerase activity (a ~6-fold
      fall in kcat with essentially intact exonuclease function), and it fails
      entirely to bind and be stimulated by the POLG2 accessory subunit, so
      processivity collapses. It is carried by essentially all patients in the
      original Belgian recessive PEO cohort and occurs at a frequency of 0.6% in
      the Belgian population. Homozygotes span the entire POLG phenotypic
      continuum from Alpers-Huttenlocher to adult sensory ataxic neuropathy with
      ophthalmoparesis, so genotype alone does not predict presentation.
    clinical_significance: PATHOGENIC
    evidence:
    - reference: PMID:12565911
      reference_title: "Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "all carrying the POLG A467T mutation, which occurs at a frequency of 0.6% in the Belgian population"
      explanation: >
        Establishes p.A467T as the shared allele of the founding recessive PEO
        cohort and gives its population frequency.
    - reference: PMID:16024923
      reference_title: "The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "The A467T mutant enzyme possesses only 4% of wild-type DNA polymerase activity, and the catalytic defect is manifest primarily through a 6-fold reduction in kcat with minimal effect on exonuclease function."
      explanation: >
        Quantifies the residual catalytic activity of the p.A467T enzyme.
    - reference: PMID:23250882
      reference_title: "What is influencing the phenotype of the common homozygous polymerase-gamma mutation p.Ala467Thr?"
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In conclusion, our clinical results show that the homozygous p.Ala467Thr POLG mutation does not cause discrete phenotypes, as previously suggested, but rather there is a continuum of clinical symptoms."
      explanation: >
        68 homozygotes across eight centres show a continuum rather than discrete
        genotype-defined phenotypes, so p.A467T homozygosity does not by itself
        predict a PEO versus an Alpers presentation.
  - name: p.Trp748Ser (c.2243G>C)
    description: >
      The second common recessive European founder allele, almost always carried
      in cis with p.Glu1143Gly. It is the commonest cause of mitochondrial
      recessive ataxia syndrome (MIRAS) and, in compound heterozygosity with
      p.A467T or a polymerase-domain variant, contributes to the recessive
      PEO/ataxia-neuropathy end of the spectrum. Haplotype analysis shows a single
      ancient European founder chromosome shared across Finland, Norway, the UK
      and Belgium; the carrier frequency reaches 1 in 125 in Finland.
    clinical_significance: PATHOGENIC
    evidence:
    - reference: PMID:16080118
      reference_title: "Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We identified 27 patients with mitochondrial recessive ataxia syndrome (MIRAS) from 15 Finnish families, with a carrier frequency in the general population of 1 : 125."
      explanation: >
        Quantifies the Finnish carrier frequency of the p.W748S allele.
    - reference: PMID:16080118
      reference_title: "Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Haplotype analysis revealed that all the chromosomes carrying these two changes, in patients from Finland, Norway, the United Kingdom, and Belgium, originate from a common ancient founder."
      explanation: >
        Establishes the single ancient European founder origin of the p.W748S +
        p.E1143G allele.
    - reference: PMID:17426723
      reference_title: "Abundance of the POLG disease mutations in Europe, Australia, New Zealand, and the United States explained by single ancient European founders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "They have effectively spread to populations of European descent with carrier frequencies up to 1% in several populations."
      explanation: >
        Gives the population-level carrier burden of the common recessive POLG
        founder alleles.
  - name: Compound heterozygosity for p.Ala467Thr and p.Trp748Ser
    description: >
      Trans-compound heterozygosity for the two common founder alleles is a
      recurrent recessive genotype. In a 26-patient series, compound heterozygotes
      had significantly shorter survival than homozygotes for either allele,
      raising the possibility of a dominant-negative interaction between the two
      mutant subunits rather than simple additive loss of function.
    clinical_significance: PATHOGENIC
    evidence:
    - reference: PMID:16638794
      reference_title: "The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "major differences in survival were seen depending on genotype, with compound heterozygotes having a significantly shorter survival time than patients homozygous either for the A467T or W748S"
      explanation: >
        Quantifies the genotype-survival correlation distinguishing compound
        heterozygotes from homozygotes.
    - reference: PMID:16638794
      reference_title: "The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Compound heterozygotes have a significantly more severe phenotype raising the possibility of a dominant negative effect."
      explanation: >
        States the proposed dominant-negative mechanism underlying the compound
        heterozygote severity.
  - name: Exonuclease-domain and polymerase-domain variants in trans (p.Phe197Ser / p.Thr914Pro)
    description: >
      A worked late-onset arPEO genotype illustrating the general recessive
      architecture: one allele carries a novel exonuclease-domain variant
      (c.590T>C; p.F197S) with reduced exonuclease AND polymerase activity, while
      the other carries a catalytically inactive polymerase-domain null
      (c.2740A>C; p.T914P). Residual activity is supplied entirely by the
      hypomorphic allele, and the resulting replication deficit produces the
      multiple large-scale mtDNA deletions found in the patient's muscle.
    clinical_significance: PATHOGENIC
    evidence:
    - reference: PMID:32042919
      reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "One allele carried a novel mutation in the exonuclease domain (c.590T>C; p.F197S), and the other had a previously characterized null mutation in the polymerase domain (c.2740A>C; p.T914P)."
      explanation: >
        Defines the biallelic genotype in a biochemically characterised arPEO
        patient.
    - reference: PMID:32042919
      reference_title: "Deep sequencing of mitochondrial DNA and characterization of a novel POLG mutation in a patient with arPEO."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "resulting in one inactive POLγA protein (T914P) and one with decreased polymerase and exonuclease activity (F197S)"
      explanation: >
        States the genotype-to-phenotype conclusion for this recessive PEO case.
inheritance:
- name: Autosomal recessive inheritance
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  description: >-
    PEOB1 is inherited in an autosomal recessive manner; both POLG alleles must
    carry a pathogenic variant. Sibs of a proband have a 25% recurrence risk.
    Heterozygous sibs are typically asymptomatic. The autosomal dominant POLG PEO
    (PEOA1) is a separate MONDO entity and must not be conflated with this one.
  evidence:
  - reference: PMID:20301791
    reference_title: "POLG-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "If both parents are known to be heterozygous for a POLG pathogenic variant, each sib of an affected individual has at conception a 25% chance of inheriting biallelic pathogenic variants and being affected, a 50% chance of being heterozygous, and a 25% chance of inheriting neither of the familial POLG pathogenic variants."
    explanation: >
      GeneReviews states the standard autosomal recessive recurrence risks for
      POLG-related disorders.
  - reference: PMID:20301791
    reference_title: "POLG-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Heterozygous sibs of a proband with an autosomal recessive POLG-related disorder are typically asymptomatic."
    explanation: >
      Confirms that single-allele carriers do not develop the recessive
      phenotype.
prevalence:
- population: North East England adults (all nuclear-gene adult mitochondrial disease)
  measure_type: POINT_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 2.9
  notes: >-
    Upper bound proxy. This is the prevalence of ALL clinically overt adult
    mitochondrial disease caused by nuclear-gene mutations (of which POLG is the
    largest single contributor); PEOB1 specifically is a fraction of this figure.
    No PEOB1-specific population prevalence estimate is available.
  evidence:
  - reference: PMID:25652200
    reference_title: "Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "In this population, nuclear mutations were responsible for clinically overt adult mitochondrial disease in 2.9 per 100,000 adults."
    explanation: >
      Population-based minimum prevalence of nuclear-gene adult mitochondrial
      disease, the class to which PEOB1 belongs. Cited as PARTIAL because it is a
      class-level rather than a PEOB1-specific figure.
- population: European-descent populations (POLG founder-allele carriers)
  measure_type: CARRIER_FREQUENCY
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 1000.0
  notes: >-
    Carrier frequency of the common recessive POLG founder alleles (p.A467T,
    p.W748S, p.G848S) reaches ~1% in several populations of European descent -
    equivalently 1000 carriers per 100,000. This is a carrier, not a disease,
    rate.
  evidence:
  - reference: PMID:17426723
    reference_title: "Abundance of the POLG disease mutations in Europe, Australia, New Zealand, and the United States explained by single ancient European founders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "They have effectively spread to populations of European descent with carrier frequencies up to 1% in several populations."
    explanation: >
      Directly reports the ~1% carrier frequency of the common recessive POLG
      alleles in European-descent populations.
- population: Finland (POLG p.W748S carriers)
  measure_type: CARRIER_FREQUENCY
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 800.0
  notes: 1 in 125 general-population carrier frequency for the p.W748S founder allele.
  evidence:
  - reference: PMID:16080118
    reference_title: "Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "with a carrier frequency in the general population of 1 : 125"
    explanation: >
      Finnish general-population carrier frequency for the p.W748S POLG allele.
treatments:
- name: Supportive and Multidisciplinary Care
  description: >
    There is no disease-modifying therapy for PEOB1. Management is supportive and
    multidisciplinary: occupational, physical and speech therapy for the myopathy,
    ataxia and dysarthria; nutritional and swallowing support; respiratory support
    where needed; and standard treatment of any epilepsy, movement, vision and
    hearing complications - subject to the valproate contraindication below.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301791
    reference_title: "POLG-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical management is largely supportive and involves standard approaches for associated complications including occupational, physical, and speech therapy; nutritional support; respiratory support"
    explanation: >
      GeneReviews specifies supportive multidisciplinary management for
      POLG-related disorders.
- name: Ptosis Surgery (Levator Advancement or Frontalis Suspension)
  description: >
    Surgical correction is the mainstay of symptomatic treatment for the ptosis of
    PEOB1, chosen according to levator excursion: levator advancement or resection
    where levator function is preserved, frontalis suspension (sling) where it is
    not. Myogenic ptosis is a particularly difficult surgical target because the
    ptosis continues to worsen and because the same mitochondrial myopathy impairs
    protective corneal mechanisms (Bell's phenomenon, orbicularis closure).
    Deliberate under-correction is therefore standard - enough to clear the visual
    axis without producing exposure keratopathy - at the cost of a high recurrence
    rate.
  treatment_term:
    preferred_term: Ophthalmologic Surgical Procedure
    term:
      id: NCIT:C15331
      label: Ophthalmologic Surgical Procedure
  therapeutic_modality: SURGERY
  target_phenotypes:
  - preferred_term: Ptosis
    term:
      id: HP:0000508
      label: Ptosis
  evidence:
  - reference: PMID:36178005
    reference_title: "A review of surgical management of progressive myogenic ptosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Surgical techniques predominantly involved levator advancement, levator resection, frontalis sling, blepharoplasty, and Fasanella-Servat."
    explanation: >
      Enumerates the surgical options used for progressive myogenic ptosis,
      including the CPEO subgroup.
  - reference: PMID:36178005
    reference_title: "A review of surgical management of progressive myogenic ptosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "However, myogenic ptosis is especially challenging as it is characterized by worsening ptosis and the loss of protective corneal mechanisms."
    explanation: >
      Explains why myogenic (mitochondrial) ptosis carries a higher surgical risk
      than other ptosis aetiologies.
  - reference: PMID:36178005
    reference_title: "A review of surgical management of progressive myogenic ptosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The goals of care with myogenic ptosis involves repairing ptosis just sufficiently to alleviate visual obstruction while avoiding adverse post-operative complications."
    explanation: >
      Establishes the deliberate-under-correction principle that governs ptosis
      surgery in mitochondrial ocular myopathy.
- name: Avoidance of Valproic Acid (Contraindicated)
  description: >
    Valproic acid (Depakene) and sodium divalproate/divalproex (Depakote) must be
    avoided in all POLG-related disorders, including PEOB1, because they can
    precipitate or accelerate liver disease and fatal hepatic failure. This is not
    a theoretical caution: in a 26-patient recessive POLG cohort, liver failure
    caused or contributed to death in eight patients, all but one of whom were on
    valproate. The risk is genotype-driven and detectable prospectively, so POLG
    genotyping should precede valproate in anyone with a suspected mitochondrial
    or unexplained epilepsy phenotype. This record is curated with negative
    valence - the intervention is withholding the drug, not administering it.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: valproic acid
      term:
        id: CHEBI:39867
        label: valproic acid
  therapeutic_modality: SMALL_MOLECULE
  evidence:
  - reference: PMID:20301791
    reference_title: "POLG-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "because of the risk of precipitating and/or accelerating liver disease"
    explanation: >
      GeneReviews lists valproic acid and sodium divalproate under
      Agents/circumstances to avoid for POLG-related disorders because of hepatic
      risk.
  - reference: PMID:16638794
    reference_title: "The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Patients with this disorder are at high risk of death from status epilepticus and from liver failure, if exposed to sodium valproate."
    explanation: >
      Direct clinical evidence of fatal valproate-associated liver failure in
      recessive POLG disease.
  - reference: PMID:21038416
    reference_title: "Polymerase gamma gene POLG determines the risk of sodium valproate-induced liver toxicity."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "These findings implicate impaired liver regeneration in VPA toxicity and show that prospective genetic testing of POLG will identify individuals at high risk of this potentially fatal consequence of treatment."
    explanation: >
      Supports pre-treatment POLG genotyping to identify patients at high risk of
      valproate hepatotoxicity.
- name: Hepatic and Anti-Seizure Medication Surveillance
  description: >
    Liver enzymes should be monitored every three months or as clinically
    indicated, and liver function retested after introduction of any new
    anti-seizure medication - the surveillance counterpart of the valproate
    contraindication.
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  evidence:
  - reference: PMID:20301791
    reference_title: "POLG-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "monitoring of liver enzymes every three months or as clinically indicated; monitoring of epilepsy with repeat liver function tests after introduction of any new anti-seizure medication."
    explanation: >
      GeneReviews surveillance recommendation for POLG-related disorders.
- name: Deoxynucleoside (dC/dT) Substrate Supplementation
  description: >
    Investigational, not standard of care. Enteral deoxycytidine plus
    deoxythymidine (dC/dT) aims to replenish the mitochondrial dNTP pool and so
    partially compensate for the reduced replication capacity of mutant
    polymerase gamma - the only curated treatment here that targets the causal
    mechanism rather than the consequences. An open-label single-arm phase 2
    trial (NCT04802707) in POLG-related disorders reported improvement in the
    Newcastle Mitochondrial Disease Scale and stable-or-falling GDF-15 at 6
    months. Important scope caveat for PEOB1: the interim cohort was children,
    six of ten with Alpers-Huttenlocher syndrome and two with ataxia-neuropathy
    spectrum, so efficacy in adult-onset recessive PEO specifically is untested.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: deoxycytidine
      term:
        id: CHEBI:15698
        label: 2'-deoxycytidine
    - preferred_term: deoxythymidine
      term:
        id: CHEBI:17748
        label: thymidine
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Impaired Mitochondrial DNA Replication
    treatment_effect: RESTORES
  evidence:
  - reference: PMID:39091670
    reference_title: "Safety and efficacy of deoxycytidine/deoxythymidine combination therapy in POLG-related disorders: 6-month interim results of an open-label, single arm, phase 2 trial."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "we assessed the safety and efficacy of combination therapy with deoxycytidine and deoxythymidine (dC/dT) in children with POLG-related disorders."
    explanation: >
      Phase 2 open-label trial of enteral dC/dT across POLG-related disorders.
      Cited PARTIAL for PEOB1 because the interim cohort was children with
      Alpers-Huttenlocher syndrome and ataxia-neuropathy spectrum, not
      adult-onset recessive PEO.
  - reference: PMID:39091670
    reference_title: "Safety and efficacy of deoxycytidine/deoxythymidine combination therapy in POLG-related disorders: 6-month interim results of an open-label, single arm, phase 2 trial."
    supports: PARTIAL
    evidence_source: HUMAN_CLINICAL
    snippet: "During the 6 months of treatment, NMDS score improved from a mean of 27.3 at baseline to 20.7 at 6 months"
    explanation: >
      Quantifies the primary efficacy signal. PARTIAL because it is an
      uncontrolled single-arm interim result in a mixed POLG cohort.
  - reference: PMID:39091670
    reference_title: "Safety and efficacy of deoxycytidine/deoxythymidine combination therapy in POLG-related disorders: 6-month interim results of an open-label, single arm, phase 2 trial."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At present, there are no effective treatments for POLG-related disorders."
    explanation: >
      Confirms that no disease-modifying therapy is established for the POLG
      spectrum, which is why the rest of this section is supportive care.
- name: Genetic Counseling
  description: >
    Autosomal recessive counselling with a 25% sib recurrence risk, carrier
    testing for at-risk relatives once the familial variants are known, and the
    option of prenatal or preimplantation genetic testing. Counselling should
    explicitly cover the valproate contraindication for heterozygous relatives,
    who are at increased risk of valproate hepatotoxicity even though they do not
    develop PEO.
  treatment_term:
    preferred_term: genetic counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:20301791
    reference_title: "POLG-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Once the POLG pathogenic variants have been identified in an affected family member, testing for at-risk family members is possible."
    explanation: >
      GeneReviews genetic counselling guidance for autosomal recessive
      POLG-related disorders.
clinical_trials:
- name: NCT04802707
  phase: PHASE_II
  description: >-
    Single-arm phase 2 trial of combined deoxycytidine (dC) and deoxythymidine
    (dT) nucleoside substrate supplementation as early treatment for
    mitochondrial DNA depletion syndromes, including POLG-related disease. The
    only interventional trial curated here that targets the mtDNA-replication
    defect underlying PEOB1 rather than its downstream consequences.
  evidence:
  - reference: clinicaltrials:NCT04802707
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In this phase II Trial a mix of Deoxynucleosides Pyrimidine (Deoxycytidine dC and Deoxythymidine dT) will be used as early treatment of MDS."
    explanation: >-
      Phase II trial of dC/dT substrate supplementation enrolling mtDNA
      maintenance/depletion disorders including POLG-related disease.
diagnosis:
- name: Molecular Diagnosis by Biallelic POLG Variants
  description: >
    Diagnosis rests on the clinical picture of progressive ptosis and external
    ophthalmoplegia (usually with a mitochondrial myopathy and neuropathy) plus
    identification of biallelic pathogenic POLG variants. Muscle biopsy showing
    ragged-red and COX-negative fibres with multiple large-scale mtDNA deletions
    supports the diagnosis and, historically, was the finding that redirected
    testing to the nuclear genome; with modern panels or exome sequencing, POLG
    sequencing often precedes biopsy. Critically, the requirement for BIALLELIC
    variants is what distinguishes PEOB1 from the autosomal dominant PEOA1, where
    a single heterozygous variant is diagnostic.
  evidence:
  - reference: PMID:20301791
    reference_title: "POLG-Related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Establishing the diagnosis of a POLG-related disorder relies on clinical findings and the identification of biallelic POLG pathogenic variants on molecular genetic testing for all phenotypes except autosomal dominant progressive external ophthalmoplegia (adPEO), for which identification of a heterozygous POLG pathogenic variant on molecular genetic testing is diagnostic."
    explanation: >
      States the biallelic requirement and explicitly contrasts it with the
      dominant form.
  - reference: PMID:21550804
    reference_title: "Relative frequency of known causes of multiple mtDNA deletions: two novel POLG mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "it is recommended to test POLG routinely in diagnostic laboratories whenever multiple mtDNA deletions are present, regardless of the age of onset of patients and their clinical phenotype"
    explanation: >
      Supports POLG sequencing as first-line whenever multiple mtDNA deletions are
      demonstrated.
differential_diagnoses:
- name: Autosomal Dominant Progressive External Ophthalmoplegia 1 (PEOA1)
  description: >
    The dominant POLG sibling disorder, caused by a single heterozygous POLG
    variant (classically p.Y955C in polymerase motif B, mapped to 15q22-q26 in the
    original Belgian pedigree). Same gene, same molecular endpoint (multiple mtDNA
    deletions), different inheritance and typically later, milder, more
    ocular-restricted disease. This is the single most important entity to keep
    distinct from PEOB1.
  evidence:
  - reference: PMID:11431686
    reference_title: "Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We mapped a new locus for dominant PEO at 15q22-q26 in a Belgian pedigree and identified a heterozygous mutation (Y955C) in the polymerase motif B of the mtDNA polymerase gamma (POLG)."
    explanation: >
      Describes the dominant POLG PEO entity, defined by a single heterozygous
      p.Y955C variant, in the same paper that identified the recessive form.
- name: SANDO / Ataxia-Neuropathy Spectrum (POLG)
  description: >
    Sensory ataxic neuropathy, dysarthria and ophthalmoparesis is caused by the
    same biallelic POLG genotypes and is arguably a phenotypic variant of
    autosomal recessive PEO rather than a separate disease - the boundary is
    clinical emphasis (neuropathy-first versus ophthalmoplegia-first), not
    mechanism.
  evidence:
  - reference: PMID:12565911
    reference_title: "Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "This is the first finding of a genetic cause of Sensory Ataxic Neuropathy, Dysarthria and Ophthalmoparesis and it implies that this disorder may actually be a variant of autosomal recessive progressive external ophthalmoplegia."
    explanation: >
      Explicitly proposes SANDO as a variant of autosomal recessive PEO, defining
      the boundary problem between the two entries.
- name: Alpers-Huttenlocher Syndrome and MIRAS (POLG)
  description: >
    The early-onset (hepatocerebral, intractable epilepsy) and ataxia-predominant
    ends of the same POLG continuum. They share the p.A467T and p.W748S founder
    alleles with PEOB1, so genotype does not separate them; age of onset and organ
    emphasis do.
  evidence:
  - reference: PMID:16621917
    reference_title: "Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "POLG1 mutations cause an overlapping clinical spectrum of disease with both dominant and recessive modes of inheritance."
    explanation: >
      Establishes the overlapping-spectrum framing that makes these entities
      differential diagnoses of one another.
- name: Other Nuclear mtDNA Maintenance Disorders (TWNK, RRM2B, SLC25A4, TYMP)
  description: >
    Other nuclear genes produce PEO with multiple mtDNA deletions - TWNK (the
    replicative helicase; formerly C10orf2/PEO1), RRM2B, SLC25A4/ANT1, and TYMP
    (MNGIE). POLG accounts for roughly half of cases, so a negative POLG result
    should prompt testing of the rest of the panel.
  evidence:
  - reference: PMID:21550804
    reference_title: "Relative frequency of known causes of multiple mtDNA deletions: two novel POLG mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Diseases affecting mtDNA stability, termed nuclear-mitochondrial intergenomic communication disorders, are caused by a primary nuclear gene defect resulting in multiple mtDNA deletions."
    explanation: >
      Frames the class of nuclear mtDNA maintenance disorders within which POLG
      accounted for 48% of cases in this cohort.
- name: Single Large-Scale mtDNA Deletion Syndromes (CPEO, Kearns-Sayre)
  description: >
    Sporadic PEO and Kearns-Sayre syndrome are caused by a SINGLE clonal
    large-scale mtDNA deletion arising in the germline or early embryogenesis,
    with no nuclear-gene lesion and negligible recurrence risk. Distinguishing
    single from multiple deletions on muscle mtDNA analysis is the decisive step.
  evidence:
  - reference: PMID:28695364
    reference_title: "Revisiting mitochondrial ocular myopathies: a study from the Italian Network."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Among the 722 patients with a definite genetic diagnosis, ocular myopathy was observed in 399 subjects (55.3%) and was positively associated with mtDNA single deletions and POLG mutations."
    explanation: >
      Shows that both single mtDNA deletions and POLG mutations converge on the
      ocular myopathy phenotype, which is why they must be separated
      molecularly.
discussions:
- discussion_id: peob1_extraocular_selectivity_gap
  prompt: >-
    Why are the extraocular muscles and levator palpebrae superioris the earliest
    and most severely affected tissue in POLG-related recessive PEO, when the
    POLG defect is present in every cell?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#Selective Extraocular and Levator Muscle Vulnerability
  rationale: >-
    Extraocular muscle carries a threefold higher burden of COX-deficient fibres
    than limb muscle in CPEO patients, and accumulates somatic mtDNA deletions
    faster during normal ageing. Candidate explanations - a lower heteroplasmy
    threshold, a faster deletion generation rate, more permissive clonal
    expansion, lower mitophagy efficiency, or fibre-type-specific mitochondrial
    fusion dynamics - have not been discriminated. This matters because the
    tissue-selectivity, not the enzymology, is what makes PEO a distinct clinical
    entity from the other POLG phenotypes carrying the same alleles.
  proposed_experiments:
  - experiment_id: peob1_single_fibre_threshold_mapping
    name: Single-fibre heteroplasmy threshold mapping across muscle groups
    description: >-
      Measure single-fibre mtDNA deletion load and the heteroplasmy threshold for
      COX negativity in extraocular, levator palpebrae and limb muscle from the
      same POLG-mutant donor, to test whether extraocular selectivity reflects a
      lower threshold or a faster accumulation rate.
  - experiment_id: peob1_fibre_type_mitophagy_imaging
    name: Fibre-type-resolved mitophagy and mitochondrial dynamics imaging
    description: >-
      Compare mitophagy flux and mitochondrial fusion/fission dynamics across
      fibre types in human extraocular versus limb muscle, to test the
      quality-control-capacity explanation for selective vulnerability.
  evidence:
  - reference: PMID:33057669
    reference_title: "Extraocular Muscle Reveals Selective Vulnerability of Type IIB Fibers to Respiratory Chain Defects Induced by Mitochondrial DNA Alterations."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Therefore, our results showing that type IIB fibers in EOMs are affected earlier and more extensively (see Figs. 3A, 3B, 3E), suggest that these fibers might either have a faster rate of mitochondrial DNA deletion accumulation, clonal expansion, or a lower threshold compared to the other fiber types."
    explanation: >
      Explicitly leaves the three candidate mechanisms unresolved.
- discussion_id: peob1_genotype_phenotype_modifier_gap
  prompt: >-
    What determines whether a given recessive POLG genotype - most starkly,
    p.A467T homozygosity - presents as late-onset PEO rather than as
    Alpers-Huttenlocher syndrome or MIRAS?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#POLG Catalytic and Proofreading Deficiency
  rationale: >-
    68 p.A467T homozygotes across eight centres span essentially the entire POLG
    phenotypic spectrum, and clinical presentation clusters within sibships,
    implying heritable modifiers. Yet a genome-directed search within POLG and its
    flanking regulatory regions, and in POLG2, TWNK/PEO1 and ANT1, found no
    correlating nuclear variant. The only signal identified was mitochondrial DNA
    haplogroup U, which was protective against epilepsy. So the modifiers that
    decide a PEO versus an Alpers presentation remain unidentified, and this is
    the central unsolved problem of POLG nosology - it is also why PEOB1 cannot
    be predicted from genotype alone.
  proposed_experiments:
  - experiment_id: peob1_genome_wide_modifier_scan
    name: Genome-wide modifier scan in phenotype-discordant POLG homozygotes
    description: >-
      Run an unbiased genome-wide (rather than candidate-gene) modifier scan in
      large sibship-matched cohorts of p.A467T homozygotes stratified by
      presentation (PEO versus Alpers versus ataxia-neuropathy).
  - experiment_id: peob1_tissue_mtdna_copy_number_profiling
    name: Tissue-resolved mtDNA copy number and deletion-load profiling
    description: >-
      Profile tissue-specific mtDNA copy number and deletion load across
      presentations to test whether the phenotype tracks a quantitative
      replication-capacity threshold rather than a discrete modifier allele.
  evidence:
  - reference: PMID:23250882
    reference_title: "What is influencing the phenotype of the common homozygous polymerase-gamma mutation p.Ala467Thr?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Interestingly, the clinical presentation was similar in siblings, implying a genetic basis for the phenotypic variability amongst homozygotes. However, the p.Ala467Thr allele was present on a shared haplotype in each affected individual, and there was no correlation between the clinical presentation and genetic variants in any of the analysed nuclear genes."
    explanation: >
      Documents both the evidence for a genetic modifier and the failure of the
      candidate-gene search to find one.
  - reference: PMID:23250882
    reference_title: "What is influencing the phenotype of the common homozygous polymerase-gamma mutation p.Ala467Thr?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our results suggest that the mitochondrial DNA background plays an important role in modifying the disease phenotype but nuclear modifiers, epigenetic and environmental factors may also influence the severity of disease."
    explanation: >
      States the residual uncertainty about which class of modifier dominates.
- discussion_id: peob1_compound_heterozygote_dominant_negative
  prompt: >-
    Is the excess severity of p.A467T/p.W748S compound heterozygotes a true
    dominant-negative interaction between the two mutant Pol-gamma-A subunits, or
    simply the additive effect of two partially-overlapping catalytic defects?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - pathophysiology#POLG Catalytic and Proofreading Deficiency
  rationale: >-
    Compound heterozygotes have significantly shorter survival than homozygotes
    for either allele, which is not what a simple additive loss-of-function model
    predicts. A dominant-negative mechanism was proposed but has not been tested
    biochemically - Pol gamma functions as a heterotrimer, so a poisoned-complex
    model is plausible but unproven. Resolving this would change how
    compound-heterozygote prognosis is counselled.
  proposed_experiments:
  - experiment_id: peob1_mixed_subunit_polgamma_reconstitution
    name: Mixed-subunit Pol gamma reconstitution assay
    description: >-
      Reconstitute heterotrimeric Pol gamma with mixed A467T and W748S catalytic
      subunits in vitro and compare polymerase activity and processivity against
      each homomeric mutant, to test for a poisoned-complex (dominant-negative)
      effect.
  - experiment_id: peob1_genotype_stratified_deletion_load
    name: Genotype-stratified muscle mtDNA deletion load comparison
    description: >-
      Compare mtDNA deletion load and copy number in matched skeletal muscle from
      compound-heterozygote versus homozygote patients.
  evidence:
  - reference: PMID:16638794
    reference_title: "The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Compound heterozygotes have a significantly more severe phenotype raising the possibility of a dominant negative effect."
    explanation: >
      Raises the dominant-negative hypothesis without testing it.
notes: >
  Naming and scope. This entry is specifically MONDO:0009783 / OMIM:258450 -
  progressive external ophthalmoplegia with mitochondrial DNA deletions,
  AUTOSOMAL RECESSIVE 1 (PEOB1, arPEO). It is NOT the autosomal dominant sibling
  PEOA1, and it is deliberately kept distinct from the neighbouring POLG entry
  already in dismech (Sensory Ataxic Neuropathy, Dysarthria, and Ophthalmoparesis
  = MONDO:0011835). The POLG spectrum is a genuine continuum and the boundaries
  between PEOB1, SANDO, MIRAS/ataxia-neuropathy spectrum and
  Alpers-Huttenlocher syndrome are clinical rather than mechanistic; the
  differential_diagnoses section records this explicitly rather than pretending
  the entities are cleanly separable.

  Histopathology term binding. The four histopathology findings carry no
  finding_term because the HistopathologyFindingTerm range is rooted in the NCIT
  Histopathology Result branch, which has no classes for ragged-red fibres,
  COX-negative fibres, or multiple mtDNA deletions. The corresponding HP terms
  (HP:0003200, HP:0003688, HP:0003557, HP:0003689) are bound on the matching
  phenotype entries instead, so the ontology coverage is not lost.

  Frequency bands. No frequency value is asserted on any phenotype in this
  entry. The available literature on recessive POLG PEO consists of small series
  and mixed-phenotype cohorts in which the denominator is either the whole POLG
  spectrum or all multiple-deletion patients, not PEOB1. Per
  docs/frequency-evidence-guidelines.md, omitting the band is preferred to
  fabricating one.

  Prevalence. There is no PEOB1-specific population prevalence estimate. The
  curated records give an upper-bound class-level figure for all nuclear-gene
  adult mitochondrial disease plus founder-allele carrier frequencies, each
  labelled in notes so they are not mistaken for a disease rate. The POLG
  diagnostic yield among patients with multiple mtDNA deletions (48%,
  PMID:21550804) is a conditional diagnostic probability rather than a
  population rate and is therefore recorded under genetic and histopathology
  rather than as a prevalence record.

📚

References & Deep Research

References

1

PMID:20301791

POLG-Related Disorders.

No top-level findings curated for this source.

Deep Research

2

Claude Code ▸

Autosomal Recessive Progressive External Ophthalmoplegia 1 (PEOB1) — Comprehensive Research Report

claude-haiku-4-5-20251001, claude-sonnet-5 23 citations 2026-07-31T16:27:08.515492

Autosomal Recessive Progressive External Ophthalmoplegia 1 (PEOB1) — Comprehensive Research Report

1. Disease Information

Overview. Autosomal recessive progressive external ophthalmoplegia with mitochondrial DNA deletions, type 1 (PEOB1) is a mitochondrial DNA-maintenance disorder caused by biallelic (homozygous or compound heterozygous) pathogenic variants in POLG, the nuclear gene encoding the catalytic subunit of mitochondrial DNA polymerase gamma (Pol γA). It is a chronic, typically adult-onset (>40 years) disease defined by progressive weakness of the extraocular muscles (bilateral ptosis and diffuse, symmetric ophthalmoparesis), exercise intolerance, and the presence of multiple mitochondrial DNA (mtDNA) deletions in skeletal muscle. PEOB1 sits within the broader "POLG-related disorders" spectrum, which ranges from the fatal infantile Alpers-Huttenlocher syndrome to the comparatively benign late-onset autosomal recessive PEO described here (Van Goethem et al., Nat Genet 2001, PMID not directly retrieved but DOI 10.1038/90034; OMIM #258450).

Key identifiers: - OMIM: #258450 — "Progressive External Ophthalmoplegia with Mitochondrial DNA Deletions, Autosomal Recessive 1; PEOB1" (gene-disease relationship: POLG, OMIM 174763, chromosome 15q26.1) - Gene: POLG (HGNC:9179), also historically POLG1 - Orphanet: ORPHA:254886 — "Autosomal recessive progressive external ophthalmoplegia" - MONDO: the umbrella MONDO term for this entity should be cross-checked against MONDO's POLG-PEO recessive class (searchable via OLS/MONDO as "progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 1") - MeSH: Ophthalmoplegia, Chronic Progressive External (D029231); Mitochondrial Diseases (D028361) - ICD-10: H49.4 (Progressive external ophthalmoplegia); G71.3 (Mitochondrial myopathy, NEC) is sometimes used for the systemic phenotype - GeneReviews: "POLG-Related Disorders" (NCBI Bookshelf NBK26471) - GTR condition:* C1850303 (autosomal recessive PEO)

Synonyms: PEOB1; Ophthalmoplegia, progressive external, autosomal recessive, with mitochondrial DNA deletions; arPEO; CPEO (chronic progressive external ophthalmoplegia) — note CPEO is the broader clinical umbrella term, not gene-specific; POLG-related PEO (recessive form); mitochondrial DNA depletion syndrome 4 nomenclature overlaps in some databases with the more severe POLG spectrum entries (Alpers syndrome, MCHS, SANDO/MIRAS) which share the same causal gene but different allele combinations.

Evidence base: Predominantly derived from aggregated case series, multi-center cohort studies (e.g., the 155-patient Hikmat et al. 2020 cohort, J Inherit Metab Dis, PMID 32068908), disease-level curated resources (OMIM, Orphanet, GeneReviews), and individual case reports — not large-scale EHR-based epidemiology, reflecting the disease's rarity.

2. Etiology

Disease causal factor: PEOB1 is a monogenic, purely genetic disease. It requires biallelic pathogenic variants in POLG (chr15q26.1), which abolish or severely impair the catalytic and/or proofreading (3′→5′ exonuclease) activity of the mitochondrial DNA polymerase, the sole DNA polymerase responsible for replicating the mitochondrial genome. There is no known environmental, infectious, or purely mechanistic (non-genetic) cause of this specific PEOB1 entity — although "environmental" or "gene-environment" stressors (below) can modulate disease severity or unmask latent POLG dysfunction.

Genetic risk factors: - Two pathogenic POLG alleles are required (true autosomal recessive; heterozygous carriers are asymptomatic or rarely mildly symptomatic). - Founder/common pathogenic variants: - c.1399G>A (p.Ala467Thr) — the single most common recessive POLG pathogenic allele; accounts for roughly 31–45% of mutant alleles in some European cohorts; gnomAD overall frequency ≈0.051% (143/282,888 alleles), rising to ≈0.098% in non-Finnish Europeans; population genetics studies (Chinnery et al./Rajakulendran, EJHG 2007) trace it to single ancient European founders. - c.2243G>C (p.Trp748Ser) — very common, frequently found in cis/trans with A467T as a compound "haplotype" allele; individually associated with more severe recessive phenotypes when combined with a second severe allele. - c.2542G>A (p.Gly848Ser) — a third recurrent founder variant, often reported in seizure-associated POLG phenotypes. - Combined carrier frequency for these founder alleles reaches ~1% in some European-descent populations (Rajakulendran et al., Eur J Hum Genet 2016). - Genotype-phenotype correlation: Variants located in the polymerase (Pol) domain (including the classic Y955C originally identified by Van Goethem et al. 2001) tend to produce more severe phenotypes when biallelic; variants in the linker region are typically associated with milder, later-onset PEO. Homozygous or compound heterozygous combinations involving at least one "severe" allele generally shift phenotype toward the ataxia-neuropathy spectrum (MIRAS/SANDO) or earlier-onset Alpers-like disease, while combinations of milder proofreading-domain alleles (e.g., A467T with another mild allele) are more likely to present as isolated late-onset PEO. - Modifier/susceptibility genes: No confirmed nuclear modifier genes for PEOB1 specifically; mtDNA haplogroup background has been proposed as a modifier of mitochondrial disease severity generally but is not established for POLG-PEO. - Digenic/oligogenic interaction: Not established for PEOB1 — this is a single-locus recessive disorder (distinguish from the broader class of "multiple mtDNA deletion disorders," MDMDs, caused by ≥20 different nuclear genes including TWNK, RRM2B, DGUOK, SLC25A4/ANT1, OPA1, MGME1, RNASEH1, TK2, TOP3A, DNA2 — genetically heterogeneous phenocopies, not modifiers of POLG-PEO itself).

Protective factors: No established genetic or environmental protective factors specific to PEOB1. General mitochondrial-supportive measures (aerobic exercise, avoidance of mitochondrial toxins) are supportive/management-oriented rather than disease-preventive (see Treatment/Prevention).

Environmental/gene-environment interaction — the critical clinical interaction: - Valproic acid (sodium valproate) is an absolute contraindication in any POLG-related disorder, including PEOB1. Valproate is metabolized via mitochondrial β-oxidation and can precipitate acute, sometimes fatal, hepatic failure in POLG-mutant patients — a well-documented gene-drug interaction (Stewart et al., Lancet Neurol 2010, and cautionary statements throughout GeneReviews). This is the single most important gene-environment interaction to flag clinically. - Other mitochondrial toxins (e.g., certain antiretrovirals affecting mtDNA polymerase, aminoglycosides affecting mitochondrial translation) are theoretically relevant to worsening mitochondrial reserve but are not disease-causal. - Physiologic stress (fasting, intercurrent infection, surgery) is reported anecdotally to unmask or worsen symptoms in POLG disease broadly, consistent with reduced mitochondrial energetic reserve, though this is best documented in the early-onset/Alpers phenotypes rather than isolated arPEO.

3. Phenotypes

Core/defining phenotypes

Phenotype	Type	Suggested HPO term
Bilateral ptosis	Clinical sign	HP:0000508 (Ptosis)
Progressive external ophthalmoplegia / ophthalmoparesis	Clinical sign	HP:0000590 (Ophthalmoplegia) / HP:0000602 (Ophthalmoparesis)
Exercise intolerance	Symptom	HP:0003546 (Exercise intolerance)
Proximal/generalized skeletal muscle weakness	Clinical sign	HP:0003701 (Proximal muscle weakness) / HP:0001324 (Muscle weakness)
Muscle atrophy	Clinical sign	HP:0003202 (Skeletal muscle atrophy)

Additional/variable manifestations (PEO-"plus" features)

Phenotype	Type	Suggested HPO term
Sensory axonal peripheral neuropathy	Clinical sign	HP:0003390 (Aplasia/Hypoplasia... ) — better: HP:0007141 (Axonal (sensory) neuropathy)
Cerebellar ataxia	Clinical sign	HP:0001251 (Ataxia)
Dysarthria	Clinical sign	HP:0001260 (Dysarthria)
Sensorineural hearing loss	Clinical sign	HP:0000407 (Sensorineural hearing loss)
Cataracts	Clinical sign	HP:0000518 (Cataract)
Depression / psychiatric symptoms	Behavioral	HP:0000716 (Depression)
Hypogonadism	Clinical sign	HP:0000135 (Hypogonadism)
Parkinsonism	Clinical sign	HP:0001300 (Parkinsonism)
Mitral valve prolapse	Clinical sign	HP:0001634 (Mitral valve prolapse)
Cardiomyopathy	Clinical sign	HP:0001638 (Cardiomyopathy)
Gastrointestinal dysmotility	Clinical sign	HP:0002015 (Dysphagia) / HP:0002251 (Aganglionic megacolon) not exact — general GI dysmotility phenotype
Elevated CSF/serum lactate	Laboratory abnormality	HP:0002151 (Increased serum lactate)
Ragged red fibers on biopsy	Laboratory/histopathology	HP:0003200 (Ragged-red muscle fibers)
COX-negative (cytochrome c oxidase-deficient) fibers	Laboratory/histopathology	HP:0033279 or related mitochondrial myopathy histology term (verify via OAK)

Onset: Classic PEOB1/arPEO manifests typically after age 40 (late-onset category in the POLG age-of-onset classification), though earlier presentations occur, especially with more severe allele combinations that push the phenotype toward the juvenile/adult ataxia-neuropathy spectrum (12–40 years) or, rarely, earlier.

Severity/progression: Progressive and generally slow. In the Hikmat et al. 2020 cohort (J Inherit Metab Dis, PMID 32068908) analyzing 155 POLG-disease patients stratified by age of onset: - Late-onset disease (>40 y): ptosis (95%), PEO (89%), ataxia (58%), peripheral neuropathy (65%) — this group has the best overall prognosis among the three age strata. - Juvenile/adult-onset (12–40 y): ataxia (90%), peripheral neuropathy (84%), seizures (71%), stroke-like episodes (54%). - Early-onset (<12 y): hepatopathy (87%), seizures (84%), feeding difficulties (84%), hypotonia (79%) — worst prognosis. - Across the whole POLG spectrum: neurological (90%), ophthalmological (74%), and gastrointestinal (63%) features predominate overall.

Many patients initially diagnosed with "isolated" arPEO develop additional systemic/neurological features (ataxia, neuropathy) over years to decades — GeneReviews explicitly cautions that "progressive PEO without systemic involvement" as a static label requires caution, since longitudinal follow-up frequently reveals evolution toward the ataxia-neuropathy spectrum (MIRAS/SANDO).

Frequency of PEO/ptosis in the general POLG-mutant population: Ptosis in ~34% (51/149) and PEO in ~38% (56/146) of a broader all-ages POLG cohort, rising to >90% when restricted to the late-onset stratum — illustrating strong age-dependence of the phenotype-frequency relationship (cite Hikmat 2020 stratified data above).

Quality of life impact: Ptosis and ophthalmoparesis cause functional visual impairment (chin-up head posture to see under ptotic lids, diplopia less common than in myasthenia because weakness is typically symmetric), corneal exposure risk after ptosis surgery, and exercise intolerance limits activities of daily living; neuropathy and ataxia (when present) contribute to gait disability and falls risk. No disease-specific validated QOL instrument was identified in this search; general neuromuscular-disease QOL tools (SF-36, individualized) are used in the small POLG literature.

4. Genetic/Molecular Information

Causal gene: POLG (OMIM 174763; HGNC:9179; chromosome 15q26.1), encoding the 140-kDa catalytic α-subunit of the heterotrimeric mitochondrial DNA polymerase γ holoenzyme (Pol γA + a dimeric Pol γB accessory subunit encoded by POLG2*). POLG is the sole DNA polymerase responsible for mtDNA replication and repair.

Variant classification and type: - Pathogenic variants span missense (majority, especially the recurrent founder alleles), nonsense, frameshift, splice-site, and rare small in-frame indels; large deletions/duplications are uncommon (~5% detection by dosage analysis per GeneReviews). - Structurally, POLG has three key functional domains: the N-terminal exonuclease (proofreading) domain, a linker region (contains the "spacer" and thumb subdomains, binds POLG2), and the C-terminal polymerase domain. Mutation location correlates loosely with mechanism and severity: - Exonuclease-domain mutations impair 3′→5′ proofreading, increasing point-mutation rate and promoting deletion formation. - Polymerase-domain mutations (e.g., the original Y955C) impair nucleotide incorporation/catalysis directly. - Linker-domain mutations (where A467T and W748S lie) can impair holoenzyme processivity/stability and POLG2 interaction. - ACMG classification: A467T, W748S, and G848S are all classified pathogenic in ClinVar for POLG-related spectrum disorders (multiple submitters); many rarer POLG variants remain VUS pending functional/segregation data.

Population/allele frequency: - p.Ala467Thr (c.1399G>A): gnomAD ~0.051% overall, ~0.098% in non-Finnish Europeans; the most common recessive pathogenic POLG allele (reported in at least 52 patients in aggregate case literature, 15 homozygous, 37 compound heterozygous, per ClinVar aggregation). - These founder mutations are traced to ancient single European founder haplotypes (Rajakulendran et al., Eur J Hum Genet 2007/2016 lineage of studies), explaining their spread across Europe, Australia, New Zealand, and the US in populations of European descent. - Carrier frequency for POLG pathogenic variants collectively approaches ~1% in some European-ancestry cohorts (relevant to ACMG carrier-screening panel design, per the 2024 gnomAD carrier-frequency estimation study, PMID 38459613).

Somatic vs. germline: PEOB1 pathogenic variants are germline. However, the disease mechanism itself operates through secondary somatic mtDNA mutagenesis: the germline nuclear POLG defect causes accumulation of somatic, clonally expanded mtDNA deletions in postmitotic tissues (especially skeletal and extraocular muscle) over the patient's lifetime — a form of accelerated somatic mitochondrial genome instability driven by a germline nuclear lesion.

Functional consequence: Loss of function / hypomorphic — reduced polymerase fidelity and/or reduced exonuclease proofreading activity, and/or reduced holoenzyme processivity, leading to (a) increased point mutation rate in mtDNA, (b) stalling of replication forks, and (c) accumulation of large-scale mtDNA deletions, ultimately (d) mtDNA depletion in severe cases. Nature Communications work (Basu et al., Nat Commun 2018, PMID 30089853 area) demonstrated that POLG's exonuclease activity is required for rapid degradation of linear mtDNA fragments generated during replication/repair; loss of this activity allows persistence of fragments and increases formation of deletions via non-homologous end joining or microhomology-mediated repair of stalled/broken replication intermediates.

Modifier genes: None firmly established for POLG-PEO specifically. POLG2 (the accessory subunit gene) causes a phenotypically overlapping but genetically and functionally distinct autosomal dominant PEO (PEOA5) and is mechanistically linked (holoenzyme partner) but is not a modifier of POLG1-driven PEOB1.

Epigenetic information: No POLG-PEO-specific DNA methylation, histone modification, or chromatin signature has been established in the literature surveyed; this is not a primary disease mechanism for a structural/catalytic enzyme defect of this kind. Not applicable/not identified.

Chromosomal abnormalities: Not applicable — PEOB1 is caused by point mutations/small indels in POLG, not by large chromosomal rearrangements. (Contrast with the mtDNA-deletion disorder Kearns-Sayre syndrome, which involves a single large mtDNA deletion, not nuclear chromosomal abnormality.)

5. Environmental Information

Environmental factors: No toxin, radiation, or pollutant exposure is established as disease-causal for PEOB1 (it is monogenic). The dominant environmentally-modifiable risk is iatrogenic: valproic acid exposure, which can precipitate acute liver failure in POLG-mutant individuals (see Etiology/Gene-Environment above) — this is the most clinically actionable environmental factor for the entire POLG-disease spectrum, including arPEO.
Lifestyle factors: Aerobic exercise has evidence (in the Polg "mutator" mouse model) of attenuating the progeroid/mitochondrial-dysfunction phenotype, and is used clinically as a supportive, not preventive, intervention in human mitochondrial myopathy generally; specific human PEOB1 exercise-outcome trial data were not identified in this search.
Infectious agents: Not applicable — PEOB1 is not an infectious disease. Intercurrent infections/febrile illness may act as nonspecific metabolic stressors that unmask or worsen symptoms in POLG disease broadly (most documented in early-onset phenotypes), analogous to metabolic decompensation patterns in other mitochondrial diseases, but this is not a primary causal factor.

6. Mechanism / Pathophysiology

Causal chain (initial trigger → clinical manifestation):

Molecular trigger: Biallelic POLG pathogenic variants reduce the catalytic fidelity, proofreading (exonuclease) activity, and/or processivity of the Pol γ holoenzyme (GO:0006261, DNA-templated DNA replication; GO:0004674 or more precisely GO:0003887 DNA-directed DNA polymerase activity; GO:0008310, single-stranded DNA 3'-5' exodeoxyribonuclease activity for the exonuclease domain).
Replication stalling and mtDNA instability: Defective Pol γ causes replication fork stalling and generates persistent linear mtDNA fragments; because the exonuclease activity that normally degrades these fragments is impaired, they persist and are aberrantly repaired, generating large-scale mtDNA deletions (somatic, clonally expanded within individual cells/fibers over years). In some genotypes, replication failure instead causes mtDNA depletion (reduced copy number) rather than deletions — genotype-dependent branch point (relevant to the broader POLG spectrum, e.g., Alpers phenotype is depletion-dominant while adult PEO is deletion-dominant).
Cellular consequence: Clonal expansion of deleted mtDNA molecules within individual postmitotic muscle fibers over decades reaches a pathogenic threshold, causing focal cytochrome c oxidase (Complex IV) deficiency (mtDNA-encoded subunits of Complexes I, III, IV, and ATP synthase are lost from deleted genomes) — the classic "COX-negative, SDH-hyperreactive (ragged-red/ragged-blue) fiber" seen on histochemistry (GO cellular component: GO:0005739 mitochondrion; GO:0005743 mitochondrial inner membrane; relevant biological process GO:0006123, mitochondrial electron transport, cytochrome c to oxygen).
Tissue-level consequence: Oxidative phosphorylation (OXPHOS) failure in a mosaic pattern of affected fibers leads to a bioenergetic deficit that is most clinically apparent in tissues with high, continuous energy/mtDNA-turnover demand and long-lived postmitotic cells — extraocular muscle is exquisitely susceptible (thought to reflect its very high mitochondrial content, tonic/high-frequency firing pattern, and high mtDNA turnover), explaining the near-universal, early involvement of eyelid levator and extraocular muscles.
Organism-level manifestation: Progressive extraocular and skeletal myopathy (ptosis, ophthalmoparesis, exercise intolerance, proximal weakness), and — as the somatic mutation burden and clinical spectrum expand — peripheral nerve (axonal sensory neuropathy), cerebellar (ataxia), auditory (sensorineural hearing loss), lens (cataract), cardiac conduction/muscle, gonadal, and CNS (depression, parkinsonism) involvement in a subset of patients, reflecting variably penetrant multi-organ mosaic mtDNA deletion burden.

Cell types involved: Skeletal/extraocular myocyte (CL:0000192 smooth muscle cell is wrong — correct: CL:0000188 skeletal muscle myoblast / mature skeletal muscle fiber; extraocular myocyte has no distinct CL term but can be annotated as CL:0008002 skeletal muscle fiber, UBERON-localized to extraocular muscle), peripheral sensory neuron (CL:0000101 sensory neuron), Purkinje/cerebellar neurons (CL:0000121 Purkinje cell) in ataxia-affected patients, cochlear hair cells (CL:0000201/CL:0000202) in hearing-loss-affected patients, lens epithelial cells in cataract.

Biochemical abnormality: Impaired mitochondrial DNA polymerase (POLG) fidelity/processivity → downstream OXPHOS enzyme complex deficiency (particularly Complex I and IV, whose subunits are partly mtDNA-encoded) → impaired ATP synthesis and elevated lactate/pyruvate (common but not universal laboratory finding).

Molecular/cellular process ontology suggestions: - GO:0006264 mitochondrial DNA replication - GO:0032042 mitochondrial DNA metabolic process - GO:0006281 DNA repair - GO:0007005 mitochondrion organization - GO:0006123 mitochondrial electron transport, cytochrome c to oxygen (Complex IV deficiency downstream effect)

Omics/advanced technologies: No large-scale transcriptomic, proteomic, or single-cell datasets specific to PEOB1 human tissue were identified in this search (reflecting rarity of biobanked tissue); most molecular characterization comes from muscle biopsy histochemistry/EM plus targeted biochemical/enzymatic assays of respiratory chain complexes, and from model-system (mouse, zebrafish, yeast) omics rather than direct human multi-omics profiling.

7. Anatomical Structures Affected

Organ level: - Primary: Extraocular muscles (levator palpebrae superioris, medial/lateral/superior/inferior recti, obliques) — UBERON:0002031 (extraocular muscle) / more general UBERON:0001772 (obturator... not relevant) — extraocular muscle is the primary UBERON target; specifically the levator palpebrae superioris (UBERON:0011343-adjacent structures should be verified via OAK). - Secondary: Skeletal (limb-girdle/proximal) muscle (UBERON:0001134, skeletal muscle tissue); peripheral nervous system (peripheral nerve, UBERON:0000010); cerebellum (UBERON:0002037) in ataxia-affected patients; inner ear/cochlea (UBERON:0001846) in hearing loss; lens (UBERON:0000965) in cataract; heart (UBERON:0000948) in the subset with cardiomyopathy/mitral valve prolapse; gonads (testis UBERON:0000473 / ovary UBERON:0000992) in hypogonadism; gastrointestinal tract (UBERON:0005409) in dysmotility. - Body systems: Neuromuscular (primary), nervous system (peripheral and central), special senses (visual — via extraocular myopathy and via cataract; auditory), cardiovascular, endocrine (gonadal), digestive.

Tissue/cell level: Skeletal/extraocular muscle fibers (mosaic COX-deficient, ragged-red fibers); peripheral sensory axons (axonal, not demyelinating, sensory neuropathy predominant); cerebellar Purkinje and granule cell circuitry.

Subcellular level: Mitochondria broadly (GO:0005739); specifically the mitochondrial matrix (GO:0005759, site of mtDNA and the replisome) and mitochondrial nucleoid (GO:0042645, mitochondrial nucleoid — the mtDNA-protein complex where Pol γ operates).

Localization/laterality: Ophthalmoplegia is characteristically bilateral and symmetric (a key distinguishing feature from myasthenia gravis, which is often asymmetric/fluctuating) — ptosis and ocular motility restriction affect both eyes in a diffuse, non-fatigable pattern.

8. Temporal Development

Onset: Classic PEOB1 = late-onset, typically after age 40 years (GeneReviews). Earlier presentations (juvenile/adult-onset, 12–40 y) occur with more severe allele combinations and blend into the ataxia-neuropathy spectrum (MIRAS/SANDO); onset before age 12 is atypical for "pure" arPEO and instead characterizes the more severe POLG phenotypes (Alpers-Huttenlocher, MCHS).
Onset pattern: Insidious/gradual — patients frequently do not notice the earliest, mild ptosis/ophthalmoparesis and are often diagnosed years after first symptoms, sometimes after being misdiagnosed with myasthenia gravis.
Progression: Slowly progressive over years to decades. Ptosis and ophthalmoparesis worsen gradually; additional features (neuropathy, ataxia, hearing loss, cataract) may accrue over the disease course, particularly in patients followed longitudinally rather than assessed cross-sectionally.
Disease course: Chronic, lifelong, non-remitting — no spontaneous remission is described. Unlike myasthenia gravis, there is no fluctuation or fatigability pattern.
Prognosis by age-of-onset stratum: Late-onset (arPEO) disease has the best prognosis of the three POLG age strata; overall survival is far more favorable than early-onset (infantile hepatocerebral/Alpers) or juvenile/adult-onset (epilepsy/stroke-like-episode-dominant) POLG disease, where survival correlates strongly with age at onset of seizures/liver disease (median survival 0.7 years when epilepsy onset is in the first 3 years of life vs. median 18.0 years when epilepsy onset is after age 16; liver involvement is an independent poor-prognostic marker) (Hikmat et al., 2020; Cohen/Naviaux natural history studies).
Critical periods: None specifically described for the adult-onset arPEO phenotype; by contrast, early recognition and valproate avoidance is critical at any age given the risk of fulminant hepatic failure if a POLG-mutant patient (of any phenotype) is inadvertently exposed.

9. Inheritance and Population

Epidemiology: PEO as a clinical syndrome overall has no precisely established population prevalence (Orphanet notes "prevalence unknown"). It is grouped among ultra-rare Mendelian mitochondrial disorders; a closely related entity (childhood-onset autosomal recessive myopathy with external ophthalmoplegia) is documented at <1/1,000,000. POLG-related disorders overall are estimated (from carrier-frequency modeling) to have a combined genetic prevalence on the order of ~1 in several thousand to ~1 in 10,000+ depending on population and specific phenotype, but PEOB1 specifically (the late-onset, comparatively mild recessive PEO subset) has no dedicated incidence/prevalence figure identified in this search.

Inheritance pattern: Autosomal recessive (biallelic POLG pathogenic variants required). Note that POLG is also independently a cause of autosomal dominant PEO (PEOA1, heterozygous variant sufficient) — the same gene causes phenotypically similar disease under different zygosity/allele-severity combinations, and recessive disease is generally more severe than the dominant form (per Orphanet/OMIM). - Penetrance: Complete for biallelic pathogenic genotypes, though age-dependent (symptoms emerge progressively rather than being present from birth) — effectively full penetrance by later adulthood for the classic late-onset genotype combinations. - Expressivity: Highly variable, both between and within families with the same genotype — even patients homozygous for the same founder allele can show a spectrum from isolated PEO to full ataxia-neuropathy-spectrum disease, indicating stochastic somatic mtDNA deletion accumulation contributes to phenotypic variability beyond genotype alone. - Anticipation: Not described — POLG disease does not follow a repeat-expansion anticipation mechanism. - Germline mosaicism: Not specifically documented for POLG in the literature surveyed. - Founder effects: Strong — A467T, W748S, and G848S are all traceable European founder alleles (see Etiology/Genetic risk factors), giving PEOB1/POLG-spectrum disease its comparatively higher (for a "rare disease") carrier frequency in European-ancestry populations relative to many other ultra-rare recessive mitochondrial disorders. - Consanguinity: As with any autosomal recessive disorder, consanguineous unions increase risk, particularly for rarer non-founder POLG alleles; not specifically quantified for PEOB1 in this search. - Carrier frequency: Combined POLG pathogenic-variant carrier frequency approaches ~1% in some European-ancestry cohorts (dominated by A467T); this is unusually high for a recessive disease of this severity and is explained entirely by founder effects rather than heterozygote advantage.

Population demographics: Predominantly reported in populations of European ancestry (consistent with founder-allele geography — Europe, Australia, New Zealand, US populations of European descent per Rajakulendran et al.). No confirmed sex predilection (autosomal, so ~1:1 male:female expected and generally observed). Age distribution of affected/diagnosed individuals for the arPEO subtype skews toward middle-aged to older adults (40s onward) at symptom onset, with diagnosis often delayed further due to the insidious onset and diagnostic overlap with myasthenia gravis and other CPEO causes.

10. Diagnostics

Clinical/laboratory tests: - Serum/CSF lactate and pyruvate (may be elevated, not universally diagnostic). - Creatine kinase (CK) — often normal or mildly elevated in mitochondrial myopathy (helps distinguish from primary myopathies with higher CK).

Muscle biopsy (a cornerstone diagnostic test): - Histochemistry: Modified Gomori trichrome stain shows ragged-red fibers (RRF) (subsarcolemmal/intermyofibrillar mitochondrial proliferation); succinate dehydrogenase (SDH) staining shows corresponding "ragged-blue" fibers; combined COX/SDH staining reveals COX-deficient fibers (blue, SDH-positive but COX-negative) — the single most sensitive histochemical marker of mtDNA-deletion disease, often more sensitive than RRF alone. - Electron microscopy: Paracrystalline mitochondrial inclusions, abnormal mitochondrial morphology/proliferation. - Molecular studies on muscle: Southern blot or long-range PCR demonstrating multiple mtDNA deletions (distinguishing this "multiple deletion" disorder from Kearns-Sayre syndrome's single large deletion); quantitative PCR may show reduced mtDNA copy number in more severe genotypes. - Biochemical respiratory chain enzymology on muscle homogenate: reduced Complex I and Complex IV activities characteristic (mtDNA-encoded subunit-dependent complexes).

Imaging: Not primary for diagnosis; orbital MRI may show extraocular muscle atrophy in advanced disease but is non-specific. Brain MRI may be used to evaluate cerebellar atrophy or white matter change in patients with ataxia/CNS features, again nonspecific.

Electrophysiology: - Nerve conduction studies/EMG to characterize the sensory axonal peripheral neuropathy when present (reduced sensory nerve action potential amplitudes with relatively preserved conduction velocities, consistent with axonal loss). - Repetitive nerve stimulation and single-fiber EMG are used to exclude myasthenia gravis (a key differential) — should be normal in PEOB1. - Audiometry to characterize sensorineural hearing loss when present.

Genetic testing (definitive diagnosis): - First-line: POLG sequence analysis (single-gene or targeted mitochondrial-disease gene panel), which detects the pathogenic variant in ~95% of cases; gene-targeted deletion/duplication analysis accounts for the remaining ~5%. - Broader approach: Given genetic heterogeneity of multiple-mtDNA-deletion disorders (POLG, POLG2, TWNK, RRM2B, DGUOK, SLC25A4, OPA1, MGME1, RNASEH1, TK2, TOP3A, DNA2, and others), a multigene mitochondrial-disease/PEO panel or exome sequencing is often used clinically, particularly when the phenotype is atypical or POLG sequencing is negative. - Whole-exome/whole-genome sequencing utility: increasingly used as first-tier or reflex testing given phenotypic overlap across the >20 known "multiple mtDNA deletion" genes; the specific yield data for PEOB1 alone were not separately quantified in this search. - Mitochondrial genome sequencing of muscle (not blood — mtDNA deletion mosaicism is tissue-specific and typically not detectable in blood in adult-onset PEO) is essential to demonstrate the pathognomonic multiple-deletion picture, but does not identify the causal nuclear gene. - Chromosomal microarray/karyotype/FISH: Not applicable/not indicated — PEOB1 is a nuclear point-mutation disorder, not a copy-number or cytogenetic disorder.

Clinical diagnostic criteria: No formal consensus scoring system specific to PEOB1 was identified; diagnosis rests on the clinical triad of (bilateral ptosis + symmetric ophthalmoparesis + exercise intolerance/myopathy), muscle biopsy evidence of mtDNA-deletion-type mitochondrial myopathy, demonstration of multiple mtDNA deletions in muscle, and confirmation of biallelic POLG pathogenic variants.

Differential diagnosis: - Ocular myasthenia gravis — key distinguishing features: MG is typically fatigable/fluctuating and often asymmetric, with positive acetylcholine receptor or MuSK antibodies and abnormal repetitive nerve stimulation/single-fiber EMG; PEOB1 is static-progressive, symmetric, antibody-negative. - Kearns-Sayre syndrome — single large mtDNA deletion (usually sporadic, not inherited in Mendelian fashion), onset before age 20, plus pigmentary retinopathy and cardiac conduction defects (triad required for KSS diagnosis) — PEOB1 lacks the KSS triad and shows multiple rather than single mtDNA deletions. - Oculopharyngeal muscular dystrophy (OPMD) — caused by GCN-repeat expansion in PABPN1; presents with ptosis/dysphagia, distinguished by dysphagia prominence and specific molecular test. - Myotonic dystrophy type 1, congenital fibrosis of the extraocular muscles, thyroid eye disease/orbitopathy, chronic orbital myositis, abetalipoproteinemia, Refsum disease — all in the broader CPEO differential. - Other genetic multiple-mtDNA-deletion disorders (TWNK-recessive, RRM2B, DGUOK, SLC25A4, MGME1, RNASEH1, TK2, TOP3A, DNA2, OPA1) — clinically similar/indistinguishable without molecular testing; distinguished only by causal gene on sequencing.

Screening: No population-based newborn or general screening program exists for this adult-onset recessive disorder. Carrier screening (e.g., expanded carrier screening panels, ACMG-aligned) for POLG founder variants (notably A467T) is available and relevant given the ~1% carrier frequency in European-ancestry populations; cascade testing of at-risk relatives (siblings: 25% recurrence risk) and genetic counseling (including reproductive options such as prenatal or preimplantation genetic testing) are appropriate once a proband's biallelic genotype is established.

11. Outcome/Prognosis

Survival/mortality: The late-onset arPEO phenotype (PEOB1) carries the best prognosis within the POLG-disease spectrum; life expectancy is not dramatically shortened relative to the general population in isolated PEO without major systemic (hepatic, cardiac) involvement, though precise actuarial life-expectancy figures specific to PEOB1 were not identified in this search. This contrasts sharply with early-onset POLG phenotypes, where survival is markedly reduced and correlates with age at seizure onset and presence of liver disease (median survival as low as 0.7 years for epilepsy onset before age 3; liver involvement independently predicts worse survival) (Hikmat et al. 2020 and related natural-history literature).
Morbidity/function: Chronic visual disability from ptosis/ophthalmoparesis (compensatory head-tilt, risk of exposure keratopathy, especially post-surgical); progressive proximal myopathy can impair mobility and activities of daily living; when ataxia/neuropathy develop, gait and fine-motor disability increase; hearing loss and cataract contribute to sensory disability in affected patients.
Complications: Corneal exposure after ptosis surgery is a specific, well-documented iatrogenic complication in this population (due to poor Bell's phenomenon/orbicularis function accompanying the myopathy) — requires careful pre-op counseling and often conservative (under-)correction. Systemic complications (when present) include cardiac conduction disease/cardiomyopathy, endocrinopathy (hypogonadism), and GI dysmotility.
Recovery potential: No disease-modifying therapy exists; the underlying mitochondrial myopathy and neuropathy are not reversible, though supportive interventions (ptosis surgery, physical therapy, hearing aids, cataract surgery) meaningfully improve function and quality of life for the specific affected organ system.
Prognostic factors: Age at onset (later onset = better prognosis), genotype severity (allele combination — polymerase-domain/severe alleles trend toward worse, more systemic phenotype), presence/absence of liver involvement and early-onset seizures (poor prognostic markers, mainly relevant to the more severe ends of the POLG spectrum rather than classic arPEO), and degree of eventual systemic (ataxia-neuropathy-spectrum) evolution.
Prognostic biomarkers: No validated molecular biomarker specific to PEOB1 progression was identified; general markers under study across POLG disease include serum/CSF lactate, GDF15/FGF21 (used more broadly as mitochondrial-disease biomarkers in other conditions), and mtDNA deletion burden on repeat muscle biopsy — the latter research-grade rather than clinically validated for prognosis specifically in this entity.

12. Treatment

No disease-modifying or curative therapy exists. Management is supportive, multidisciplinary, and focused on symptom management and monitoring for multisystem involvement, mirroring general mitochondrial-disease care.

Pharmacotherapy: - Coenzyme Q10 (ubiquinone/ubidecarenone) supplementation (100–600 mg/day in small studies) — general mitochondrial-supportive therapy with reported (limited-evidence) benefits including reduced serum lactate/pyruvate and possible partial functional improvement; not POLG-PEO-specific, extrapolated from broader mitochondrial-disease "mitochondrial cocktail" practice. NCIT term: treatment_term NCIT:C15986 (Pharmacotherapy); therapeutic_agent CHEBI (ubidecarenone/coenzyme Q10, CHEBI:46245). - Other components of the empiric "mitochondrial cocktail" (L-carnitine, riboflavin, alpha-lipoic acid, creatine) are used in general mitochondrial-myopathy practice with weak evidence; specific PEOB1 trial data were not identified. - Critical avoidance: Valproic acid / sodium divalproate are contraindicated across the POLG spectrum, including PEOB1, due to hepatotoxicity risk — this should be flagged as a therapeutic counter-indication rather than a treatment.

Pharmacogenomics: The principal pharmacogenomic relevance is the valproate-hepatotoxicity gene-drug interaction described above; POLG genotype should be checked (or at minimum strongly suspected clinically) before initiating valproate in any patient with unexplained epilepsy, ataxia, or PEO-like features.

Advanced therapeutics: No approved gene therapy, cell therapy, RNA-based therapy, or targeted molecular therapy exists specifically for POLG-PEO at the time of this research; deoxynucleoside-substrate replacement therapies under investigation for other mtDNA-maintenance disorders (e.g., TK2 deficiency) are not established for POLG-PEO. No relevant ClinicalTrials.gov interventional trials specific to PEOB1 were identified in this search (searches for POLG-PEO-specific trials did not surface active NCT-registered studies beyond general mitochondrial-disease natural-history/biomarker studies).

Surgical/interventional: - Ptosis surgery (levator resection, frontalis/brow suspension sling) — mainstay surgical intervention for functionally significant ptosis, but with meaningful risk of postoperative exposure keratopathy due to poor Bell's phenomenon/blink mechanics in this myopathic population; conservative under-correction is often favored. NCIT: procedure best captured under NCIT:C15329 (Surgical Procedure) or a more specific ophthalmic surgical term if available. - Strabismus surgery is used more cautiously and less frequently than in comitant strabismus, given the progressive, restrictive nature of the myopathy. - Cataract surgery for visually significant cataracts. - Cochlear implantation/hearing aids for sensorineural hearing loss (device-based, not curative of the underlying disease).

Supportive/rehabilitative: - Nonsurgical ptosis aids: ptosis crutches/props, Fresnel prisms for symptomatic misalignment/diplopia. - Scleral contact lenses for ocular surface protection/rehabilitation in advanced disease. - Physical therapy (resistance/aerobic exercise) to preserve muscle function, address proximal weakness, and (by analogy with mouse-model data showing exercise attenuates the Polg mutator progeroid phenotype) potentially support mitochondrial biogenesis, though direct human PEOB1 exercise-trial evidence was not identified. - Occupational therapy, speech-language therapy (for dysarthria/dysphagia when present in the ataxia-neuropathy-spectrum-evolved phenotype). - Genetic counseling (NCIT:C15240) for the patient and at-risk relatives given the 25%/50%/25% recessive recurrence-risk pattern.

Treatment strategy/monitoring: Regular multidisciplinary follow-up including periodic liver function testing (e.g., every 3 months per GeneReviews guidance, reflecting vigilance for hepatotoxic drug exposures and any evolving hepatic involvement), cardiac evaluation (ECG/echocardiogram) for conduction disease/cardiomyopathy surveillance, audiometry, ophthalmologic exam (cataract, corneal surface), and neurologic assessment for evolving ataxia/neuropathy — consistent with the "PEO-plus" surveillance philosophy given the phenotype's tendency to expand over time.

13. Prevention

Primary prevention: Not applicable in the classic sense (this is a fixed germline genetic disease); the closest analog is avoidance of valproate exposure in genetically at-risk or POLG-confirmed individuals to prevent iatrogenic hepatic catastrophe — arguably the single most important "preventive" clinical action in this disease.
Secondary prevention: Early diagnosis (via genetic testing once PEO is clinically suspected) enables anticipatory monitoring (liver, cardiac, audiologic, ophthalmologic) before complications become symptomatic/advanced.
Tertiary prevention: Conservative surgical planning (ptosis under-correction) to prevent exposure keratopathy; proactive management of ataxia/neuropathy-related fall risk; cardiac monitoring to catch conduction disease before syncope/sudden events.
Genetic screening:
Carrier screening for POLG founder pathogenic variants (notably A467T) is commercially available (e.g., expanded carrier screening panels referenced by Myriad/Foresight) and increasingly incorporated given the relatively high (~1%) carrier frequency in European-ancestry populations.
Prenatal testing/preimplantation genetic testing (PGT-M) is an option for couples where both partners are known carriers or where a proband's biallelic genotype has been characterized.
Cascade family testing of siblings/relatives of an affected proband, given 25% recurrence risk for full siblings.
Genetic counseling: Central to prevention strategy — informing reproductive decision-making, clarifying that arPEO is generally the mildest end of the POLG spectrum (important reassurance context) while noting variable expressivity means the same genotype can theoretically manifest more severely in a given individual.
Public health/behavioral/immunization/prophylaxis: Not applicable — this is not an infectious, environmentally-driven, or vaccine-preventable disease.

14. Other Species / Natural Disease

Taxonomy: No naturally occurring veterinary/companion-animal disease caused by POLG mutations was identified in this search (searches for OMIA POLG entries were not directly performed but no evidence of natural veterinary POLG-PEO disease surfaced in the broader literature reviewed). This appears to be a human-specific documented clinical entity at present, though POLG orthologs exist broadly across mammals (used experimentally, see Model Organisms below).
Orthologous gene: Mouse Polg (MGI:1338062; NCBI Gene ortholog), highly conserved catalytic and exonuclease domains — the basis for the mouse model described below.
Comparative biology: The core biochemical mechanism (Pol γ proofreading/catalytic function in mtDNA replication) is deeply evolutionarily conserved from yeast (MIP1, the yeast Pol γ ortholog) through zebrafish (polg1/polg2) to mammals, which is precisely why yeast, zebrafish, and mouse models (below) are informative surrogates for human POLG disease mechanism, even though naturally occurring animal disease has not been documented.
Zoonotic potential/transmission: Not applicable — non-infectious, non-transmissible monogenic disease.

15. Model Organisms

Yeast: Saccharomyces cerevisiae MIP1 (Pol γ ortholog) mutants have been used to model POLG catalytic and exonuclease domain mutations, informative for basic replication-fidelity mechanism studies (per the 2025 Cell Death & Disease review "Model organisms in POLG-related disorders: insights from yeast to multicellular systems").

Zebrafish: - A stable CRISPR/Cas9-generated polg2 knockout zebrafish line (allele polg2^ia304^) recapitulates human POLG-disorder phenotypes: homozygous mutants show slower development, decreased viability, remarkable mtDNA depletion, altered mitochondrial network/dynamics, and reduced mitochondrial respiration (PMC11032366). While this specific model targets polg2 (the accessory-subunit ortholog) rather than polg1 directly, it is used as a platform for drug-treatment screening relevant to the broader POLG-disorder mechanism. - Zebrafish models more broadly are highlighted as useful for probing the neurological manifestations of POLG disease (encephalopathy, epilepsy, ataxia) given their amenability to behavioral and imaging assays.

Mouse — the "mtDNA mutator" model (most extensively characterized): - The classic Polg^D257A/D257A "mutator" mouse carries a proofreading-domain (exonuclease-dead) knock-in mutation, causing an ~2,500-fold increase in mtDNA point-mutation rate and marked linear-fragment/deletion accumulation (an 11-kb linear mtDNA fragment corresponding to most of the mtDNA major arc has been specifically characterized, mechanistically linking loss of exonuclease-mediated fragment degradation to deletion formation — directly relevant to the human PEOB1 deletion mechanism). - Phenotype recapitulation: This model reproduces a systemic premature-aging (progeroid) phenotype — accelerated sarcopenia, hearing loss, osteoporosis, hair graying/alopecia, thymic involution, testicular atrophy, cardiac hypertrophy, anemia, weight loss, and markedly shortened lifespan — overlapping substantially with several "PEO-plus" features seen in human POLG disease (hearing loss, cardiomyopathy, hypogonadism), though the mouse model's dominant aging-phenotype framing is broader than isolated human arPEO. - Mechanistic insight from the model: Muscle from mutator mice shows increased mitochondrial fission (elevated Fis1) and heightened autophagy, proposed to contribute to the sarcopenic phenotype — a plausible parallel to human myopathic muscle wasting. - Intervention data: Endurance exercise is the only reported intervention shown to attenuate the progeroid phenotype and extend healthspan/lifespan in this model — informing (by extrapolation, not direct trial) the rationale for exercise as supportive therapy in human patients. - Newer, refined mouse models (2025): A study titled "Modelling POLG mutations in mice unravels a critical role of POLγB in regulating phenotypic severity" (Nat Commun 2025) specifically dissects how the POLG2 (Pol γB) accessory subunit modulates phenotypic severity of POLG catalytic mutations — directly relevant to understanding genotype-phenotype variability in human disease. A separate 2025 bioRxiv-reported "inducible mtDNA mutator mouse model" adds temporal/spatial control, addressing the limitation that constitutive mutator mice can show embryonic lethality or phenotypes that are difficult to dissect tissue-specifically.

Model limitations: Existing constitutive POLG mouse mutants can present either embryonic lethality (very severe alleles) or comparatively mild/non-specific phenotypes, limiting fidelity to the specific adult-onset, tissue-restricted (extraocular-muscle-predominant) human PEOB1 phenotype and limiting utility for high-throughput drug screening — a limitation explicitly motivating development of the newer inducible and zebrafish models.

Research applications: These models collectively enable study of (a) the exonuclease-fragment-degradation mechanism of deletion formation, (b) POLG2/Pol γB modulation of severity, (c) tissue-specific bioenergetic failure and its downstream cellular consequences (mitochondrial fission/autophagy), and (d) candidate interventions (exercise; pharmacologic screening in zebrafish).

Resources: MGI (Mouse Genome Informatics) for Polg knock-in/flox alleles (e.g., the C57BL/6JCya-Polg^em1flox^ conditional model cataloged commercially); ZFIN for zebrafish polg1/polg2 alleles.

Summary of Key Ontology Term Suggestions for KB Curation

Domain	Suggested terms
Disease	OMIM:258450; ORPHA:254886; MONDO (verify exact PEOB1-specific term via OLS)
Gene	HGNC:9179 (POLG), lowercase `hgnc:9179` per repo convention
Phenotypes (HP)	HP:0000508 Ptosis; HP:0000590 Ophthalmoplegia; HP:0000602 Ophthalmoparesis; HP:0003546 Exercise intolerance; HP:0001324 Muscle weakness; HP:0003202 Skeletal muscle atrophy; HP:0007141 Axonal sensory neuropathy; HP:0001251 Ataxia; HP:0001260 Dysarthria; HP:0000407 Sensorineural hearing loss; HP:0000518 Cataract; HP:0001634 Mitral valve prolapse; HP:0001638 Cardiomyopathy; HP:0002151 Increased serum lactate; HP:0003200 Ragged-red muscle fibers
Biological processes (GO)	GO:0006264 mitochondrial DNA replication; GO:0032042 mitochondrial DNA metabolic process; GO:0006281 DNA repair; GO:0006123 mitochondrial electron transport, cytochrome c to oxygen
Molecular function (GO)	GO:0003887 DNA-directed DNA polymerase activity; GO:0008310 single-stranded DNA 3'-5' exodeoxyribonuclease activity
Cell types (CL)	Skeletal/extraocular muscle fiber; CL:0000101 sensory neuron; CL:0000121 Purkinje cell (ataxia-affected patients)
Anatomy (UBERON)	UBERON:0002031 extraocular muscle; UBERON:0001134 skeletal muscle tissue; UBERON:0002037 cerebellum; UBERON:0001846 cochlea; UBERON:0000965 lens
Treatment (NCIT)	NCIT:C15986 Pharmacotherapy (CoQ10, avoid valproate); NCIT:C15329 Surgical Procedure (ptosis repair); NCIT:C15240 Genetic Counseling; NCIT:C15315 Rehabilitation
Chemicals (CHEBI)	CHEBI:46245 ubidecarenone (coenzyme Q10); note valproate/valproic acid as a contraindicated agent, not a treatment

Notes on Evidence Gaps

Precise population prevalence/incidence figures specific to PEOB1 (as opposed to POLG-disease overall, or CPEO as a clinical umbrella) were not found — flag as "prevalence unknown" per Orphanet, consistent with rare-disease reporting limits.
No dedicated QOL instrument data, omics (transcriptomic/proteomic) human-tissue datasets, or active interventional clinical trials specific to PEOB1 were identified in this search — likely reflects genuine absence of such studies for this specific rare recessive subtype rather than a search limitation, though a targeted ClinicalTrials.gov/GEO query would be a reasonable follow-up before concluding definitively.
Exact PMIDs for several foundational papers (Van Goethem et al. 2001 Nat Genet; the Hikmat et al. 2020 JIMD cohort, PMID 32068908; Basu et al. 2018 Nat Commun on exonuclease/fragment degradation) should be independently re-verified against PubMed/cached abstracts before use as curated evidence snippets, per standard dismech verification SOP — this report should be treated as a lead-generation document, not pre-verified evidence.

Sources: - OMIM #258450 — PEOB1 - OMIM *174763 — POLG - OMIM #616479 — PEOB2 (RNASEH1) - OMIM #617070 — PEOB4 (DGUOK) - Orphanet — Autosomal recessive PEO (ORPHA:254886) - GeneReviews — POLG-Related Disorders (NBK26471) - MalaCards — PEOB1 - MedlinePlus — Progressive external ophthalmoplegia - MedlinePlus — POLG gene - Nature Genetics — Van Goethem et al., Mutation of POLG associated with PEO - Nature Communications — POLG exonuclease degrades linear DNA fragments precluding deletions - Nature Communications — POLγB regulates phenotypic severity in mouse POLG models (2025) - Cell Death & Disease — Model organisms in POLG-related disorders - PMC — Zebrafish polg2 knockout recapitulates POLG-disorders - Journal of Inherited Metabolic Disease — Hikmat et al. 2020, simplifying POLG clinical classification - Genetics in Medicine — natural history of early-onset POLG disease - ClinVar — POLG c.1399G>A (p.Ala467Thr) - European Journal of Human Genetics — Abundance of POLG mutations from single ancient founders - PubMed — Estimation of carrier frequencies via gnomAD for carrier screening - PMC — RNASEH1 mutations and PEO with multiple mtDNA deletions - MedLink Neurology — Chronic progressive external ophthalmoplegia - Medscape — CPEO Treatment & Management - PMC — Treatment of ptosis in chronic progressive external ophthalmoplegia

Falcon ▸

Autosomal Recessive Progressive External Ophthalmoplegia 1: Disease-Characteristics Report

Edison Scientific Literature 36 citations 2026-07-31T16:24:10.353388

Autosomal Recessive Progressive External Ophthalmoplegia 1: Disease-Characteristics Report

Executive summary and evidence scope

Autosomal recessive progressive external ophthalmoplegia 1 (arPEO1) is a nuclear-encoded mitochondrial DNA-maintenance disorder caused by biallelic germline variants in POLG, which encodes the catalytic subunit of mitochondrial DNA polymerase γ. The defining manifestation is slowly progressive, usually bilateral ptosis and external ophthalmoparesis; limb, bulbar, peripheral-nerve, cerebellar, auditory, epileptic, or other systemic features produce a “PEO-plus” phenotype. POLG dysfunction causes secondary mitochondrial-DNA (mtDNA) deletions and sometimes depletion, followed by respiratory-chain failure in energy-demanding tissues. The entity is one phenotype on a continuous POLG-related disease spectrum rather than a sharply isolated syndrome. (wong2008molecularandclinical pages 1-2, kurtz2021wholeexomesequencingidentifies pages 7-7, ali2024mitochondrialchronicprogressive pages 6-8)

Evidence specific to molecularly confirmed arPEO1 is sparse. Accordingly, this report distinguishes arPEO-specific evidence, broader POLG-spectrum evidence, and genetically heterogeneous PEO evidence. The most recent disease-focused source retrieved was the January 2024 CPEO review (DOI 10.3390/brainsci14020135); it is authoritative for current recognition and management but not arPEO1-specific. No arPEO1-specific randomized trial, population natural-history registry, or 2023–2024 mechanistic cohort was identified. (ali2024mitochondrialchronicprogressive pages 6-8, ali2024mitochondrialchronicprogressive pages 3-5, rahman2019polgrelateddisordersand pages 11-13)

The following table provides a knowledge-base-ready overview.

Field	Summary	Suggested ontology/identifier(s)	Evidence
Scope / definition	Autosomal recessive progressive external ophthalmoplegia 1 is best resolved here as a POLG-related adult/late-onset mitochondrial disease phenotype within the broader POLG disorder spectrum, characterized by progressive weakness of extraocular muscles causing ptosis and ophthalmoparesis; it is distinct from dominant POLG PEO and from PEO caused by TWNK, RNASEH1, TK2, RRM2B, or primary mtDNA defects.	OMIM phenotype name: Autosomal recessive progressive external ophthalmoplegia 1; disease label also reported as arPEO / POLG-related arPEO.	(wong2008molecularandclinical pages 1-2, ali2024mitochondrialchronicprogressive pages 6-8, somai2025mitochondrialdnareplication pages 6-8, rodriguezlopez2020clinicalpathologicaland pages 2-3)
OMIM identifier	OMIM 258450 was explicitly associated with autosomal recessive progressive external ophthalmoplegia in the gathered evidence.	OMIM: 258450	(wong2008molecularandclinical pages 1-2)
Likely MONDO mapping caveat	A MONDO term was not verified in the gathered evidence. If a MONDO mapping is added downstream, it should be manually checked because PEO entities are genetically heterogeneous and MONDO may group phenotype-level and gene-level concepts differently.	MONDO: not verified from gathered sources	(wong2008molecularandclinical pages 1-2, ali2024mitochondrialchronicprogressive pages 6-8)
Causal gene / protein	Causal gene: POLG, encoding the catalytic subunit of mitochondrial DNA polymerase gamma (DNA polymerase γA / POLγA), the only mitochondrial DNA polymerase responsible for mtDNA replication and repair.	Gene: POLG; Protein: DNA polymerase subunit gamma-1 / POLγA; HGNC/NCBI Gene IDs not verified from gathered sources	(wong2008molecularandclinical pages 1-2, rahman2019polgrelateddisordersand pages 10-11, chan2009dnapolymerasegamma pages 4-5)
Inheritance	Autosomal recessive; usually biallelic pathogenic germline variants, often compound heterozygous, though homozygous A467T cases occur. Yeast modeling of the A467T-analog supports recessive behavior.	Inheritance: autosomal recessive; germline	(wong2008molecularandclinical pages 1-2, rajakulendran2016aclinicalneuropathological pages 2-3, stuart2006mitochondrialandnuclear pages 8-9)
Hallmark phenotypes	Core phenotype: progressive external ophthalmoplegia/ophthalmoparesis with bilateral ptosis; early subtle slowed/incomplete saccades may occur. Additional POLG-associated “PEO-plus” features can include limb weakness, bulbar involvement, exercise intolerance, peripheral neuropathy, ataxia, hearing loss, tremor, seizures, and other multisystem manifestations, but these are not specific to arPEO1 alone.	HPO suggestions: Ptosis (HP:0000508, verified code not checked here), External ophthalmoplegia / Ophthalmoparesis (code not verified), Exercise intolerance (code not verified), Peripheral neuropathy (code not verified), Ataxia (code not verified), Sensorineural hearing impairment (code not verified), Tremor (code not verified), Seizure (code not verified)	(kurtz2021wholeexomesequencingidentifies pages 7-7, ali2024mitochondrialchronicprogressive pages 6-8, ali2024mitochondrialchronicprogressive pages 3-5, rodriguezlopez2020clinicalpathologicaland pages 2-3)
Common pathogenic variant themes	Recurrent POLG variants in broader POLG disease include A467T, W748S, G848S, and T251I-P587L; A467T is the most common disease-associated allele in Europeans and functionally recessive. W748S commonly occurs in cis with E1143G, which can modify severity. Variant-level pathogenic classifications were not systematically verified from ClinVar in gathered evidence.	Variant examples: A467T; W748S; G848S; T251I-P587L; E1143G modifier/polymorphic context	(rajakulendran2016aclinicalneuropathological pages 2-3, somai2025mitochondrialdnareplication pages 6-8, rahman2019polgrelateddisordersand pages 10-11, rajakulendran2016aclinicalneuropathological pages 11-13)
Mechanism / pathophysiology	Upstream defect: impaired POLγ-mediated mtDNA replication/maintenance. A467T reduces polymerase activity to ~4% of wild type and disrupts interaction with the POLG2 accessory subunit; W748S reduces catalytic activity/processivity and impairs DNA binding. Downstream consequences include multiple mtDNA deletions and sometimes mtDNA depletion, leading to respiratory-chain dysfunction in high-energy tissues such as extraocular muscle, skeletal muscle, and nervous system.	GO suggestions: mitochondrial DNA replication (GO code not verified), DNA repair (GO code not verified), oxidative phosphorylation (GO code not verified), mitochondrial genome maintenance (GO code not verified)	(kurtz2021wholeexomesequencingidentifies pages 7-7, somai2025mitochondrialdnareplication pages 6-8, rahman2019polgrelateddisordersand pages 10-11, chan2009dnapolymerasegamma pages 4-5)
Tissues / cells / compartments affected	Primary tissues: extraocular muscles and skeletal muscle; broader involvement can include peripheral and central nervous system, liver, and heart in the wider POLG spectrum. Cell populations likely implicated include skeletal muscle fibers and neurons, but exact CL terms were not verified. Key compartment: mitochondrion, especially mtDNA nucleoid/mitochondrial matrix replication machinery.	UBERON suggestions: extraocular muscle (code not verified), skeletal muscle tissue (code not verified), peripheral nerve (code not verified), brain (code not verified); CL suggestions: skeletal muscle cell / myofiber, neuron (codes not verified); GO cellular component suggestions: mitochondrion, mitochondrial matrix, mitochondrial nucleoid (codes not verified)	(wong2008molecularandclinical pages 1-2, ali2024mitochondrialchronicprogressive pages 6-8, rodriguezlopez2020clinicalpathologicaland pages 2-3)
Diagnostic signature	Diagnostic clues include progressive bilateral ptosis and ophthalmoparesis, often adult onset, with muscle biopsy frequently showing mitochondrial myopathy changes such as ragged-red/COX-negative fibers and molecular evidence of multiple mtDNA deletions; CK may be normal or elevated in broader PEO cohorts. Genetic confirmation relies on sequencing of POLG (now often via exome/genome/panel testing); muscle biopsy remains highly informative in broader mitochondrial PEO when etiology is uncertain.	Diagnostic modalities: POLG sequencing; mtDNA deletion analysis in muscle; muscle biopsy; WES/WGS/panel testing. Biomarker codes not verified.	(kurtz2021wholeexomesequencingidentifies pages 7-7, ali2024mitochondrialchronicprogressive pages 3-5, kierdaszuk2020progressiveexternalophthalmoplegia pages 2-4, rodriguezlopez2020clinicalpathologicaland pages 2-3)
Treatment / prevention	No disease-modifying therapy was identified. Current care is supportive: ptosis aids/crutches, ptosis surgery (levator procedures or frontalis suspension), prism or strabismus surgery if diplopia/strabismus occur, rehabilitation/exercise as tolerated, and multidisciplinary surveillance for extraocular and systemic complications. In the broader POLG spectrum, valproate is contraindicated because of risk of liver failure. Prevention is mainly reproductive/genetic: genetic counseling, carrier/family testing, and consideration of prenatal or preimplantation testing where appropriate.	NCIT suggestions: genetic counseling, ptosis surgery, strabismus surgery, physical therapy / rehabilitation (codes not verified); Prevention: cascade testing, prenatal diagnosis, PGT (codes not verified)	(ali2024mitochondrialchronicprogressive pages 3-5, rahman2019polgrelateddisordersand pages 11-13)
Epidemiology / frequency	Disease-specific prevalence for arPEO1 was not found in gathered evidence. For a major recurrent allele, A467T carrier frequency was reported around 0.2–0.3% in mixed European populations, up to 1.3–1.4% in Belgian/British populations, with predicted homozygote prevalence ~1 in 500,000 to 1,000,000; these figures describe a variant, not arPEO1 prevalence.	Epidemiology for disease: not established from gathered sources	(rajakulendran2016aclinicalneuropathological pages 2-3, rahman2019polgrelateddisordersand pages 10-11)
Model systems / translational evidence	Yeast MIP1 models reproduce recessive behavior and mtDNA instability of human POLG variants; the A467T-analog behaves as a mild recessive defect in diploids. Broader POLG mutator mice model mtDNA deletion-driven mitochondrial dysfunction and premature aging, but no model perfectly recapitulates human POLG disease. Patient fibroblast and biochemical assays support defective holoenzyme assembly and replication failure.	Model classes: yeast, mouse, patient fibroblasts, biochemical enzyme assays	(stuart2006mitochondrialandnuclear pages 1-2, stuart2006mitochondrialandnuclear pages 8-9, chan2009dnapolymerasegamma pages 4-5, rahman2019polgrelateddisordersand pages 8-10)
Key evidence limitations	Much evidence is for the broader POLG spectrum or heterogeneous mitochondrial PEO cohorts rather than arPEO1 alone. Verified MONDO/HPO/GO/CL/UBERON/HGNC codes were not directly retrieved in the gathered sources and should not be auto-filled without ontology lookup. No arPEO1-specific interventional trial, single-cell/spatial omics profile, validated protective factor, or robust natural-history epidemiology study was identified in gathered evidence.	Limitation flags: ontology IDs unverified; arPEO1-specific trials absent in gathered evidence	(ali2024mitochondrialchronicprogressive pages 6-8, rodriguezlopez2020clinicalpathologicaland pages 2-3, rahman2019polgrelateddisordersand pages 11-13, rahman2019polgrelateddisordersand pages 8-10)

Table: This table condenses the key knowledge-base fields for autosomal recessive progressive external ophthalmoplegia 1 as supported by the gathered POLG-related evidence. It highlights what is well supported, what is broader-spectrum rather than arPEO1-specific, and which ontology identifiers still require external verification.

1. Disease information

Definition and classification

arPEO1 is a Mendelian, autosomal-recessive mitochondrial disease in which impaired POLG-dependent mtDNA replication and maintenance predominantly injure extraocular and skeletal muscle. It is distinct from:

autosomal-dominant PEO caused by dominant POLG variants;
PEO caused by other nuclear genes, including TWNK, POLG2, RNASEH1, SLC25A4, TK2, and RRM2B;
primary mtDNA point variants or single large-scale mtDNA deletions; and
syndromic PEO such as Kearns–Sayre syndrome. (ali2024mitochondrialchronicprogressive pages 6-8, kierdaszuk2020progressiveexternalophthalmoplegia pages 2-4, rodriguezlopez2020clinicalpathologicaland pages 2-3)

Identifiers and synonyms

OMIM: 258450, explicitly identified as POLG-associated arPEO in the retrieved primary literature. (wong2008molecularandclinical pages 1-2)
MONDO: not verified in the retrieved corpus; manual ontology reconciliation is recommended because databases may represent PEO as a phenotype-level, gene-specific, or umbrella mitochondrial-disease concept.
Common names: autosomal recessive progressive external ophthalmoplegia 1; PEOA1; arPEO; POLG-related autosomal recessive PEO; POLG-related PEO; chronic progressive external ophthalmoplegia when chronicity is emphasized.
ICD-10/ICD-11 and MeSH: no uniquely specific arPEO1 code was verified; coding commonly falls under mitochondrial metabolism/myopathy or ophthalmoplegia categories. A generic code should not be represented as disease-specific without local terminology verification.

This report is synthesized from aggregated disease-level literature, published cohorts, individual case reports, biochemical experiments, and model systems, not from an individual EHR.

2. Etiology, risk, protective factors, and gene–environment interaction

Primary cause

The cause is two pathogenic or likely pathogenic POLG alleles in trans. POLG encodes POLγA, the catalytic polymerase/proofreading component of the mitochondrial replisome. Recessive variants reduce polymerase activity, processivity, DNA binding, interaction with the POLG2 accessory subunit, or protein abundance, destabilizing mtDNA. In one approximately 350-patient referral series, two mutant alleles were found in 31 unrelated recessive cases, of whom 4/31 (13%) had arPEO; this is a referral-series proportion, not population prevalence. (wong2008molecularandclinical pages 1-2)

Genetic risk factors

Recurrent disease alleles across the broader POLG spectrum include p.Ala467Thr (A467T), p.Trp748Ser (W748S), p.Gly848Ser (G848S), and the p.Thr251Ile–p.Pro587Leu cis pair. A467T represented approximately 36% of disease-associated POLG alleles in a major review; these four recurrent alleles together constituted about 50% of identified variants, and roughly 75% of patients carried at least one. These values concern all POLG-related disease, not arPEO1 alone. (rahman2019polgrelateddisordersand pages 10-11)

A467T carrier frequency was reported as approximately 0.2–0.3% in mixed European populations and 1.3–1.4% in Belgian/British populations, with a theoretical homozygote frequency of approximately 1:500,000–1:1,000,000. This is allele epidemiology, not clinical arPEO1 prevalence, because homozygous A467T can cause widely differing POLG phenotypes. (rajakulendran2016aclinicalneuropathological pages 2-3, rajakulendran2016aclinicalneuropathological pages 11-13)

Modifiers and protective factors

E1143G, usually found in cis with W748S, partially compensates for biochemical impairment and may modify severity; it should not be treated as a stand-alone protective allele. (somai2025mitochondrialdnareplication pages 6-8, rahman2019polgrelateddisordersand pages 10-11)
Homozygous A467T has produced Alpers–Huttenlocher syndrome, MELAS-like disease, MEMSA, and SANDO, implicating mtDNA haplotype, other nuclear variants, and environmental stress as modifiers. No validated clinical modifier panel exists. (rajakulendran2016aclinicalneuropathological pages 2-3, rajakulendran2016aclinicalneuropathological pages 11-13)
No reproducible genetic or environmental protective factor specific to arPEO1 was identified.

Environmental and lifestyle factors

No toxin, infection, diet, occupation, smoking pattern, alcohol exposure, or radiation exposure causes this Mendelian disorder. Physiological stress may unmask mitochondrial insufficiency, but arPEO1-specific gene–environment effect sizes are unavailable. The most consequential established drug interaction in the broader POLG spectrum is valproate-associated hepatic failure; valproate is therefore contraindicated in patients with pathogenic POLG variants. (rahman2019polgrelateddisordersand pages 11-13)

3. Phenotypes

Core and associated manifestations

Manifestation	Type and characteristics	Suggested HPO annotation
Progressive external ophthalmoplegia/ophthalmoparesis	Defining sign; bilateral, insidious, slowly progressive limitation of extraocular movement. Slowed or incomplete saccades can precede obvious restriction.	Progressive external ophthalmoplegia; Ophthalmoparesis
Ptosis	Common defining sign, usually bilateral and progressive; levator excursion may fall below 8–10 mm versus normal ≥12 mm in generic CPEO.	HP:0000508 Ptosis; Bilateral ptosis
Diplopia/strabismus	Variable and often less prominent than motility loss because restriction can be relatively symmetric. In a heterogeneous 89-person PEO cohort, more than one-third reported diplopia.	Diplopia; Strabismus
Exercise intolerance and myopathy	Variable PEO-plus manifestations; proximal limb, neck, facial, or generalized weakness can impair mobility and endurance.	Exercise intolerance; Proximal muscle weakness; Myopathy
Bulbar dysfunction	Dysarthria or dysphagia in syndromic/POLG PEO-plus disease.	Dysarthria; Dysphagia
Peripheral neuropathy/sensory ataxia	Particularly suggests a nuclear mtDNA-maintenance defect and can produce SANDO-spectrum disease.	Peripheral neuropathy; Sensory ataxia
Cerebellar ataxia/tremor	Variable PEO-plus neurological manifestations.	Cerebellar ataxia; Intention tremor
Sensorineural hearing loss	Recognized within the wider POLG spectrum, not established as uniformly frequent in arPEO1.	Sensorineural hearing impairment
Seizures/encephalopathy	Possible in broader POLG disease; their presence suggests substantial syndromic overlap rather than isolated arPEO.	Seizure; Encephalopathy
Laboratory/pathology abnormalities	CK may be normal or elevated; muscle may contain ragged-red and cytochrome-c-oxidase-negative fibers, multiple mtDNA deletions, and occasionally mtDNA depletion.	Elevated serum CK; Ragged-red muscle fibers; COX-negative muscle fibers; mtDNA depletion

(kurtz2021wholeexomesequencingidentifies pages 7-7, ali2024mitochondrialchronicprogressive pages 6-8, ali2024mitochondrialchronicprogressive pages 3-5, rodriguezlopez2020clinicalpathologicaland pages 2-3)

Onset, progression, frequency, and quality of life

The classic arPEO phenotype is generally adult-onset, chronic, and slowly progressive, although POLG disease spans infancy through late adulthood. Reliable phenotype percentages for arPEO1 alone are unavailable. A heterogeneous mitochondrial PEO cohort of 89 patients comprised 42% pure PEO, 10% Kearns–Sayre syndrome, 33% myopathic PEO-plus, 12% bulbar PEO-plus, and 3% other PEO-plus; these figures should not be imported as arPEO1 frequencies. In that cohort, POLG was more often associated with PEO-plus than pure PEO. (rodriguezlopez2020clinicalpathologicaland pages 2-3)

Quality-of-life effects include impaired superior and peripheral visual fields from ptosis, abnormal head posture, difficulty reading/driving, fatigue, reduced walking endurance, falls from neuropathy/ataxia, dysphagia, and psychosocial burden. No arPEO1-specific EQ-5D, SF-36, PROMIS, or utility study was identified.

4. Genetic and molecular information

Gene and protein

Gene: POLG, chromosome 15q region; HGNC identifier should be verified directly before database import.
Protein: catalytic subunit POLγA; it contains exonuclease, spacer, and polymerase domains and works with a POLG2-encoded accessory dimer.
Origin: pathogenic variants are constitutional/germline, not somatic drivers.

Variant classes and functional consequences

Reported pathogenic classes include missense, nonsense, frameshift, canonical/noncanonical splice, and small insertion/deletion variants. A 2021 adult PEO case carried compound-heterozygous c.67_88del, p.Gly23Serfs*236 and c.3104+3A>T; the latter causes exon-19 skipping. Muscle showed mitochondrial myopathy, multiple mtDNA deletions, and depletion. (kurtz2021wholeexomesequencingidentifies pages 7-7)

A467T lies in the spacer domain. Recombinant enzyme retained only about 4% of wild-type polymerase activity, had impaired DNA binding/processivity, and failed to interact normally with the POLG2 accessory subunit. W748S reduces polymerase activity, processivity, and DNA binding while retaining accessory-subunit interaction. These are primarily loss-of-function/hypomorphic mechanisms in recessive disease, not classic gain-of-function or dominant-negative effects. (rahman2019polgrelateddisordersand pages 10-11, rajakulendran2016aclinicalneuropathological pages 11-13, stuart2006mitochondrialandnuclear pages 8-9)

Population allele frequencies must be assessed variant by variant in gnomAD; the retrieved corpus did not provide validated gnomAD frequencies for every pathogenic allele. ClinVar classifications should likewise be imported per exact HGVS allele rather than assigning one classification to all variants.

Other genomic and epigenetic findings

No recurrent chromosomal aneuploidy, translocation, inversion, repeat expansion, or disease-defining copy-number abnormality is established. No validated arPEO1-specific methylation episignature, histone signature, or chromatin defect was identified. A reported mtDNA-deletion case involving reduced POLG/SSBP1 expression and methylation is not sufficient to define an arPEO1 epigenetic mechanism.

5. Environmental information

Environmental exposures are not primary etiologic agents. There is no evidence that infection is causal or transmissible; zoonotic transmission is not applicable. Practical exposure management follows general mitochondrial-disease principles: avoid fasting, dehydration, excessive heat, and unaccustomed exhaustive exertion when these provoke decompensation, while maintaining safe activity. These are precautionary practices rather than proven arPEO1-preventive interventions. Valproate avoidance has the strongest POLG-specific evidence. (rahman2019polgrelateddisordersand pages 11-13)

6. Mechanism and pathophysiology

Causal chain

Upstream genetic trigger: biallelic POLG dysfunction.
Primary biochemical defect: reduced polymerase catalysis/processivity, DNA binding, proofreading in selected alleles, holoenzyme assembly, or protein abundance.
Genome-maintenance failure: replication fork stalling, mtDNA depletion and/or clonally expanded multiple mtDNA deletions in post-mitotic tissues.
Respiratory defect: loss or imbalance of mtDNA-encoded oxidative-phosphorylation subunits impairs electron transport and ATP production.
Cellular injury: energy failure, abnormal redox state, compensatory mitochondrial proliferation, and eventual myofiber/neuronal dysfunction or loss.
Clinical expression: extraocular-muscle weakness causes ptosis and ophthalmoplegia; broader skeletal-muscle and neural injury causes PEO-plus manifestations. (wong2008molecularandclinical pages 1-2, kurtz2021wholeexomesequencingidentifies pages 7-7, somai2025mitochondrialdnareplication pages 6-8, chan2009dnapolymerasegamma pages 4-5)

Extraocular muscles are especially vulnerable because of continuous activity, specialized motor units, and high oxidative demand. Adult-onset PEO has been associated with multiple deletions affecting more than 60% of muscle mtDNA genomes in reviewed data, although this is not a universal diagnostic threshold. (somai2025mitochondrialdnareplication pages 6-8)

Ontology suggestions

GO biological process: mitochondrial DNA replication; mitochondrial genome maintenance; DNA repair; oxidative phosphorylation; ATP metabolic process; mitochondrial organization.
GO molecular function: DNA-directed DNA polymerase activity; 3′–5′ exonuclease activity; DNA binding.
GO cellular component: mitochondrion; mitochondrial matrix; mitochondrial nucleoid; mitochondrial respiratory-chain complex.
Cell Ontology: skeletal muscle fiber/myocyte; extraocular skeletal muscle cell where supported; peripheral sensory neuron; cerebellar neuron.

Exact ontology accessions other than HP:0000508 were not verified in the retrieved literature and should undergo ontology-service validation.

Molecular profiling and advanced technologies

Routine diagnosis measures mtDNA quantity/rearrangement and respiratory histochemistry rather than a validated transcriptomic, proteomic, metabolomic, or lipidomic signature. No arPEO1-specific single-cell atlas, spatial-transcriptomic map, integrated multi-omics classifier, or CRISPR-screen-derived clinical biomarker was identified. The absence of retrieved evidence should be encoded as “not established,” not “normal.”

7. Anatomical structures affected

Primary organ/tissue: bilateral extraocular muscles and levator palpebrae superioris; skeletal muscle.
Secondary systems in PEO-plus disease: peripheral and central nervous systems, auditory system, swallowing musculature, liver, heart, endocrine and renal systems—variable and not obligatory in isolated arPEO1. (ali2024mitochondrialchronicprogressive pages 6-8)
Subcellular site: mitochondrial matrix/nucleoid and downstream inner-membrane respiratory-chain system.
Lateralization: typically bilateral, often relatively symmetric; asymmetric ptosis can occur clinically.

Suggested anatomy annotations include extraocular muscle, levator palpebrae superioris, skeletal muscle tissue, peripheral nerve, cerebellum, brain, liver, and heart. UBERON/FMA accessions should be verified before import.

8. Temporal development

Onset is usually insidious and adult, beginning with subtle saccadic slowing, ptosis, or gaze limitation. Early disease may remain ocular; intermediate disease can add diplopia, exercise intolerance, and limb weakness; advanced PEO-plus disease can include bulbar dysfunction, neuropathy, ataxia, hearing loss, or other organ involvement. The course is chronic and usually slowly progressive rather than episodic or relapsing. Spontaneous remission is not expected, although ptosis and diplopia can improve symptomatically after intervention. (kurtz2021wholeexomesequencingidentifies pages 7-7, ali2024mitochondrialchronicprogressive pages 3-5)

There is no accepted staging system or validated arPEO1 progression-rate biomarker. Early molecular diagnosis is the main actionable window because it enables surveillance, avoids harmful treatment, and informs relatives before irreversible disability accumulates.

9. Inheritance and population

Inheritance is autosomal recessive. Parents of an affected individual are usually heterozygous carriers; each full sibling has a theoretical 25% probability of being affected, 50% of being an unaffected carrier, and 25% of inheriting neither familial allele, assuming both variants are confirmed in trans and standard Mendelian segregation applies.

Penetrance is likely high for genuinely pathogenic biallelic combinations but is age- and allele-dependent; expressivity is markedly variable. Anticipation is not established. Germline mosaicism has not emerged as a characteristic mechanism. Consanguinity increases the probability of homozygous rare alleles but is not required. Founder enrichment exists for selected alleles such as A467T in European-derived populations. No consistent sex bias is established. (rajakulendran2016aclinicalneuropathological pages 2-3, rahman2019polgrelateddisordersand pages 10-11)

Neither incidence nor prevalence of clinically defined arPEO1 is robustly known. Carrier-frequency estimates for A467T must not be converted directly into disease prevalence because penetrance, allelic heterogeneity, and phenotype heterogeneity intervene.

10. Diagnostics

Recommended workflow

Clinical recognition: bilateral progressive ptosis plus external ophthalmoparesis, slowed saccades, exercise intolerance, neuropathy, ataxia, or family history.
Exclude common mimics: ocular myasthenia gravis, thyroid eye disease, oculopharyngeal muscular dystrophy, myotonic dystrophy, congenital cranial dysinnervation disorders, inflammatory/infiltrative orbital disease, and other mitochondrial PEO causes.
First-line molecular testing: a mitochondrial-disease/PEO nuclear panel that includes POLG plus complete mtDNA sequencing and deletion analysis, or exome/genome sequencing with reliable mtDNA and copy-number/rearrangement analysis. Definitive arPEO1 diagnosis requires two disease-causing POLG alleles in trans. WES identified the novel frameshift in the 2021 adult case. (kurtz2021wholeexomesequencingidentifies pages 7-7)
Tissue-aware mtDNA testing: blood can miss low-level or tissue-restricted deletions; skeletal muscle is often more informative for multiple mtDNA deletions and depletion.
Muscle biopsy when genetics is unresolved or tissue mtDNA analysis is required: modified Gomori trichrome, COX/SDH histochemistry, respiratory-chain studies, mtDNA copy number, and deletion testing.

In a heterogeneous 89-person PEO cohort, muscle biopsy showed mitochondrial dysfunction in 95%, and a genetic diagnosis was reached in 96%; 63% had a single large mtDNA deletion, 26% multiple deletions, and 7% an mtDNA point variant. Among multiple-deletion cases, causal genes included TWNK (n=8), POLG (n=7), TK2 (n=6), and RRM2B (n=2). These data demonstrate diagnostic yield but are not arPEO1 prevalence estimates. (rodriguezlopez2020clinicalpathologicaland pages 2-3)

CK has limited sensitivity: in the same broader cohort, 31/68 had CK below 200 U/L; elevated results averaged 780 U/L and ranged from 203–5,195 U/L. Normal CK therefore does not exclude disease. FGF21 and GDF15 may support a mitochondrial diagnosis, but neither is specific for POLG arPEO1. (rodriguezlopez2020clinicalpathologicaland pages 2-3)

EMG may show myopathy or neuropathy; nerve-conduction testing is useful when sensory ataxia is present. ECG/echocardiography, audiology, swallowing assessment, pulmonary testing, EEG, and brain MRI should be driven by phenotype. CMA, karyotyping, FISH, and repeat-expansion testing are not first-line unless another diagnosis is suspected.

Screening

Population and newborn screening are not established. Appropriate strategies are cascade testing for known familial variants, partner testing where relevant, and surveillance of genetically affected relatives. Carrier screening is targeted rather than universal.

11. Outcome and prognosis

Isolated adult arPEO is generally chronic and disabling but not necessarily life-shortening. Prognosis becomes less favorable with seizures, encephalopathy, severe neuropathy/ataxia, dysphagia, respiratory weakness, cardiomyopathy, or hepatic involvement. Published survival rates, median life expectancy, disease-specific mortality rates, and validated prognostic models for arPEO1 were not identified.

The major durable morbidity is ocular and neuromuscular disability. Recovery of lost mitochondrial myofibers is not expected; supportive interventions improve function rather than cure the molecular defect. Variant alone is an imperfect prognostic marker: even homozygous A467T produced four markedly different clinical phenotypes in a four-patient study. (rajakulendran2016aclinicalneuropathological pages 2-3, rajakulendran2016aclinicalneuropathological pages 11-13)

12. Treatment and current implementation

Disease-modifying therapy

No approved disease-modifying pharmacotherapy, gene therapy, cell therapy, RNA therapy, or gene-editing treatment exists for arPEO1. An authoritative review stated that evidence-based POLG therapies were lacking and no randomized controlled trials had been performed. Vitamin/antioxidant “mitochondrial cocktails” are widely used but lack a proven arPEO1 response rate. (rahman2019polgrelateddisordersand pages 11-13)

Symptomatic and supportive care

Ptosis: eyelid crutches may be tried but are often poorly tolerated. Mild levator dysfunction may be treated by levator resection/advancement; severe dysfunction often requires frontalis/brow suspension. Corneal exposure risk must be balanced against visual-field benefit. Suggested NCIt concepts: Ptosis Repair; Frontalis Suspension Procedure; Supportive Care. (ali2024mitochondrialchronicprogressive pages 3-5, rahman2019polgrelateddisordersand pages 11-13)
Diplopia/strabismus: prisms when feasible; selected patients may undergo strabismus surgery, with counseling that progression can alter alignment. Suggested NCIt: Prism Therapy; Strabismus Surgery. (ali2024mitochondrialchronicprogressive pages 3-5)
Rehabilitation: individualized aerobic and resistance activity below symptom-provoking thresholds, physical/occupational therapy, falls prevention, and mobility aids. Suggested NCIt: Physical Therapy; Occupational Therapy; Rehabilitation Therapy.
Bulbar/respiratory care: swallowing evaluation, diet modification, speech therapy, aspiration prevention, nutritional support, and noninvasive ventilation where indicated.
Hearing/cataract care: hearing aids or cochlear assessment and cataract surgery when clinically appropriate. Cataract removal and brow suspension are specifically cited supportive interventions in POLG disease. (rahman2019polgrelateddisordersand pages 11-13)
Seizures: specialist management; lamotrigine, clobazam, levetiracetam, or topiramate have been used, but comparative arPEO1 data are absent. Valproate is absolutely contraindicated because of potentially fatal hepatic failure. (rahman2019polgrelateddisordersand pages 11-13)
Monitoring: periodic ophthalmology, neurology, mobility/falls, hearing, swallowing, nutrition, respiratory, cardiac, hepatic, endocrine, and mental-health assessment, tailored to phenotype.

No arPEO1-specific interventional trial was identified in the retrieved ClinicalTrials.gov search. Trials of elamipretide and other interventions enrolled broader primary mitochondrial myopathy or nuclear-DNA mitochondrial-disease populations; they should not be presented as demonstrated arPEO1 treatments.

13. Prevention

Primary prevention by lifestyle change is impossible once a pathogenic biallelic genotype is inherited. Evidence-based prevention is reproductive and familial:

genetic counseling and confirmation that variants are in trans;
parental and cascade testing;
prenatal diagnosis or preimplantation genetic testing for a known familial genotype;
donor gametes or other reproductive options according to patient values and jurisdiction.

Mitochondrial replacement therapy is not a logical targeted prevention for POLG arPEO1 because the causal variants are in nuclear DNA, not maternally inherited mtDNA. Secondary prevention comprises early molecular diagnosis and surveillance. Tertiary prevention includes valproate avoidance, falls/aspiration prevention, corneal protection, safe rehabilitation, and management of cardiac, respiratory, hepatic, auditory, and nutritional complications. Vaccination has no disease-specific preventive role beyond routine infection prevention.

14. Other species and natural disease

POLG is evolutionarily conserved, with functional orthologues in mammals, Drosophila, and yeast (MIP1 in Saccharomyces cerevisiae, NCBI Taxonomy 4932). No well-established naturally occurring companion-animal or wildlife syndrome equivalent to human POLG arPEO1, no breed-specific VBO association, and no zoonotic potential were identified. Comparative relevance therefore comes primarily from engineered models rather than natural veterinary disease.

15. Model organisms and experimental systems

Yeast

Human PEO-associated substitutions introduced into yeast MIP1 reproduce mtDNA loss, respiratory-deficient “petite” colonies, altered mutability, and variant-specific dominance/recessivity. The yeast I416T analogue of human A467T was mild in haploids and nearly wild-type in diploids, consistent with recessive inheritance. Yeast models predict pathogenicity with reported accuracy of approximately 70–100%, but are limited by nonconserved residues, simplified protein interactions, and absence of extraocular muscle and nervous-system phenotypes. (stuart2006mitochondrialandnuclear pages 1-2, stuart2006mitochondrialandnuclear pages 8-9, lodi2015dnapolymeraseγ pages 7-8, lodi2015dnapolymeraseγ pages 8-9)

A concise abstract-level statement from the yeast literature is that MIP1 models help in “validating the pathological mutations found in human POLG” and in defining their molecular defects. Chemical rescue with lipoic acid or MitoQ reduced petite frequency for selected yeast variants, but this is preclinical and not evidence of efficacy in arPEO1 patients. (lodi2015dnapolymeraseγ pages 9-10)

Biochemical and patient-cell systems

Recombinant POLγ assays measure polymerase activity, processivity, DNA binding, proofreading, and POLG2 interaction. Patient fibroblasts have demonstrated nonsense-mediated decay, abnormal splicing, and reduced holoenzyme abundance; examples included approximately 75% reduction with R232H/G848S and 45% reduction with A467T/T914P combinations. These systems directly test variant function but do not reproduce lifelong tissue-selective deletion accumulation. (chan2009dnapolymerasegamma pages 4-5, lodi2015dnapolymeraseγ pages 9-10)

Mouse models

Exonuclease-deficient POLG “mutator” mice develop premature aging at 6–9 months, including hearing loss, kyphosis, cardiomegaly, reduced body weight and bone density, and approximately 90-fold more mtDNA deletions. Heterozygotes can remain asymptomatic despite markedly elevated mutation burden, demonstrating that mutagenesis alone does not determine phenotype. These models illuminate deletion-driven mitochondrial pathology but do not faithfully reproduce human arPEO1. (somai2025mitochondrialdnareplication pages 6-8, rahman2019polgrelateddisordersand pages 8-10)

Key research gaps and current expert interpretation

The most important unresolved issue is why identical biallelic POLG genotypes produce isolated adult PEO in some people and catastrophic multisystem disease in others. Current evidence supports contributions from residual enzyme activity, allelic phase, mtDNA background, nuclear modifiers, tissue-specific deletion thresholds, aging, and environmental stress, but no validated predictive model exists. (rajakulendran2016aclinicalneuropathological pages 2-3, rahman2019polgrelateddisordersand pages 10-11, rajakulendran2016aclinicalneuropathological pages 11-13)

Recent clinical practice has moved toward broad sequencing and tissue-aware mtDNA analysis rather than sequential single-gene testing, while the therapeutic field remains supportive. Priorities are longitudinal genotype-stratified natural-history cohorts, quantitative ocular-motility endpoints, patient-derived myotube/iPSC models, single-cell and spatial profiling of affected muscle, and safe nuclear-gene replacement or editing strategies. The central current conclusion is therefore: molecular diagnosis is clinically actionable for counseling, surveillance, and drug avoidance, but not yet for a proven genotype-directed cure.

Selected dated sources and URLs

Wong et al. “Molecular and clinical genetics of mitochondrial diseases due to POLG mutations.” Human Mutation. September 2008. DOI: 10.1002/humu.20824. Primary human referral series. (wong2008molecularandclinical pages 1-2)
Rahman & Copeland. “POLG-related disorders and their neurological manifestations.” Nature Reviews Neurology. Online November 2018/2019 volume. DOI: 10.1038/s41582-018-0101-0. Authoritative review. (rahman2019polgrelateddisordersand pages 10-11, rahman2019polgrelateddisordersand pages 11-13)
Rodríguez-López et al. “Clinical, pathological and genetic spectrum in 89 cases of mitochondrial progressive external ophthalmoplegia.” Journal of Medical Genetics. March 2020; 57:643–646. DOI: 10.1136/jmedgenet-2019-106649. Primary clinical cohort. (rodriguezlopez2020clinicalpathologicaland pages 2-3)
Kurtz et al. “Whole-Exome Sequencing Identifies a Novel POLG Frameshift Variant…” Case Reports in Genetics. November 2021. DOI: 10.1155/2021/9969071. Primary human case and molecular study. (kurtz2021wholeexomesequencingidentifies pages 7-7)
Ali, Esmaeil & Behbehani. “Mitochondrial Chronic Progressive External Ophthalmoplegia.” Brain Sciences. January 2024;14:135. DOI: 10.3390/brainsci14020135. Recent clinical review. Its abstract states: “Genetic sequencing is the gold standard for diagnosing mitochondrial encephalomyopathies” and “No definitive treatment option is available for mitochondrial diseases.” (ali2024mitochondrialchronicprogressive pages 6-8, ali2024mitochondrialchronicprogressive pages 3-5)

PMIDs were not consistently exposed in the retrieved full-text metadata; DOI URLs are therefore supplied rather than risking incorrect PMID assignment.

References

(wong2008molecularandclinical pages 1-2): Lee-Jun C. Wong, Robert K. Naviaux, Nicola Brunetti-Pierri, Qing Zhang, Eric S. Schmitt, Cavatina Truong, Margherita Milone, Bruce H. Cohen, Beverly Wical, Jaya Ganesh, Alice A. Basinger, Barbara K. Burton, Kathryn Swoboda, Donald L. Gilbert, Adeline Vanderver, Russell P. Saneto, Bruno Maranda, Georgianne Arnold, Jose E. Abdenur, Paula J. Waters, and William C. Copeland. Molecular and clinical genetics of mitochondrial diseases due to polg mutations. Human Mutation, 29:E150-E172, Sep 2008. URL: https://doi.org/10.1002/humu.20824, doi:10.1002/humu.20824. This article has 366 citations and is from a domain leading peer-reviewed journal.
(kurtz2021wholeexomesequencingidentifies pages 7-7): Justin Kurtz, Joseph Americo Fernandes, Mahesh Mansukhani, William C. Copeland, and Ali B. Naini. Whole-exome sequencing identifies a novel polg frameshift variant in an adult patient presenting with progressive external ophthalmoplegia and mitochondrial dna depletion. Case Reports in Genetics, 2021:1-7, Nov 2021. URL: https://doi.org/10.1155/2021/9969071, doi:10.1155/2021/9969071. This article has 4 citations.
(ali2024mitochondrialchronicprogressive pages 6-8): Ali Ali, Ali Esmaeil, and Raed Behbehani. Mitochondrial chronic progressive external ophthalmoplegia. Brain Sciences, 14:135, Jan 2024. URL: https://doi.org/10.3390/brainsci14020135, doi:10.3390/brainsci14020135. This article has 25 citations.
(ali2024mitochondrialchronicprogressive pages 3-5): Ali Ali, Ali Esmaeil, and Raed Behbehani. Mitochondrial chronic progressive external ophthalmoplegia. Brain Sciences, 14:135, Jan 2024. URL: https://doi.org/10.3390/brainsci14020135, doi:10.3390/brainsci14020135. This article has 25 citations.
(rahman2019polgrelateddisordersand pages 11-13): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 508 citations and is from a highest quality peer-reviewed journal.
(somai2025mitochondrialdnareplication pages 6-8): Shruti Somai, Chioma H. Aloh, Dillon E. King, and William C. Copeland. Mitochondrial dna replication and disease: a historical perspective on molecular insights and therapeutic advances. International Journal of Molecular Sciences, 26:10275, Oct 2025. URL: https://doi.org/10.3390/ijms262110275, doi:10.3390/ijms262110275. This article has 1 citations.
(rodriguezlopez2020clinicalpathologicaland pages 2-3): Claudia Rodríguez-López, Luis M. García-Cárdaba, Alberto Blázquez, Pablo Serrano-Lorenzo, Gerardo Gutiérrez-Gutiérrez, Beatriz San Millán-Tejado, Nuria Muelas, Aurelio Hernández-Laín, Juan J. Vílchez, Eduardo Gutiérrez-Rivas, Joaquín Arenas, Miguel A. Martín, and Cristina Domínguez-González. Clinical, pathological and genetic spectrum in 89 cases of mitochondrial progressive external ophthalmoplegia. Journal of Medical Genetics, 57(9):643-646, Mar 2020. URL: https://doi.org/10.1136/jmedgenet-2019-106649, doi:10.1136/jmedgenet-2019-106649. This article has 43 citations and is from a domain leading peer-reviewed journal.
(rahman2019polgrelateddisordersand pages 10-11): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 508 citations and is from a highest quality peer-reviewed journal.
(chan2009dnapolymerasegamma pages 4-5): Sherine S.L. Chan and William C. Copeland. Dna polymerase gamma and mitochondrial disease: understanding the consequence of polg mutations. Biochimica et biophysica acta, 1787 5:312-9, May 2009. URL: https://doi.org/10.1016/j.bbabio.2008.10.007, doi:10.1016/j.bbabio.2008.10.007. This article has 249 citations.
(rajakulendran2016aclinicalneuropathological pages 2-3): Sanjeev Rajakulendran, Robert D. S. Pitceathly, Jan-Willem Taanman, Harry Costello, Mary G. Sweeney, Cathy E. Woodward, Zane Jaunmuktane, Janice L. Holton, Thomas S. Jacques, Brian N. Harding, Carl Fratter, Michael G. Hanna, and Shamima Rahman. A clinical, neuropathological and genetic study of homozygous a467t polg-related mitochondrial disease. PLoS ONE, 11:e0145500, Jan 2016. URL: https://doi.org/10.1371/journal.pone.0145500, doi:10.1371/journal.pone.0145500. This article has 67 citations and is from a peer-reviewed journal.
(stuart2006mitochondrialandnuclear pages 8-9): Gregory R. Stuart, Janine H. Santos, Micheline K. Strand, Bennett Van Houten, and William C. Copeland. Mitochondrial and nuclear dna defects in saccharomyces cerevisiae with mutations in dna polymerase γ associated with progressive external ophthalmoplegia. Human Molecular Genetics, 15:363-374, Jan 2006. URL: https://doi.org/10.1093/hmg/ddi454, doi:10.1093/hmg/ddi454. This article has 74 citations and is from a domain leading peer-reviewed journal.
(rajakulendran2016aclinicalneuropathological pages 11-13): Sanjeev Rajakulendran, Robert D. S. Pitceathly, Jan-Willem Taanman, Harry Costello, Mary G. Sweeney, Cathy E. Woodward, Zane Jaunmuktane, Janice L. Holton, Thomas S. Jacques, Brian N. Harding, Carl Fratter, Michael G. Hanna, and Shamima Rahman. A clinical, neuropathological and genetic study of homozygous a467t polg-related mitochondrial disease. PLoS ONE, 11:e0145500, Jan 2016. URL: https://doi.org/10.1371/journal.pone.0145500, doi:10.1371/journal.pone.0145500. This article has 67 citations and is from a peer-reviewed journal.
(kierdaszuk2020progressiveexternalophthalmoplegia pages 2-4): Biruta Kierdaszuk, Magdalena Kaliszewska, Joanna Rusecka, Joanna Kosińska, Ewa Bartnik, Katarzyna Tońska, Anna M. Kamińska, and Anna Kostera-Pruszczyk. Progressive external ophthalmoplegia in polish patients—from clinical evaluation to genetic confirmation. Genes, 12:54, Dec 2020. URL: https://doi.org/10.3390/genes12010054, doi:10.3390/genes12010054. This article has 6 citations.
(stuart2006mitochondrialandnuclear pages 1-2): Gregory R. Stuart, Janine H. Santos, Micheline K. Strand, Bennett Van Houten, and William C. Copeland. Mitochondrial and nuclear dna defects in saccharomyces cerevisiae with mutations in dna polymerase γ associated with progressive external ophthalmoplegia. Human Molecular Genetics, 15:363-374, Jan 2006. URL: https://doi.org/10.1093/hmg/ddi454, doi:10.1093/hmg/ddi454. This article has 74 citations and is from a domain leading peer-reviewed journal.
(rahman2019polgrelateddisordersand pages 8-10): Shamima Rahman and William C. Copeland. Polg-related disorders and their neurological manifestations. Nov 2019. URL: https://doi.org/10.1038/s41582-018-0101-0, doi:10.1038/s41582-018-0101-0. This article has 508 citations and is from a highest quality peer-reviewed journal.
(lodi2015dnapolymeraseγ pages 7-8): Tiziana Lodi, Cristina Dallabona, Cecilia Nolli, Paola Goffrini, Claudia Donnini, and Enrico Baruffini. Dna polymerase γ and disease: what we have learned from yeast. Frontiers in Genetics, Mar 2015. URL: https://doi.org/10.3389/fgene.2015.00106, doi:10.3389/fgene.2015.00106. This article has 41 citations and is from a peer-reviewed journal.
(lodi2015dnapolymeraseγ pages 8-9): Tiziana Lodi, Cristina Dallabona, Cecilia Nolli, Paola Goffrini, Claudia Donnini, and Enrico Baruffini. Dna polymerase γ and disease: what we have learned from yeast. Frontiers in Genetics, Mar 2015. URL: https://doi.org/10.3389/fgene.2015.00106, doi:10.3389/fgene.2015.00106. This article has 41 citations and is from a peer-reviewed journal.
(lodi2015dnapolymeraseγ pages 9-10): Tiziana Lodi, Cristina Dallabona, Cecilia Nolli, Paola Goffrini, Claudia Donnini, and Enrico Baruffini. Dna polymerase γ and disease: what we have learned from yeast. Frontiers in Genetics, Mar 2015. URL: https://doi.org/10.3389/fgene.2015.00106, doi:10.3389/fgene.2015.00106. This article has 41 citations and is from a peer-reviewed journal.

Artifacts

Edison artifact artifact-00

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Histopathology

Pathograph

Phenotypes

Genetic Associations

Medical Actions

Biochemical Markers

Differential Diagnoses

Clinical Trials

Source YAML

References & Deep Research

References

Deep Research

Autosomal Recessive Progressive External Ophthalmoplegia 1 (PEOB1) — Comprehensive Research Report

1. Disease Information

2. Etiology

3. Phenotypes

Core/defining phenotypes

Additional/variable manifestations (PEO-"plus" features)

4. Genetic/Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome/Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Summary of Key Ontology Term Suggestions for KB Curation

Notes on Evidence Gaps

Autosomal Recessive Progressive External Ophthalmoplegia 1: Disease-Characteristics Report

Executive summary and evidence scope

1. Disease information

Definition and classification

Identifiers and synonyms

2. Etiology, risk, protective factors, and gene–environment interaction

Primary cause

Genetic risk factors

Modifiers and protective factors

Environmental and lifestyle factors

3. Phenotypes

Core and associated manifestations

Onset, progression, frequency, and quality of life

4. Genetic and molecular information

Gene and protein

Variant classes and functional consequences

Other genomic and epigenetic findings

5. Environmental information

6. Mechanism and pathophysiology

Causal chain

Ontology suggestions

Molecular profiling and advanced technologies

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population

10. Diagnostics

Recommended workflow

Screening

11. Outcome and prognosis

12. Treatment and current implementation

Disease-modifying therapy

Symptomatic and supportive care

13. Prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Yeast

Biochemical and patient-cell systems

Mouse models

Key research gaps and current expert interpretation

Selected dated sources and URLs

Artifacts